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--------------------------SUMMARY--------------------------- 
 
The ErbB2 receptor tyrosine kinase has been shown to play an important role in cancer cell 
motility and metastases formation. This receptor is often overexpressed in human tumors of 
diverse origins, including breast and ovarian cancer. Individuals with ErbB2 over expressing 
tumors have shown poor clinical outcome.  
Our studies are focused on signaling molecules that interact with autophosphorylated tyrosine 
residues of the cytoplasmic tail of the receptor. Two of the sites, Tyr 1201 (YC) and Tyr 1227 
(YD) are fully able to restore the migratory phenotype of breast carcinoma cells. Studies of 
the functional role of ErbB2 phosphorylation sites identified PLCγ1 as an interacting partner 
of the YC autophosphorylation site, and Memo (Mediator of ErbB2-driven cell Motility) as a 
binding partner of the YD site that is required for ErbB2 induced cell motility.  
Memo is encoded by a unique gene that is found in all branches of life, from bacteria to 
humans. Memo has no characterized domains, nor does it have obvious catalytic activity. 
Various approaches were used to position Memo in a signaling pathway and to uncover its 
biochemical function. Memo was initially detected based on its important role in ErbB2-
induced cell motility. In fact, tumor cells with a specific knock-down (KD) of Memo failed to 
grow microtubules in response to Heregulin (HRG)-induced ErbB2 activation and were 
impaired in their migration.  
Cell migration proceeds in distinct steps. In response to a chemotactic stimulus, cells extend 
protrusions at the front that help in attachment. This is followed by contraction of the cell 
body and tail detachment at the rear allowing movement in the direction of the ligand. The 
initial event in the process is sensing of the ligand in response to activation of cellular 
receptors like EGFR or ErbB2. Their activation initiates signaling pathways that lead to 
polymerization of new actin at the leading edge, which is necessary for generating the 
protrusive force allowing migration. An important goal of my thesis work has been to 
investigate the step(s) of the migratory process that require Memo. 
 
In the first study, we explored migration using Dunn chambers and analyzed the chemotactic 
response of tumor cells in a shallow gradient of ligand. By tracing HRG-stimulated cell 
migration in time-lapse video microscopy, we found that Memo or PLCγ1 KD strongly 
impairs cell directionality, reflecting an important role for Memo and PLCγ1 in orchestrating 
directional cell migration. We also demonstrated that depletion of Memo or PLCγ1 resulted in 
very similar phenotypes, with a strong impairment of HRG-induced cytoskeletal organization. 
To gain more insight into Memo’s function, we carried out a Yeast-2-Hybrid (YTH) analysis 
and found a number of interesting new partners of interaction for Memo. Of particular interest 
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is the small protein cofilin, one of the major cellular actin severing and depolymerizing 
factors that is known to have an essential role in directional sensing during chemotaxis. This 
interaction was confirmed in vitro using recombinant proteins and in vivo in co-
immunoprecipitation experiments where Memo was detected in complexes with cofilin, 
ErbB2 and PLCγ1. Interestingly, we also found that HRG-induced PLCγ1 phosphorylation 
was decreased in Memo KD cells, suggesting that Memo regulates PLCγ1 activation. 
Furthermore, by introducing GFP-tagged cofilin into control, Memo or PLCγ1 siRNA 
transfected breast tumor cells, we showed that HRG-induced recruitment of GFP-cofilin to 
lamellipodia is impaired in Memo- and in PLCγ1 KD cells, suggesting that both proteins lie 
upstream of cofilin in models of ErbB2-driven tumor cell migration. Finally, we examined the 
effect of Memo on cofilin binding and severing/depolymerizing properties. In vitro F-actin 
binding assays showed that Memo does not impair cofilin binding to F-actin, and revealed 
that Memo is a novel F-actin binding protein. In vitro F-actin depolymerization assays 
indicated that Memo promotes cofilin depolymerizing/severing activity. Altogether, these 
data suggest a novel role for Memo during the migratory process and its implication in the 
regulation of actin dynamics through cofilin binding. 
 
In the second study, we used two different Memo-defective cellular models to examine 
Memo’s function in more detail. We demonstrated that inhibition of Memo impairs activation 
of a number of signaling molecules including Src, Shc, ERK and PLCγ1. We also provide 
evidence that Memo interacts with the three Shc isoforms, p46shc, p52shc, and p66shc, and 
showed that Shc is required for Memo binding to the ErbB2 receptor. Control and Memo-
deficient cells were also scored for their migration and adhesion properties. These assays 
indicated that Memo is important in both cell migration and adhesion processes. Also, 
morphological and biochemical analyses of control and Memo-deficient cells suggested that 
Memo is involved in focal adhesion organization and rear cell deadhesion during the 
migratory process.  
Altogether, these two studies revealed important roles for Memo at different steps of cell 
migration and metastasis, making it a potential interesting target for cancer therapy.  
 
Genetic approaches in model organisms have been important for gaining insight into the 
function of evolutionarily conserved proteins. To position Memo within a genetic network, 
experiments in the model organism S. cerevisae that lends itself to rapid genetic screening 
were performed. We investigated cellular localization of Memo in yeast and found that Memo 
is located in the nucleus and cytoplasm of the cell. A S. cerevisae memo ∆ strain has been 
generated and is viable. Considering the role of Memo in the microtubule and actin networks 
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that we described in mammalian cells, we examined the memo ∆ strain for defects in different 
cytoskeletal dynamics. No significant effect was observed. We also performed a Synthetic 
Lethal Screen of genetic interactions between a memo ∆ strain and an ordered array of 4700 
Yeast strains containing non-essential gene deletions. This analysis revealed a limited number 
of synthetic interactions. Lethality was observed in combination with the plc1∆ strain. PLC1 
encodes for the unique isoform of phosphatidylinositol-specific phospholipase C of S. 
cerevisiae. The results are intriguing and exciting considering the data obtained in the 
mammalian models; in fact, we demonstrated that Memo and PLCγ1 interact with ErbB2 
autophosphorylation sites and are essential for directional migration. We also showed that 
Memo is found in a complex with PLCγ1 and ErbB2 and that Memo is likely contributing to 
PLCγ1 activation. We hypothesize that in Yeast, Memo and PLC1 act in the same or in 
distinct but related pathways, and suggest that the connection between PLC and Memo 
induced-pathways is also conserved through evolution.  
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-----------------------INTRODUCTION---------------------- 
 
A. The Epidermal Growth Factor (EGF/ErbB) family of Receptor 
Tyrosine Kinases (RTK) 
 
  Cellular signaling processes are essential to the life cycle and for cellular biological 
functions. On the one hand, cells are constantly exposed to a variety of external stimuli, 
ranging from soluble factors to signaling molecules from neighboring cells. On the other 
hand, cells have to correctly interpret these extracellular signals in order to induce an 
appropriate response. 
 
The family of Receptor Tyrosine Kinases (RTK) is part of a large number of systems that 
induce amplification from the external signal stimuli to the internal cell compartment. Indeed, 
RTKs are key regulator transmembrane proteins that are able to integrate a wide range of 
external stimuli with specific internal signals and responses. RTKs belong to the wider 
Tyrosine Kinase (TK) family and form a protein superfamily of 58 known members which is 
present in all metazoans and is divided into 20 different sub-families defined by their sub-
domain composition.  
The subfamily I, also called Epidermal Growth Factor (EGF/ErbB) family, originally named 
because of their homology to the erythroblastoma viral gene product, v-erbB (Downward et 
al., 1984), encompasses four structurally related type I growth factor receptors: EGF receptor 
(also called ErbB1/HER1), ErbB2 (Neu/HER2), ErbB3 (HER3) and ErbB4 (HER4), and a 
number of soluble ligands which bind to their cognate receptor (Yarden and Sliwkowski, 
2001). 
 
The ErbB receptors have a common cysteine-rich extracellular ligand binding domain, a 
single hydrophobic transmembrane spanning region and a cytoplasmic tyrosine kinase 
containing domain that is flanked by non-catalytic regulatory regions (Ullrich and 
Schlessinger, 1990). Ligand binding to the extracellular domain induces receptor activation 
with the formation of specific receptor homo or heterodimeric complexes, resulting in auto 
and trans-autophosphorylation of specific residues within the cytoplasmic kinase domain of 
the activated receptor (Schlessinger, 2000). These phosphorylated residues serve as docking 
sites for specific signaling SH2 (Src Homology 2) and phosphotyrosine-binding domain 
containing molecules (Yaffe, 2002; Olayioye et al., 2000). Additional effector proteins are 
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then recruited which turn on a plethora of cellular responses including cell growth, 
proliferation, differentiation, migration, survival, metabolism and ultimately, subsequent 
activation or repression of various subsets of genes (Holbro and Hynes, 2004).   
                        
 
            
                               The ErbB signaling network 
 
                                        
                                             Adapted from Holbro and Hynes, Annu Rev Pharmacol Toxicol 2004 
 
 
Figure 1. Ligands of the EGF family bind to their receptors causing the formation of different ErbB 
dimers. ErbB2, which has no direct ligand inducing homodimerization, needs a partner to acquire 
signaling potential (indicated by the encircled P). Following receptor activation, various molecules 
(violet) with adaptor or enzymatic functions are directly recruited to the ErbBs. These then activate 
downstream signaling components (dark blue), which ultimately lead to changes in the activity of 
multiple nuclear transcription factors (yellow). For illustrative clarity, many components in each of the 
signaling layers are omitted.  
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 1. The ErbB signaling network in evolution 
The components of the ErbB signaling pathway are evolutionarily conserved. In contrast with 
higher organisms where the ErbB pathway has developed an elaborated network, both 
Caenorhabditis elegans and the fruitfly Drosophila melanogaster ErbB pathways display a 
linear version with a single ErbB homologue for each species. 
 
 
 In the Caenorhabditis elegans organism, the let-23 and lin-3 genes encode the single 
epidermal growth factor receptor homologue and an EGF-like/TGFα-like ligand, respectively 
(Aroian et al., 1990; Hill and Sternberg, 1992). LET-23 is differentially expressed at the 
beginning of the third larval stage of development (L3) in six vulval precursor cells (P3.p-
P8.p also called VPCs) which are located along the ventral side of the hermaphrodite. Indeed, 
at this stage, LET-23 displays an increased expression on the surface of P6.p and a decreased 
expression on the surface of the other precursor cells. Lin-3 is secreted by the anchor cell that 
is located in the somatic gonad, just above P6.p. The inductive signal results from the binding 
of Lin-3 to the juxtaposed LET-23 receptor on P6.p, which in turn undergoes a determined 
number of cell divisions. This results in the formation of the primary fate, surrounded by the 
secondary fate presumably arising from the activation of LIN-12/NOTCH receptors and low 
levels of active LET-23 on the precursor cells flanking P6.p, namely P5.p and P7.p. The other 
three VPCs generate non-specialized hypodermis. Mutations in LET-23 and lin-3 resulted in 
defective formation of vulval tissue (Aroian and Sternberg, 1991; Liu and al., 1999 
respectively). Additionally to the role of the LET-23/lin-3 pathway in vulval development and 
differentiation, this epidermal growth factor system is also involved in other processes such as 
viability (Aroian and Sternberg, 1991), spicule development (Chamberlin and Sternberg., 
1994) and ovulation (Bui and Sternberg, 2002). Finally, epidermal growth factor signaling 
also has a neuronal function with an important role for EGF signaling in the regulation of 
behavioral quiescence (Van Buskirk and Sternberg, 2007). 
 
 
 The fruitfly Drosophila Melanogaster has a single receptor homologous to the four 
mammalian ErbB receptors also called DER (Wadsworth et al., 1985; Schejter et al., 1986), 
and a complex network of ligands composed by five activating ligands and one inhibitory 
ligand (Shilo, 2002). DER is repeatedly used at several stages during development. DER was 
shown to be involved during oogenesis in the establishment of both the anterior/posterior and 
dorsal/ventral body axes and in the pattern of the embryo (Gonzalez-reyes et al., 1995; 
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Wasserman and Freeman, 1998). A role for DER is also established during embryogenesis, 
where among other functions (Clifford and Schüpbach, 1992), DER is involved in the 
development of the central nervous system (Udolph et al., 1998). Wing vein formation and 
eye development in the Drosophila melanogaster larva are also controlled by DER 
(Sturtevant et al., 1993; Dominguez et al., 1998).  
 
DER is activated in a versatile mode by ligand binding to the extracellular region. Four 
activating ligands are described: Spitz (Rutledge et al., 1992) is the primary activating ligand 
that similarly to Keren (Reich and Shilo, 2002) and Gurken (Neuman-Sillberberg and 
Schüpbach, 1993), is produced as a transmembrane precursor that is cleaved to generate the 
active secreted ligand. Vein (Schnepp et al., 1996) is the fourth activating ligand which is 
produced as a secreted protein. Argos is also a secreted protein which contains an atypical 
EGF-like motif and functions as an inhibitory ligand by competing with the activating ligands 
for the binding to the receptor (Schweitzer et al., 1995). Interestingly, a more recent study 
suggested that Argos sequesters the activating ligand Spitz without binding directly to the 
receptor (Klein et al., 2004). Moreover, Kekkon and Sprouty are two other proteins which 
interfere negatively with the DER signaling in some tissues (Ghiglione et al., 2003; Casci et 
al., 1999). These positive and negative feedback loops therefore regulate the different cell fate 
choices induced by DER activation 
 
 
 
                             
                                                                                              Adapted from Shilo, Exp Cell Res, 2003 
Figure 2. Activating and inhibitory Drosophilia epidermal growth factor (EGF) receptor (DER) 
ligands. Five ligands are interacting with DER. Spitz, Keren, and Gurken are produced as 
transmembrane precursors and are cleaved (arrows) to generate the active secreted ligand. Vein and 
Argos are produced as secreted protein. The EGF domain (red) of Argos mediates binding to DER and 
inhibits binding of other ligands, as well as receptor dimerization. 
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The ErbB receptor family has evolved in higher vertebrates with the combination of a 
multitude of EGF-related ligands binding to four ErbB receptors which translate the 
information from the extracellular compartment to intracellular signaling pathways that 
modulate cellular biological responses. An important diversity in signaling is therefore 
possible with the numerous combinations between ligands and receptors. ErbB receptors are 
expressed in a variety of tissues throughout development where they play essential roles in 
cell proliferation and differentiation. Importantly, aberrant ErbB signaling has been correlated 
with the progression of human malignancies. Deregulated expression of the ErbB receptors, in 
particular ErbB1 and ErbB2, is associated with a more aggressive disease and with parameters 
predicting a poor clinical outcome (Hynes and Stern, 1994; Salomon and al., 1995). 
Accordingly, ErbB receptors are under intense scrutiny not only for their role in cancer 
biology, but also as therapeutic targets. Different approaches have been developed using 
ectodomain- binding antibodies or small-molecule tyrosine kinase inhibitors (TKIs) that 
compete with ATP in the tyrosine kinase domain (Mendelsohn and Baselga, 2000, de Bono 
and Rowinski, 2002, Rowinsky, 2004). Some of these therapies are either already in clinical 
use or in advanced clinical development. 
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 2. The ErbB receptor/ligand network 
The coordination of several processes such as cell morphology, proliferation, differentiation, 
motility, and survival is required for the formation and the maintenance of tissue organization 
during development. It is therefore vital that cells correctly interpret signals from their 
environment.  
 
  2.1. The first step: binding of EGF-related ligands to specific receptors 
       2.1.1. Classification of the ErbB receptors ligands  
 Growth factors that bind and activate the ErbB receptors belong to the EGF-family of growth 
factors (Harris et al., 2003; Falls, 2003). These specific agonists for ErbB receptors are each 
the product of a single gene. They are processed from large precursors into small soluble 
peptides. 
There are 11 soluble and small (6-10 kDa) growth factors, and   according to their affinity for 
one or more ErbB receptors, the EGF-related growth factors can be divided into three distinct 
groups (Riese and Stern, 1998). 
The first group includes ligands for the EGF receptor, namely EGF (Carpenter and Cohen, 
1990), transforming growth factor α (TGF-α) (Massague, 1990), amphiregulin (AR) (Shoyab 
et al., 1988) and epigen (Strachan et al., 2001). 
 The second group encompasses growth factors that have dual binding specificity for EGFR 
and ErbB4, such as betacellulin (BTC) (Dunbar et al., 2000), heparin-binding growth factor 
(HB-EGF) (Higashiyama et al., 1992) and epiregulin (EPR) (Toyoda et al., 1995).   
The third group comprises the neuregulins (NRGs also frequently referred to as Heregulins 
HRGs) (Falls, 2003) which can be divided into two subgroups: NRG-1 and NRG-2 which can 
bind to ErbB3 and ErbB4 receptors, and NRG-3 and NRG-4 which only bind to ErbB4. Of 
note is the fact that none of the EGF-family ligands directly bind ErbB2. However, despite 
having no soluble ligand, ErbB2 is activated via heterodimerization with the other ligand 
bound family members (Olayioye et al., 2000). In fact, ErbB2 appears to be the preferred 
heterodimerization partner of the other ligand-bound ErbB receptors (Graus-Porta et al., 
1997). 
 
This family of growth factors displays a similar structure with a characteristic consensus 
sequence containing six spatially conserved cysteine residues that form three intramolecular 
disulfide-bonds. This sequence composes the EGF-like domain or EGF motif which confers 
the specificity of binding (Jones et al., 1999). EGF ligands also contain additional structural 
motif such as immunoglobulin-like domains, heparin-binding sites and glycosylation sites 
(Harris et al., 2003). 
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                                                                      Adapted from Olayioye et al., Embo J, 2000,  
Figure 3. Binding specificities of the EGF-related peptide growth factors. There are four categories 
of      ligands that bind ErbB receptors. EGF, AR and TGF  bind ErbB1; BTC, HB-EGF and EPR bind 
ErbB1 and ErbB4; NRG-1 and NRG-2 bind ErbB3 and ErbB4; and NRG-3 and NRG-4 bind ErbB4.  
   
    
  2.1.2. The production of soluble EGF family ligands 
  The mammalian ligands are regulated autocrine/paracrine and/or juxtacrine growth factors. 
Paracrine ErbB ligands are released from the stromal cells. Autocrine ligands are produced as 
transmembrane precursors that undergo proteolytic cleavage at the cell surface to release a 
mature soluble ectodomain which stimulate receptors on neighboring cells (Massague and 
Pandiella, 1993). The soluble rather than membrane-anchored forms of the ligands were 
shown to mediate most of the biological effects of EGFR ligands (Dong et al., 1999). This 
proteolytic cleavage is an important step in the process of receptor activation which is 
dependent on ligand availability. In fact, the presence of EGF ligands in tumors was 
correlated with constitutive activation of ErbB receptors (Baker, 2002). Therefore, this 
mechanism that controls ligand processing appears to be a potential therapeutic target 
(Borrell-Pagès et al., 2003; Higashiyama et al., 2008). 
 
The proteases involved in the cleavage of the growth factors belong to the metalloproteinase 
family, in particular the zinc binding matrix metalloproteinases (MMPs) and ADAMs (a 
disintegrin-like and metalloproteinase-containing protein) family (Seals and Courtneidge, 
2003; Sanderson et al., 2006). The first mechanism describing the production of soluble EGF 
family ligands through ectodomain shedding involve the activation of G-protein-coupled-
receptors (GPCRs) (Prenzel et al., 1999; Daub et al., 1996). In this particular study, treatment 
of cells with different GPCRs agonists induces a rapid EGFR phosphorylation. This 
mechanism has been termed EGFR transactivation and resulted from metalloproteinase 
activation leading to the cleavage and release of HB-EGF, which in turn activated EGFR. 
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Importantly, these processes lead to the stimulation of intracellular signaling pathways such 
as MAPK (Luttrell et al., 1999). GPCR-induced transactivations of EGFR and ErbB2 have 
been extensively studied; however, it is important to mention that neuregulins, which are the 
ligands for ErbB3 and ErbB4, are processed by the same metalloproteinases (Wakatsukiet al., 
2004). 
 
 This mechanism of proteolytic cleavage is also described in cancer cells, where members of 
the ADAM family were shown to be involved in the shedding of diverse EGF-like ligands 
(Fisher et al., 2003; Hynes and Schlange, 2006). Other physiological ligands inducing ErbB 
transactivation were recently identified. For instance, transactivation of EGFR by binding of 
WNT to the seven-pass membrane receptor Frizzled (FZD) was described (Civenni et al., 
2003) 
            
                                                                                 Adapted from Higashiyama et al., cancer Sci, 2008, 
Figure 4. Ligand-shedding dependent epidermal growth factor receptor (EGFR) transactivation. 
Disintegrin and metalloprotease (ADAM) proteins are activated by various stimuli including wounding, 
ion influx, G-protein coupled receptor (GPCR) signaling, growth factor and cytokine signaling, protein 
kinase C (PKC) activation, and binding of cytoplasmic interactive proteins. EGFR ligand molecules are 
proteolytically cleaved by specific metalloprotease-activity of ADAMs, resulting in the production of 
soluble ligands and stimulation of EGFR in autocrine and paracrine manners. AngII, angiotensin II; 
Cyts, cytokines; GFs, growth factors; HB-EGF, Heparin-binding epidermal growth factor carboxy-
terminal fragment; LPA, lysophosphatidic acid; MAPK, mitogen-activated protein kinase; NRG, 
neuregulin; PI3K, phosphatidyl inositol 3-kinase; PKC, protein kinase C; ROS, reactive oxygen 
species; TGF-α, transforming growth factor-α; TPA, 12-O-tetradecanoylphorbol- 13-acetate. 
 
In addition, juxtacrine stimulation of growth factor receptors has been described where the 
membrane-associated uncleaved form of HB-EGF could activate EGFR in adjacent cells 
(Higashiyama et al., 1995). 
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       2.1.3. Architecture of the ErbB receptors 
The ErbB receptors are type I transmembrane proteins containing a large extracellular 
ectodomain of 600-630 amino acids subdivided into four domains (I-II-III and IV). This 
extracellular domain is heavily N- glycosylated at 12 sites and characterized by two cysteine-
rich domains (domain II and IV) that form 25 disulfide bonds. Domains I and III (also called 
L1 and L2) have a beta helical fold and constitute the ligand-binding site. A beta hairpin also 
called dimerization loop or dimerization arm (composed of a 10-reside sequence) in the 
subdomain II is involved in the process of dimerization between two receptors (Burgess et al., 
2003). 
The receptors also contain a single transmembrane-spanning α-helix that was usually 
assumed to play a passive role in ligand-induced activation of the receptor. However, 
mutations within some of these receptors, and studies with the EGFR and ErbB2 receptors 
have indicated that interactions between transmembrane domains do contribute to stabilization 
of ligand-independent and/or ligand-induced receptor dimerization and activation (Bell et al., 
2000; Bennasroune et al., 2004). 
The large cytoplasmic region (about 500 amino acids) encodes a juxtamembrane region, a 
highly conserved tyrosine kinase domain divided into two lobes, and a C-terminal region 
containing multiple autophosphorylation sites. The ErbB3 receptor is kinase inactive due to 
amino-acid substitutions in important residues (Kraus et al., 1989; Plowman et al., 1990; Guy 
et al., 1994). Therefore, ErbB3 has to dimerize with another ErbB receptor in order to be 
phosphorylated and signal. 
These receptors are subjected to different co and post-translational modifications (N-
glycosylation, phosphorylation and ubiquitination) (Blagoev et al., 2004; Wu et al., 2006; 
Guo et al., 2003; Huang et al., 2006). Many phosphotyrosine and some 
phosphoserine/threonine sites have been identified by conventional sequencing and more 
recently by the use of the mass spectrometry technique (Zhang et al., 2005). A multitude of 
signaling molecules associate with the ErbB receptor family through the phosphotyrosine 
residues (Schulze et al., 2005). Many of these associated proteins are tyrosine phosphorylated 
by the receptor. Others, like Grb-2, are not phosphorylated but act as adaptators to enhance 
downstream signaling pathways (Lim et al., 2000).  
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                                                                                                Adapted from Burgess et al., Mol Cell, 2003 
 
 Figure 5. Domain organization of the ErbB receptors (residue numbers for domain boundaries are 
for EGFR) 
 
 
 
       2.1.4. Alternative forms of ErbB receptors 
Differential splicing or proteolytic processing results in the production of variant forms of the 
ErbB receptors. Oncogenic forms of the EGF receptor have been described in breast cancer 
(Moscatello et al., 1995). A spliced variant of ErbB2, deltaHER2 (with a deletion of an exon 
16 amino acids long in the extracellular domain) has also been described to induce 
constitutive dimerization and transformation (Kwong and Hung, 1998). Also, soluble 
extracellular domains of EGF receptor and ErbB2 can be produced either through direct 
coding by spliced variant mRNAs or through proteolytic processing of full-length receptors 
(Petch et al., 1990; Doherty et al., 1999). An extracellularly truncated form of ErbB-2 which 
is produced through proteolytic cleavage of full-length molecules and which may be 
associated with lymph node metastasis is found in a subset of tumors that overexpress ErbB-2 
(Christianson et al., 1998). ErbB4 is also cleaved to release a soluble 80 KDa intracellular 
domain termed s80, which translocates to the nucleus to promote cell differentiation (Linggi 
and Carpenter, 2006). 
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  2.2. Mechanism of ErbB receptor activation upon ligand binding 
       2.2.1 Ligand induced dimerization of the ErbB receptors 
The binding of the growth factors to the extracellular ectodomain results in homo- or hetero-
dimerization of ErbB receptors, and activates the cytoplasmic tyrosine kinase, enhancing the 
stimulation of signaling pathways that direct cellular responses (Olayioye et al., 2000). 
 
The mechanism of receptor activation by ErbB-ligand induced dimerization is well 
established since many years (Schlessinger, 2000), however, the exact mechanism of 
receptor-receptor interaction was unknown until recently. Significant improvement in the 
knowledge and the understanding of the molecular mechanism involved in ligand induced- 
receptor dimerization has emerged from high-resolution structure and crystal studies on the 
soluble ectodomains of EGFR (Garrett et al., 2002; Ogiso et al., 2002; Ferguson et al., 2003), 
ErbB2 (Garrett et al., 2003), ErbB3(Cho and Leahy, 2002) and ErbB4 (Bouyain et al., 2005).  
These studies indicated that in the absence of ligand, EGFR, ErbB3 and ErbB4 exist in a so 
called “tethered” intramolecular conformation due to an interaction between the dimerization 
loop in subdomain II and subdomain IV that leads to a closed conformation unable to mediate 
the interaction between monomers of receptors (Ferguson et al., 2003; Cho and Leahy, 2002). 
By contrast, a competent dimerization conformation is observed in ligand-bound EGFR with 
the exposition on the receptor surface of the dimerization arm. The contact between two 
monomers occurs mainly through this dimerization arm and leads to the formation of a dimer 
composed of two 1:1 receptor/ligand complex (Garrett et al., 2002; Ferguson et al., 2003). 
 
The structure of ErbB2 differs significantly from that of the other receptors. Indeed, in the 
absence of ligand and, similarly to the structure of EGF-bound EGFR, ErbB2 is in a 
competent dimerization conformation which exhibits a protruding loop (Garrett et al., 2003). 
In this particular conformation, the proximity between the subdomains L1 and L2 prevents the 
binding of the ligand, which can explain the inability of ErbB2 to bind EGF-family ligands. 
More importantly, this particular conformation also explains the potential of ErbB2 to hetero-
dimerize with other receptors, and highlights the position of ErbB2 as the preferred 
dimerization partner for all others ErbB receptors (Graus-Porta et al., 1997; Tzahar et al., 
1996). 
 
                                 Introduction: the EGF/ErbB family 
                                                       - 18 -
 
                                                                                           Adapted from Burgess et al., Mol Cell, 2003 
 
Figure 6. Model for NRG-Induced Heterodimerization of ErbB2 and ErbB3. At left, a tethered 
ErbB3 monomer is depicted. Binding of NRG (red) is proposed to promote the extended configuration 
of ErbB3, with the dimerization arm exposed. Extended ErbB3 is thought to form homodimers only 
very inefficiently. On the right are shown ErbB2 molecules, constitutively in the extended 
configuration, that are thought to be primarily monomeric (although homodimerization can presumably 
be driven by substantial overexpression). When NRG-bound ErbB3 molecules are present in the cell 
membrane, ErbB2 preferentially forms hetero-oligomers with ErbB3, leading to receptor activation and 
mitogenic signaling. Additional interactions involving the transmembrane and kinase domains may also 
contribute to receptor oligomerization. 
                                    
 
 
 When associated with other ErbB receptors, ErbB2 induces amplification but also, 
diversification of the signal output. Evidence is provided that the EGF receptor homodimer 
signals differently from the EGFR-ErbB2 heterodimer (Muthuswamy and Muller, 1995). 
Interestingly, the ErbB2-containing heterodimeric receptor groups are the most potent 
complexes which induce cell proliferation and transformation (Citri et al., 2003). In fact, 
activation of this heterodimeric complex between a ligandless receptor (ErbB2) and a kinase-
deficient receptor (ErbB3) enhances potent signaling pathways. (Harari and Yarden, 2000; 
Prigent and Gullick, 1994). Moreover, rapid internalization of the ErbB2/ErbB3 heterodimer 
is impaired, leading to prolonged signaling (Sorkin et al., 1993; Lenferink et al., 1998). 
Furthermore, the rate of ligand dissociation from the complex is decreased, leading to an 
increased affinity of the ErbB3 receptor to the ligands (Sliwkowski et al., 1994; Pinkas-
Kramarski et al., 1997). 
It is also important to highlight that autologous signaling by ErbB2 occurs when the receptor 
is mutated like in the rat Neu or over expressed, a situation that is observed in a variety of 
human cancers (Brennan et al., 2000; Sharpe et al., 2000; Penuel et al., 2002). 
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   2.2.2 Ligand induced activation of the ErbB receptors 
The kinase domain of the ErbB receptors is divided into two lobes, termed N and C domains 
that cooperate to form the active site. A recent study has brought new insights into the process 
of kinase activation following receptor dimerization (Zhang et al., 2006). The proposed model 
is the following: the C-lobe of one receptor kinase domain allosterically activates the kinase 
module of the other receptor by contacting its N-lobe. This interaction repositions the 
activation loop in a conformation which facilitates catalysis. The mechanism whereby ErbB2 
gets phosphorylated in an ErbB2/ErbB3 heterodimer containing an enzymatically inactive 
ErbB3-kinase domain is poorly understood. However, this model proposed by Zhang and 
colleagues predicts that activation of ErbB2 is possible due to the interaction between the C-
lobe of ErbB3 and the N-lobe of ErbB2. Moreover, a possible role of the juxtamembrane 
region and the C-terminal region in modulating receptor kinase activity has also been 
proposed (Aifa et al., 2005; Landau et al., 2004). 
 
 
  2.3. Activation of intracellular signaling pathways 
Auto or trans-autophosphorylation of the ErbB receptors provides specific docking sites for a 
cascade of intracellular signaling SH2 or PTB domain- containing molecules leading to their 
recruitment and assembly at the receptor (Marmor and Yarden, 2004; Yarden and 
Sliwkowski, 2001). 
In addition to their role in controlling the formation of defined ErbB partners through 
selective binding to the receptors, the ErbB ligands are also regulating the binding of specific 
adaptators proteins to the docking sites of the receptor, and consequently, influencing the 
downstream cellular responses (Olayioye et al., 1998; Sweeney et al., 2000). 
 
Two major signaling pathways are activated downstream of all ErbB receptors: the Ras and 
Shc/Grb2-activated mitogen-activated protein-kinase (MAPK) pathway which is activated 
through the binding of Shc and/or Grb2 to the receptor, and the phosphatidylinositol-3-kinase 
(PI3K) pathway which is turned on following the recruitment of the p85 regulatory subunit to 
the activated receptor (Olayioye et al., 2000; Grant et al., 2002). Of note is the fact that the 
potency of the PI3K signaling differs among the homologous receptors. In fact, the p85 
subunit is directly binding to the ErbB3 receptor, consequently positioning this receptor as the 
most efficient activator of this pathway (Prigent and Gullick, 1994; Fedi et al., 1994). ErbB4 
has several isoforms that differ in their juxtamembrane and carboxyl terminal region and 
which therefore, contain or lack the PI3K binding sites (Elenius et al., 1999). PI3K activation 
is only possible if distinct isoforms are expressed. The E3 ubiquitin ligase Cbl is another 
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signaling molecule that binds preferentially to one member of the ErbB receptor family, in 
this particular case, EGFR, on a single tyrosine residue of the kinase domain. Cbl targets the 
EGFR to the lysosomal compartment, enhancing subsequent EGFR signaling downregulation 
by promoting receptor ubiquitination (Levkowitz et al., 1998). 
 
The activated intracellular signaling pathways translate into the nucleus, where many cell 
cycle regulators and transcription factors determine the biological output of ErbB activation. 
Cyclin D1, which promotes the G1/S phase cell cycle progression, is a downstream regulator 
which appears to be up regulated and stabilized upon phosphorylation (Lee et al., 2000). A 
number of transcription factors are also activated downstream of ErbB receptors, including c-
fos, c-myc, (Cutry et al, 1989) c-jun (Quantin et al., 1988), signal transducer and activators of 
transcription (STATs) (Olayioye et al., 1999), NF-kB (Biswas et al., 2000) and Ets family 
members (O’Hagan and Hassell, 1998).  
Downstream effects on the expression of these targeted genes determine the biological 
response to receptor activation, ranging from cell division, migration, adhesion, 
differentiation and survival.  
 
 
 
Figure 7. The ErbB signaling network.     From Yarden and Sliwkowski, Net Rev Mol Cell Biol, 2001 
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2.4. Endocytosis and sorting of ErbB receptors 
Endocytic removal of ligand-receptor complexes from the cell surface, and their subsequent 
sorting to degradation is a major process that regulates the amplitude of the signal induced by 
the activation of the ErbB receptors. Consistent with this paradigm, a mutant of EGFR whose 
endocytosis is impaired can deliver oncogenic signals (Wells et al., 1990). Receptor mediated 
endocytosis is a selective adsorptive uptake of specific ligand-bound membrane receptors. 
Caveolae and clathrin-coated pits are specialized in this internalization process (Waterman 
and Yarden, 2001). EGFR is rapidly internalized and degraded following activation, while 
internalization of ErbB2, ErbB3 and ErbB4 receptors is relatively slow (Baulida et al., 1996). 
Enzymatic tyrosine kinase activity has been shown to be essential for degradation of 
internalized receptors (Felder et al., 1990). Therefore, ErbB3, which is devoid of tyrosine 
kinase activity, recycles back to the plasma membrane presumably after unloading its ligand 
in an endosomal compartment (Waterman et al., 1998). Interestingly, more recent studies 
suggest a possible involvement of this endocytic pathway in the regulation of signal 
transduction through localized assembly of effector complexes, but also in the delivery of 
signaling molecules to the nucleus where these receptors enhance the induction of specific 
genes (Miaczynska et al., 2004; Lo et al., 2006; Giri et al., 2005). 
 
 
  2.5. The ErbB family: a broad and complex signaling network 
The complexity of the ErbB signaling network is based on the diversity of interactions 
between ligands, receptors, downstream signaling effectors and transcription factors that 
translate into biological responses. The nature of the EGF-like ligand composes the first level 
of diversity. In fact, the activation of specific subsets of ErbB receptors and subsequent 
biological effects depend on the identity of the EGF ligand (Beerli and Hynes, 1996). Of note 
also is the fact that ligand affinity and pH stability of the ligand-receptor complex are 
important parameters that can influence signal response (French et al., 1995; Waterman et al., 
1998). In this regard, it has been suggested that low-affinity ligands can induce a more potent 
signaling due to decreased receptor degradation and downregulation. Another level of 
diversity is achieved by the broad collection of intracellular signaling molecules which are 
recruited upon receptor stimulation and activate downstream signaling cascades, leading to a 
specific cellular response (Yarden and Sliwkowski, 2001). 
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  2.6. Transactivation of ErbB receptors by other signaling pathways 
Transactivation of ErbB receptors by different classes of membrane receptors leads to rapid 
receptor tyrosine phosphorylation and subsequent stimulation of downstream signaling 
pathways. This transactivation occurs through two different mechanisms: (i) phosphorylation 
of the ErbB receptors by other kinases, (ii) autophosphorylation in response to increased 
kinase activity. The representative example of the first mechanism is the phosphorylation of 
the cytoplasmic domains of EGFR and ErbB2 by activation of the Janus tyrosine kinase 2 
(Jak2) following binding of the growth hormone and prolactin to their respective receptors 
(Yamauchi et al., 1997; Yamauchi et al., 2000). Src is another non receptor tyrosine kinase 
shown to induce phosphorylation of EGFR (Biscardi et al., 1999). Also, integrin-dependent 
EGFR activation has been described (Moro, 1998). The second mechanism involves G-
protein coupled receptors (GPCRs) ligands, such as endothelin-1, bombesin, thrombin and 
lysophosphatidic acid which upon binding to GPCRs, induce rapid stimulation of 
metalloproteinases and cleavage of EGF-like precursors, therefore increasing ligand 
availability for ErbB receptors (Prenzel et al., 1999; Gschwind et al., 2002). Interestingly, 
ErbB receptor transactivation by GPCRs has been observed in both normal and cancer cells. 
For instance, deregulated expression of GPCRs and their ligands has been linked to tumor 
development in prostate models of cancer (Daaka, 2004). Interestingly, EGFR activation is 
well described in prostate tumors (Scher et al., 1995), indicating a possible link with GPCR 
altered expression. Another similar mechanism has been described where the binding of Wnt 
to frizzeled receptor enhanced stimulation of EGFR tyrosine kinase activity through the 
metalloproteinase-induced cleavage of EGF-like ligands in both normal and breast cancer 
cells (Civenni et al., 2003; Schlange et el., 2007). Also, another model of ErbB transactivation 
following the binding of oestradiol to the plasma-membrane-associated oestrogen receptor has 
been described (Razandi et al., 2003).  
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3. Role of ErbB receptors and their ligands in development 
  3.1. ErbB receptors in development  
  ErbB receptors are widely expressed in a number of organs and tissues. To examine their 
physiological role in vivo and gain more insight into the role of these receptors during 
development, mouse models carrying null mutations in the genes encoding these receptors 
have been created and resulted in embryonic or perinatal lethality.  
 
EGFR null mice survive for up to 20 days after birth depending on the genetic background, 
and suffered from multiorgan failure and defects in the epithelial structures of different organs 
such as skin, lung, pancreas and gastrointestinal tract (Miettinen et al., 1995; Sibilia and 
Wagner., 1995, Threadgill and al., 1995). A post natal neurodegeneration characterized by 
increased apoptosis in the cortical and thalamic regions of the brain was also observed in 
EGFR null mice (Sibilia et al., 1998). 
 
Embryos deficient in ErbB2 expression succumb during embryogenesis at day E10.5. These 
mutant embryos display an aberrant cardiac development associated with the absence of 
formation of the cardiac trabeculae (Lee and al., 1995). Interestingly, ventricular-restricted 
conditional deletion of ErbB2 resulted in a viable phenotype, however, these mice showed 
increased susceptibility for developing cardiomyopathy, highlighting a possible role of ErbB2 
in the prevention of pathologic heart dilatation (Crone et al., 2002). ErbB2 has also been 
shown to be involved in the terminal differentiation of oligodendrocytes and myelin 
development (Park et al., 2001). Also, defects in the development of neural structures, such as 
neuromuscular synapses, show the importance of ErbB2 in neural development (Lee and al., 
1995; Leu et al., 2003, Erickson et al., 1997).  
 
ErbB3 null mutation resulted in embryonic lethality at day E13.5, with appearance of cardiac 
cushion abnormalities leading to blood reflux through defective valves. In addition to cranial 
ganglia defects similar to those observed in ErbB2 or ErbB4-deficient mice, a dramatic 
reduction in neural structures suggests a general effect of ErbB3 on the neural crest. 
Abnormal development of different organs such as stomach and pancreas has also been 
described (Erickson et al., 1997).  
 
ErbB4 deficient mice also die during mid-embryogenesis at E10.5 due to aborted 
development of myocardial trabeculae in the heart ventricule. An important role for ErbB4 in 
the regulation of axon guidance in the central nervous system has been discussed (Gassmann 
et al., 1995). In addition, altered motor and behavioral activities were observed in ErbB4-
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conditional deficient mice, suggesting a role for this receptor not only in the development but 
also in neuronal function (Golub et al., 2004). 
   
  3.2. ErbB ligands in development 
 Similarly to the studies performed for ErbB receptor characterization during development, 
animal models with null mutations for the expression of the ErbB ligands have been 
developed in order to investigate their role in different organs and tissues. 
A functional role for EGF and TGF-α in prostate development has been suggested (Abbott et 
al., 2003). Also, expression of ErbB ligands such as EGF, HB-EGF and TGF-α has been 
detected in the central and peripheral nervous system where they regulate cellular functions 
such as proliferation, migration and differentiation (Xian and Zhou, 2004). Interestingly, the 
development and function of the nervous system is not significantly affected in knock-out 
TGF-α mice, however, a reduction in the number of neurons was observed in some brain 
areas (Blum, 1998; Tropepe et al., 1997). Moreover, abnormalities in the skin architecture, the 
hair and the cornea have been detected (Mann et al., 1993; Luetteke et al., 1993). A possible 
compensation for the defects in TGF-α function by other ErbB ligands has been suggested at 
different levels of development (Xian et al., 2001; Luetteke et al., 1999). In fact, in contrast to 
EGF receptor (EGFR) knockout mice, triple null mice lacking half of the EGFR ligand family 
(EGF, AR and TGF-α) were healthy and fertile, indicative of overlapping or compensatory 
functions among EGF family members. 
HB-EGF-null mice display reduced lifespan and developed severe heart failure with dilated 
ventricular chambers and enlarged cardiac valves (Iwamoto et al., 2003). Betacellulin knock-
out in mice did not affect survival and fertility, however, double null HB- EGF (-/-)/BTC (-/-) 
mice have a further reduced life span due to accelerating heart failure (Jackson et al., 2003). 
Epiregulin-deficient mice develop chronic dermatitis and defective immune-related responses 
(Shirasawa et al., 2004). 
As observed for mice defective in ErbB2 or ErbB4 expression, NRG-1 knock-out resulted in 
embryonic lethality at E10 due to defective cardiac trabeculae formation (Meyer and 
Birchmeier, 1995). In contrast, NRG-2 deficient mice survive embryogenesis without 
developing any apparent heart defect. However, an early growth retardation and reduced 
reproductive capacity were characterized (Britto et al., 2004). 
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  3.3. ErbB family in mammary gland development 
ErbB receptor signaling pathway is involved in normal mammary gland development. The 
mammary gland is a powerful model that helps to understand the potential role of the ErbB 
signaling in the adult organism. In fact, proliferation and differentiation mechanisms can be 
analyzed postnatally in this organ which undergoes extensive development from birth, where 
it consists in a rudimentary system of ducts, to puberty, where it develops under the influence 
of hormones and finally to pregnancy, when lobulo-alveolar proliferation occurs, followed by 
lobulo-alveolar-produced milk secretion (Hennighausen and Robinson, 1998).  
 
ErbB receptors: All four ErbB family receptors are expressed in the mammary gland of adult 
females, but EGF receptor and ErbB-2 are preferentially expressed in young females 
(Sebastian et al., 1998) (Troyer and Lee, 2001).. Interestingly, the expression of the ErbB 
receptors in this organ is cell-type and developmental stage specific (Schroeder and Lee, 
1998; Darcy et al., 2000). In fact, in the first postnatal episode of mammary development 
which occurs at puberty, EGF receptor and ErbB-2 are present and are tyrosine-
phosphorylated, which is indicative of signaling activity (Sebastian et al., 1998; Schroeder 
and Lee, 1998). Hence, EGFR and ErbB2 seem to play a role at puberty, but also during late 
pregnancy and lactation, while ErbB3 and ErbB4 mostly act during pregnancy and lactation. 
The analysis of the role of ErbB receptors on the mammary gland development was not 
possible due to embryonic or early lethality.  Consequently, other approaches such as 
dominant-negative (DN) receptor expression or reconstitution experiments were performed in 
order to elucidate the role of these receptors in this particular event.  DN- ErbB2 or ErbB4 
expressing transgenic animals display normal ductal outgrowth. However, defective lobulo-
alveolar development and reduced milk secretion were observed in these strains (Jones and 
Stern, 1999; Jones et al., 1999). In contrast, transgenic experiments using DN EGFR (Xie and 
al., 1997) or reconstituted EGFR-/- neonatal mammary gland (Wiesen et al., 1999), resulted in 
abnormal ductal outgrowth. 
 
ErbB ligands: numerous EGF ligands are expressed at various phases of mammary 
development, where they act on proliferation and differentiation (Sebastian et al., 1998; 
Schroeder and Lee, 1998). HRG-α has been show to be the only HRG isoform expressed in 
the mouse mammary gland. Severe defects in the development of the mammary gland lobulo-
alveolae together with impaired lactogenesis were detected in HRG-α deficient mice (Li et 
al., 2002). In addition, mice with individual targeted disruption of EGF, AR, and TGF-α as 
well as triple null mice have been generated. Consistent with the abundant expression levels 
of AR in the mammary gland (Kenney et al., 1995), this ligand has been identified, among the 
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three of them, as a particularly important regulator of ductal outgrowth and lactation (Ciarloni 
et al., 2007). Indeed, AR knock out mice display an aberrant elongation of mammary ducts, 
pointing out the absence of functional redundancy of ErbB ligands in this particular process. 
Moreover, triple knock out mice lacking expression of AR, EGF and TGF-α showed aberrant 
mammary alveolar growth and reduced milk production. Furthermore, disruption of the AR 
gene also resulted in a significant impairment of activation of Stat5, which is an important 
mediator of mammary development that regulates production of milk proteins (Luetteke et al., 
1999). Importantly, a possibly significant role for AR in driving human breast cancer 
progression has been suggested (McBryan et al., 2008). 
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4. ErbB family and cancer 
Receptor tyrosine kinase activity is tightly controlled in normal cells. However, when they are 
mutated or structurally altered, RTKs become potent oncoproteins. In fact, the development 
and progression of many human cancers has been correlated with abnormal activation of these 
receptors that consequently, have become rational targets for therapeutic intervention.  
 
  4.1. Deregulation of ErbB signaling in human cancer 
Different mechanisms leading to deregulation of the ErbB pathway have been reported; in 
fact, hyperactivation can be induced by either autocrine or paracrine overproduction of 
ligands, overexpression or constitutive activation of the receptors due to mutation. Also, 
impaired receptor downregulation is another described mechanism of RTK deregulation that 
could play a significant role in the pathogenesis of cancer (Peschard and Park, 2003).                            
                   
EGFR in cancer: Overexpression and structural alterations of EGFR are frequent in human 
malignancies. In fact, amplification of the EGFR has been detected in a majority of carcinoma 
types (Normanno et al., 2003; Sibilia et al., 2007). In lung carcinomas, high levels of 
expression of EGFR have been associated with poor prognosis (Veale et al., 1993). However, 
a real correlation between EGFR expression and patient prognosis is still under debate. 
Interestingly, different studies suggest that EGFR overexpression requires ligand binding to 
induce receptor activation (Di Fiore et al., 1987). Accordingly, the relationship between co-
expression of ErbB ligand/EGFR and tumorigenesis has been described (Salomon et al., 1995; 
Nicholson et al., 2001). Also, several deletions and point mutations resulting in increased 
catalytic tyrosine kinase activity of the receptors have been characterized. One frequent 
EGFR mutation is the EGFR vIII form (Voldborg et al., 1997) that is distinguished by a large 
deletion of the extracellular domain and results in a constitutive activation of the receptor. 
This mutation has been frequently found in gliomas, but also to a less extent in breast, 
ovarian, and lung carcinomas (Pedersen et al., 2001). Furthermore, in frame deletions or point 
mutations in the tyrosine kinase domain of the EGFR have been identified in non-small cell 
lung cancer (NSCLC) (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004).  
 
ErbB3 in cancer: High expression of ErbB3 has been detected in certain human cancers, 
highlighting this ErbB member as a potential therapeutic target (Gullick, 1996). However, due 
to its impaired tyrosine kinase activity, ErbB3 is not a direct target of kinase inhibitors. 
Considering that ErbB3 is a positive regulator of the ErbB network (Citri and Yarden, 2006), 
impaired signaling downstream of this receptor is prone to lead to tumorigenesis. For 
instance, an increasing body of evidence shows that ErbB3 plays a critical role in EGFR- and 
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ErbB2-driven tumors (Hsieh and Moasser, 2007). In addition, the levels of expression of 
ErbB3 are generally comparable to EGFR. In ovarian and prostate cancer, ErbB3 is 
overexpressed and associated with poor prognosis (Tanner et al., 2006; Myers et al., 1994, 
respectively). Increased expression of ErbB3 has also been detected in primary human breast 
cancers (Lemoine et al., 1992), but also in diverse gastrointestinal cancers (Maurer et al., 
1998; Slesak et al., 1998) and in human squamous cell carcinomas (Funayama et al., 1998). 
The prognostic role of this receptor in human carcinomas is still under debate. 
 
ErbB4 in cancer: Neuregulins, betacellulin and heparin-binding EGF-like growth factor are 
binding to and activating ErbB4, leading to cellular proliferation, chemotaxis or 
differentiation (Carpenter, 2003). Although the structure and mechanism of action of ERBB4 
are similar to those of other ERBB members, relatively little is known about the general or 
specific roles ERBB4 in the development of human tumors. However, high expression levels 
of ErbB4 have been reported in thyroid (Haugen et al., 1996), breast (Srinivisan et al., 2000), 
ovarian (Furger et al., 1998), endometrial (Srinivisan et al., 1999) and oral squamous cell 
cancer (Bei et al., 2001), as well as in medulloblastoma (Gilbertson et al., 1997), 
ependymoma (Gilbertson et al., 2002), and osteosarcoma (Hugues et al., 2004). Interestingly, 
ErbB4 expression has been shown to be down-regulated in prostate (Lyne et al., 1997), renal 
(Thomasson et al., 2004) and pancreatic (Graber et al., 1999) cancer. In addition, the 
significance of ErbB4 expression levels for clinical outcome is still unclear. Of note however 
is the prognostically-favourable ER phenotype associated with ErbB4 overexpression in 
breast cancer (Knowlden et al., 1998). 
 
ErbB ligands in cancer: EGF-like ligands have been detected in a majority of human 
carcinomas (Normanno et al., 2001). For instance, overexpression of TGF-α has been 
observed in many tumors (Salomon et al., 1995) such as breast carcinomas or colon adenomas 
(Révillion et al., 2008; Habel et al., 2002), where a potential role for this growth factor in the 
early phases of tumorigenesis has been suggested. AR and HB-EGF have also been associated 
with several types of human cancer (Yotsumoto et al., 2008). In particular, a strong 
correlation between AR overexpression and rapidly growing keratinocytic tumors was 
purposed (Billings et al., 2003). Expression of AR was also shown to be up regulated in 
human hepatocellular carcinoma tissues and cell lines (Castillo et al., 2006). An important 
role for AR in breast cancer progression is also described (Willmarth and Ethier, 2008). 
Overexpression of HB-EGF has been observed in several tumors (eg, liver, pancreatic, colon, 
gastric, breast, and esophageal tumors) and HB-EGF has been implicated in tumor 
progression, increased proliferation, and metastasis (Raab and Klagsbrun, 1997; Ito et al., 
2001; Miyamoto et al., 2004). Neuregulins may also play a role in human malignancies. Their 
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expression has been mainly investigated in breast cancer where NRG are detected in about 
25-30% of human primary breast carcinomas (Normanno et al., 1995). NRG are also shown 
to be involved in other types of cancer such as ovarian, endometrial, colon, gastric, lung, 
thyroid, glioma, medulloblastoma, melanoma as well as head and neck squamous carcinoma 
(Breuleux, 2007). 
 
 
  4.2. Focus on the role of ErbB2 in cancer and metastasis 
 In 1985, the complete primary sequence of a putative RTK that showed a high level of 
homology to both the human EGFR product and the v-erbB oncogene, was described; this 
receptor was therefore named human EGFR-related 2 (HER2) (Coussens et al., 1985). 
Another independent study identified this new EGFR relative and named it ErbB2 (King et 
al., 1985). Interestingly, the chromosomal location of the gene for this protein was similar to 
the neu oncogene, an erb-B-related gene present in rat neuron/glioblastomas (Schechter et al., 
1984). Importantly, in 1987, the HER2 gene was found to be amplified in 25 to 30 percent of 
invasive breast cancers.  For the first time, a significant correlation between the 
overexpression of the HER2/neu oncogene in tumors and reduced patient relapse and survival 
was advanced (Slamon et al., 1987; Berger et al., 1988). As identified for breast cancers, 
HER2/neu was also shown to be involved in the pathogenesis of different human cancers such 
as ovarian cancer (Slamon et al., 1989), colon cancer (Cohen et al., 1989) and non-small cell 
carcinomas of the lung (Weiner et al. 1990). Since this discovery, ErbB2 has been intensely 
studied in order to understand not only its role in cancer biology, but also and very 
importantly, as a therapeutic target (Hynes and Lane, 2005). 
 
 
       4.2.1. ErbB2: the preferred heterodimerization partner 
ErbB2 is widely expressed in normal human organs and tissues, including ovarian epithelium, 
endometrium, heart, lung, prostate, kidney, pancreas, and liver. ErbB2 encodes an 185kDa 
orphan receptor tyrosine kinase for which no direct ligand inducing homodimerization has 
been identified. Therefore, its role within the cellular network was largely unknown until 
1988, when EGFR was shown for the first time to induce transactivation of ErbB2 through 
heterodimerization (Stern and Kamps, 1988). The ErbB2 receptor can mediate the lateral 
signal transduction of all ErbB receptors (Carraway et al., 1994; Graus-Porta et al., 1997; 
Plowman et al., 1993). Therefore, activation of ErbB2 is highly dependent on the expression 
of other family members, to which it is recruited as a preferred heterodimeric partner (Graus-
Porta et al., 1997). Alternatively, overexpression and/or mutation of ErbB2 lead to 
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constitutive activation of ErbB2 and spontaneous dimerization and stabilization of the homo-
dimeric complex in a ligand-independent manner (Hynes and Stern, 1994).  
 A major coordinating role in the ErbB network is proposed for ErbB2 (Graus-Porta et al., 
1997); in fact, ErbB2 enhances and stabilizes the dimerization with another ErbB partner 
(Olayioye et al., 1998), leading to the formation of ErbB2-containing heterodimers 
characterized by extremely high signaling potency (Tzahar et al., 1996). Indeed, ErbB2 
strongly reduces the rate of ligand dissociation, therefore allowing potent and prolonged 
activation of downstream signaling pathways (Sliwkowski et al., 1994).  
Furthermore, the ErbB2 receptor can be involved in the regulation of a variety of vital 
functions controlled by the ErbB-receptor family members, such as cell growth, 
differentiation, and apoptosis (Schlessinger, 2000).  
 
 
       4.2.2. ErbB2 overexpression and cancer metastasis 
ErbB2 is overexpressed in breast, cervix, colon, endometrial, esophageal, lung, and pancreatic 
cancers (Blume-Jensen and Hunter, 2001; Salomon and al., 1995; Yarden and Sliwkowski, 
2001). Studies of patients with ErbB2-overexpressing tumors have shown that they have a 
significantly poorer clinical outcome compared to patients whose tumors do not overexpress 
ErbB2 (Berchuck et al., 1990; Slamon et al., 1987; Slamon et al., 1989). Two major 
mechanisms underlie ErbB2-overexpression mediated poor clinical outcome. On the one 
hand, overexpression of ErbB2 enhances cellular properties such as invasion, angiogenesis, 
and increased survival of cancer cells, leading to increased cancer metastasis. On the other 
hand, overexpression of ErbB2 confers increased resistance of cancer cells to various cancer 
therapies (chemotherapeutic agents, hormones, γ-radiation and cytokines) that will result in 
poor response to cancer treatment. 
 
The metastatic process: a therapeutic target for cancer.  
 Metastasis is the major driver of mortality in patients with cancer. Many cancers at the 
primary site are effectively controlled by surgery and radiation therapy. However, the 
development of metastatic disease correlates with a poor prognosis. Most metastatic lesions 
are not treated by surgery, but rather by chemotherapy, hormonal therapy, and radiation that 
serve palliative purposes in the metastatic development and sometimes lead to a significant 
extension of survival time. 
Tumor metastasis consists of a series of biological processes that move tumor cells from the 
primary neoplasm to a distant location (Figure 8). Tumor cells invade the tissue surrounding 
the primary tumor, enter either the lymphatics or the bloodstream where they must survive 
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and eventually arrest in the circulation, then extravasate into a tissue and grow at the new site 
(Steeg, 2006).  
 
 
                    
                                                            Adapted from Bacac and Stamenkovic, Annu Rev Pathol, 2008 
Figure 8. The tumor metastatic process. Transformation of normal epithelial cells leads to carcinoma 
in situ. At the primary tumor site, tumor cells invade into the lymphatics or directly into the circulation. 
Once in the bloodstream, tumor cells must survive and avoid immune attack to extravasate. Arrest is 
most often by size restriction in capillary beds but can involve specific adhesive interactions. The 
process by which tumor cells form micrometastases and then progressively growing, vascularized 
macrometastases in a distant organ is termed metastatic colonization. Metastatic colonization involves 
reciprocal interactions between tumor cells and cells in the microenvironment of the distant organ, and 
can pause for periods of dormancy. 
 
 
Invasion 
Invasion is the first step of the metastatic process. To invade the surrounding tissue, adhesion 
properties of cancer cells are modified. Cadherins mediate tumor cell-cell adhesion (Cavallaro 
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and Christofori, 2004), while tumor cell-extracellular matrix (ECM) adherence is mediated by 
integrins (Guo and Giancotti, 2004). Matrix metalloproteinases (MMPs), cathepsins and 
serine proteases at the cell surface induce proteolytic degradation of the surrounding tissue 
(Friedl and Wolf, 2003; Folgueras et al., 2004; Overall and Kleifeld, 2006). Tumor cell 
migration through the tissue is a dynamic mechanism involving the polarized extension of 
protrusions at the leading edge of the cell, translocation of the cell body, and cell contraction 
inducing migration through the tissue. In a tumor setting, chemokines and chemotactic 
cytokines induce cell migration (Balkwill, 2003; Wilson and Balkwill, 2002). Activation of 
cell migration may be also cell autonomous or may involve paracrine loops with cells in the 
environment (Goswami et al., 2005). Receptor tyrosine kinase interaction with integrins 
stimulates the formation of a focal adhesion kinase (FAK)-Src complex (McLean et al., 2005; 
Mclean et al., 2004; Mitra et al., 2005; Playford and Schaller, 2004). Downstream cellular 
changes in invasion are triggered by sequential binding of protein cascades to FAK (Steeg, 
2006).  
 
Survival and arrest in the bloodstream  
Beyond survival in the bloodstream which is a harsh environment, metastasizing tumor cells 
must arrest in the circulatory system. The generally accepted model of arrest and 
extravasation is that a proportion of cells nonspecifically arrest by binding coagulation factors 
and by size restriction in the capillary beds (Weiss et al., 1986). Tumor cells extravasate by 
attaching to the subendothelial ECM, followed by reformation of the capillary (Al-Mehdi et 
al., 2000). 
 
Metastatic colonization 
Breast, prostate carcinomas and multiple myeloma metastasize to bone. Brain metastases are 
most common in individuals with lung and breast cancer, and are also frequent in individuals 
with melanoma. The majority of metastasis assays measure lung metastases. (Steeg, 2006).  
Growth of metastases in a tissue requires blood supply, which provides oxygen, growth 
factors, nutrients and metabolites. Angiogenesis is the formation of a new blood supply from 
preexisting vasculature (Rak and Yu, 2004; Hicklin and Ellis, 2005). Multiple factors 
stimulate endothelial cells to induce angiogenesis including vascular endothelial growth factor 
(VEGF), angiopoietin, ephrin (Eph), platelet-derived growth factor (PDGF), transforming 
growth factor (TGF)-  and basic fibroblast growth factor (bFGF) families. VEGF is the best 
studied and has advanced as a molecular target through clinical approval of VEGF inhibitors 
(Leung et al., 1989; Yang et al., 2003; Cobleigh et al., 2003; Motzer et al., 2006; Weis et al., 
2005).  
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Finally, many pathways involved in cell survival and resistance to cell death have been shown 
to promote metastasis and/or survival of cells after extravasation into the distant organ (Yu 
and Stamenkovic, 2004; Wong et al., 2001).  
 
 
 
The contribution of ErbB2 overexpression to increased metastatic potential of cancer cells is 
evident from a number of studies. In fact, a correlation between the number of lymph node 
metastases and ErbB2 overexpression has been established in positive breast cancer patients 
(Slamon et al., 1987; Slamon et al., 1989).  Furthermore, experiments using transgenic mice 
showed that introduction of the erbB2 gene into mice can induce mammary tumors and 
metastases (Guy et al.,1992; Suda et al., 1990). In addition, expression of activated rat Neu 
oncogene in 3T3 cells was shown to be sufficient to induce metastasis in nude mice (Yu and 
Hung, 1991). Also, overexpression of p185 ErbB2 enhanced the metastatic potential of 
human breast and lung cancer cells (Tan et al., 1997; Yu et al., 1994). Moreover, ErbB2 
overexpression can up-regulate MMP-9 and MMP-2 protease activities and increase the 
invasiveness of breast cancer cells (Tan et al., 1997; Kossakowska et al., 1996). An increase 
in VEGF expression was also found in breast ErbB2 overexpressing cancer cells suggesting 
an enhanced angiogenic response (Petit et al., 1997). Additionally, ErbB2 overexpression 
confers resistance to apoptosis of breast cancer cells (Yu and al., 1998).  Altogether, up 
regulation of matrix metalloproteinases, enhanced angiogenesis and resistance to apoptosis 
are factors that contribute to increased metastatic potential.  
The molecular signaling mechanisms that are responsible for ErbB2-mediated cancer 
metastasis are under investigation. Multiple ErbB2 downstream signals (e.g., Shc/Grb-2-Ras, 
PI3K-Akt, MEK-ERK, JNK, p38MAPK, PKC, PLC etc…) may be involved in inducing a 
variety of metastasis-related properties that can contribute to higher metastatic potential of 
ErbB2-overexpressing cancer cells. Understanding and further manipulation of the signal 
transduction networks that are critical for ErbB2-mediated metastasis should facilitate the 
development of novel anti-metastatic therapies for ErbB2-overexpressing cancers. 
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5. The ErbB network as a target for cancer therapy 
ErbB receptors are important mediators of growth factor signaling, cell proliferation, cell 
survival and cell migration, important processes that are involved in the development of 
malignancy. Aberrant activation of the ErbB receptors has been described in a wide number 
of human tumors, making the ErbB receptor family an important therapeutic target for 
selective anticancer therapies. Both academic and industrial researches are focusing on 
evaluating ErbBs as promising molecular targets for cancer treatment. Neutralizing 
antibodies, which block the bioactivity of RTK ligands, ErbB-targeted antibodies, which 
either target overexpressed receptors or receptor heterodimerization, and small molecule 
inhibitors of receptor tyrosine kinase activity have been developed to interfere with ErbB 
signaling. Owing to their increased expression in many tumor types, EGFR and ErbB2 have 
become very attractive targets for pharmacological intervention. 
 
Two major therapeutic strategies are used in clinical or at advanced developmental stages to 
target the ErbB receptor family of RTK: inhibition of the tyrosine kinase (catalytic) domain 
with small molecules called TKIs, or targeting the extracellular domain of the receptors with 
monoclonal antibodies (Strome et al., 2007). Many of the intracellular pathways that are 
essential for cancer development and progression such as PI3K-AKT, MAPK, SRC and 
STAT signaling are affected by the treatment of tumor cells with these compounds (Hynes 
and Lane, 2005; Yu and Jove, 2004; Sliwkowski, 1999; Petit et al., 1997; Lane et al., 2000; 
Nagata et al., 2004). To note is the fact that toxicity of ErbB-directed therapeutics is related to 
their physiological roles (Hynes and Lane, 2005).  
 
Antibody approach: EGFR and ErbB2 are currently considered as molecular targets for 
immunological cancer therapy (Friedlander et al., 2008).  
- ErbB2 has been successfully targeted by the humanized monoclonal antibody Trastuzumab 
(Herceptin) in breast cancers where it is overexpressed (Yeon and Pegram, 2005) (Perez and 
Baweja, 2008). In addition to its binding to the extracellular domain of ErbB2 and 
antagonizing function, Herceptin induces the cyclin-dependent kinase inhibitor p27Kip1 and 
the Rb-related protein p130, which in turn significantly reduce the number of cells undergoing 
S phase. Furthermore, interaction of Herceptin with the human immune system via its human 
immunoglobulin G1 Fc domain may potentiate its antitumor activities (Sliwkowski, et al., 
1999). Herceptin has been approved for clinical use in metastatic breast cancer, both alone or 
in combination with chemotherapeutic agents. However, little or no effectiveness against 
cancers such as prostate (Ziada et al., 2004), pancreas (Safran et al., 2004), colon and rectum 
(Ramanathan et al., 2004), or lung epithelia (Clamon et al., 2005) has been observed.  
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Pertuzumab is a recombinant humanized monoclonal antibody (rhuMab 2C4) that binds to the 
extracellular domain II of the ErbB2 receptor and blocks its ability to dimerize with other 
ErbB receptors. It is one of the first in a new class of targeted therapeutics known as HER 
dimerization inhibitors (Agus et al., 2005) (Attard et al., 2007) that is in phase II/III of clinical 
trials for the treatment of ovarian, breast, prostate cancer, NSCLC and low ErbB2 expressing 
tumors.  
MDX-H210, another targeting ErbB2 antibody, is in phase I of clinical trial for the treatment 
of advanced breast cancer. Ertumaxomab also targets ErbB2 and is in phase II against 
advanced metastatic breast cancer (Kiewe et al., 2006). The scFvFRP5 toxin fusion directed 
against ErbB2 is in phase I/II for the treatment of metastatic breast, prostate, head and neck, 
NLCSC and transitional cell carcinoma (Azemar et al., 2003; von Minckwitz et al., 2005) 
 
- EGFR is being targeted with the monoclonal chimeric anti-EGFR IgG1 antibody Cetuximab 
which has been approved for the treatment of metastatic colorectal cancer as single agent or in 
combination with chemotherapy, in locally and regionally advanced head and neck squamous 
cell carcinoma in combination with radiation, and as monotherapy for recurrent and 
metastatic head and neck squamous cell carcinoma after failing platinum-based chemotherapy 
(Vincenzi et al., 2008). Other humanized mAb targeting EGFR are in clinical trials, such as 
Matuzumab (Schmiedel et al., 2008; Seiden et al., 2007; Kim, 2004) for the treatment of 
NSCLC, gynaecological, pancreatic and oesophageal cancers and Panitumumab for the 
treatment of metastatic colorectal cancer, renal cell cancer and NSCLC (Giusti et al., 2007). 
Nimotuzumab (Arteaga et al., 2007; Spicer, 2005) is another mAb targeting EGFR that has 
been approved for the treatment of head and neck cancer, and is in phase I of clinical trial for 
the treatment of pancreatic cancer. A number of other mAbs targeting EGFR are being 
studied in phase I clinical trial such as ch806 (Scott et al., 2007) and MDX-447 (Fury et al., 
2008).  
 
Combinations with radiopharmacons, peptide toxins, anticancer drugs, or drug-loaded 
liposomes are also tested to target the ErbB receptors (Friedlander et al., 2008).  
 
 
Low molecular weight inhibitors approach: Inhibitors that block the activity of tyrosine 
kinases and the signaling pathways they activate provide a useful basis for drug development. 
(Levitzki and Gazit, 1995). Both reversible and irreversible inhibitors have been developed. 
- EGFR is targeted with two low molecular weight ATP-competitive tyrosine kinase 
inhibitiors, Gefitinib and Erlotinib (Baselga and Arteaga, 2005). Several types of epithelial 
cancer with mutated or highly expressed EGFR have successfully been treated, including 
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head and neck, pancreatic, colorectal and a subset of NSCLC (Mendelsohn and Baselga, 
2006). 
Lapatinib is a dual (ErbB-1 and ErB-2) receptor tyrosine kinase inhibitor (TKI) that was 
recently approved for the treatment of advanced breast cancer (Mukherjee et al., 2007). 
AEE788 (Kuwai et al., 2008; Oehler-Jänne et al., 2007) and EXEL 7647/ EXEL 0999 (Trowe 
et al., 2008) are in clinical development and both target EGFR/ErbB2 and VEGFR. CI-1033 
and EKB-569 are irreversible TKIs which target EGFR/ErbB2 and for which phase II trials 
are underway in NSCLC (Jänne et al., 2007; Erlichman et al., 2006). 
 
 
In contrast to their receptors, the ligands of the EGF family of growth factors have not yet 
been considered as targets for cancer therapy. This can be explained because of the 
redundancy of EGFR ligands for each receptor, which has led to a general consensus that 
inhibiting receptor function is more effective than inhibiting multiple ligands for cancer 
therapy. However, EGFR ligands may be considered as valuable target molecules for cancer 
therapy (Yotsumoto et al 2008). For instance, HB-EGF has been proposed as a promising 
target for ovarian cancer (Miyamoto et al., 2004). 
 
 
However, despite the broad development of ErbB-directed cancer therapy, multiple 
mechanisms appear to contribute to allow tumor cells to escape from the ErbB-targeted 
therapeutics. The concept of targeting several kinases using agents with dual activity, or using 
combination strategies has emerged (Hynes and Lane, 2005).  
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B. Cell migration: integrating signals from the front to the back 
 
1. Cell migration: a central process in the development and 
maintenance of uni and multicellular organisms 
Cell migration is a vital cellular response that plays a critical role during the life cycle of 
simple, uni-cellular organisms such as amoeba and of complex multi-cellular organisms such 
as mammals. In simple organisms, its main functions comprise mating and the search for 
food (Manahan et al., 2004). In multicellular organisms, specialization requires cell 
migration-mediated tissue organization, organogenesis and homeostasis (Ridley et al., 2003). 
Directed cell movement accompanies human life from conception to death. During 
embryogenesis, proper tissue formation requires complex patterns of cell migration. In adult 
life, wound healing which involves the migration of different cell types, including 
leucocytes, is required for the development of immune responses. Cell movement is also 
seen during remodeling of the vascular system in mature organisms. Finally, cell migration 
also occurs in diverse diseases, like in various chronic inflammatory and vascular diseases or 
in cancer where it leads to invasion and metastasis.  
   
 
  1.1 Cell migration in embryonic development 
The cell migration process orchestrates morphogenesis throughout embryonic development. 
Gastrulation is the morphogenetic process in embryos of multicellular organisms by which 
the future mesoderm and endoderm move inside the ectoderm to form a three-layered 
embryo, consisting of the ectoderm on the outside, the endoderm on the inside, and the 
mesoderm between these two layers (Lu et al., 2001). During gastrulation, large groups of 
cells migrate individually or collectively as sheets to form this resulting three-layered 
embryo. The collective migration includes coordinated changes in cell shape and coordinated 
rearrangements (Keller, 2005). Following this three-layer formation, cells migrate to target 
locations where they differentiate to form the specialized cells that constitute the different 
tissues and organs (Locascio and Nieto, 2001). In fact, cell movement plays a critical role in 
the formation of the nervous system (Suzuki, 2007; Marín and Rubenstein, 2001) and 
organogenesis (Hogan and Kolodziej, 2002).  
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  1.2 Cell migration during adult life 
Cell migration is important in homeostatic processes such as immunity or wound healing. In 
fact, cell motility is a prominent component of immune surveillance that is mediated by 
leukocytes which migrate into the surrounding tissue to destroy invading microorganisms, 
debris and infected cells (Sànchez-Madrid and del Pozo, 1999). Leukocyte migration is 
controlled by a number of known attractants such as the extensive family of chemokines that 
are released by leucocytes and other cells in response to different stimuli, and mediate 
inflammation (Luster, 1998; Luster et al., 2005). Coordinated cellular movements also 
underlie response and repair of injured tissues during wound healing (Martin, 1997). 
Furthermore, cell migration is important during renewal of skin and intestine, where fresh 
keratinocytes or epithelial cells migrate up from the basal layer and the crypts, respectively 
(Fuchs and Raghavan, 2002; Heath, 1996).  
 
 
 
  1.3 Cell migration and disease 
The cell migration process exhibits so many regulatory steps that many deficiency can impair 
or enhance cell migration, thus contributing to numerous pathological processes. At the initial 
steps of embryonic and fetal development, impairment of regulators of cell motility can lead 
to the failure of blastocyst implantation into the uterus or to malformed embryos with 
disorganized tissues (Stephens et al., 1995; Dominguez et al., 2005). A number of congenital 
abnormalities in brain development, such as epilepsy (Frotscher et al., 2003), neurological 
deficits (Givogri et al., 2006), mental retardation (Thelen et al., 2002), and also heart 
development defects (Davis and Katsanis, 2007), derive from deregulated cell migration 
processes. Chemotaxis has also been linked with pathological disorders such as osteoporosis 
(Susva et al., 2000), vascular diseases (Roque et al., 2002), or chronic inflammatory diseases 
such as rheumatoid arthritis and multiple sclerosis (Hilden et al., 2006). Importantly, cell 
migration plays a critical role in cancer where it contributes to the formation of metastasis 
(Yamaguchi et al., 2005; Kedrin et al., 2007). In fact, the initial step in tumor metastasis 
requires chemotactic migration of cancer cells that invade the surrounding tissue and the 
lymphatic and blood vasculature which they subsequently leave and migrate into another site 
(Chambers et al., 2002; Friedl and Wolf, 2003; Steeg and Theodorescu, 2008). 
Accordingly, the studies on the fundamental mechanisms underlying the migratory process 
should yield promising advances for the development of effective therapeutic approaches for 
the treatment of migration-related disorders.  
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2. Cell migration: a cyclic process 
The current model of cell migration is derived from diverse studies performed on a wide 
number of migratory cell types and environments. As an example, cancer cells have a broad 
spectrum of migration and invasion mechanisms that include both individual and collective 
cell migrations strategies (Friedl and Wolf, 2003). As a general description, cell migration can 
be viewed as a physically integrated molecular system consisting in a sequence of coordinated 
steps which act in a cycle (Lauffenburger and Horwitz, 1996). The initial response of a cell to 
a migration-inducing agent is a morphological polarization and extension of a directed 
protrusion. These protrusions are stabilized by formation of cell adhesions to the extracellular 
matrix (ECM) or to adjacent cells. These cell-substratum adhesions serve as anchoring sites 
for cell body contraction and movement. In the last step of the migratory process, cell 
adhesions disassemble, resulting in a rear cell detachment.  
Chemotaxis defines the ability of a cell to sense spatial heterogeneities in the concentration of 
extracellular chemoattractants and to respond by polarizing and migrating toward the source 
of stimulation (Iglesias and Devreotes, 2008). 
        
                                   
                                                                                                                  Adatped from Ridley et al., 2003 
                                                           Figure 9. Steps in cell migration                                         
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  2.1 The first step: directional sensing and polarization 
Chemotactic models, such as Dictyostelium discoideum that has the advantage of being a 
genetically and biochemically tractable organism, have been intensely studied to uncover the 
general principles by which cells sense asymmetric environmental stimuli (Chung et al., 2001; 
Iijima et al., 2002; Iijima et al., 2004). The molecular mechanisms of chemotaxis are highly 
conserved between mammalian cells and the Dictyostelium discoideum amoebae (Devreotes 
and Zigmond, 1998; Franca-Koh et al., 2006).  
Directional sensing refers to the ability of a cell to detect an asymmetric extracellular signal 
and generate an internal amplified response (Parent and Devreotes, 1999; Iglesias and 
Levchenko, 2002). When cells are exposed to external gradients of chemoattractant, signaling 
molecules accumulate at the membrane and locally initiate the downstream signaling 
response. Polarization refers to the ability of a cell to assume an asymmetrical shape with a 
defined leading and trailing edge with distinct sensitivities for chemoattractants 
(Huttenlocher, 2005). Signals from the environment, including chemoattractants, growth 
factors and extracellular matrix, regulate cell polarization through the spatially controlled 
recruitment of signaling complexes that modulate the actin cytoskeleton and mediate the 
extension of membrane protrusions at the leading edge. Although directional sensing does not 
require actin polymerization, polarization depends critically on a signal input as well as on a 
reorganization of the cytoskeleton.  
In both neutrophils and Dictyostelium discoideum models, PtdIns(3,4,5)P3 has emerged as an 
important player of this first chemotactic step (Funamoto et al., 2001; Curnock et al., 2002; 
Charest and Firtel, 2006; Franka-Koh et al., 2007). In fact, upon gradient sensing in 
Dictyostelium discoideum, receptor-mediated activation of heterotrimeric G-proteins 
(Janetopoulos et al., 2001; Xu et al., 2005) enhances intracellular signaling activation with a 
graded activation of Ras-family small G proteins (Kae et al., 2004). PI3K that contain a Ras 
binding domain, is subsequently recruited to the plasma membrane (Sasaki et al., 2004), 
where the cell is exposed to a higher concentration of chemoattractant. This leads to the local 
activation and production of PtdIns(3,4,5)P3 with localized accumulation of PtdIns(3,4,5)P3 
on the side of the cell facing the highest chemoattractant concentration. This polarized 
PtdIns(3,4,5)P3 response is generated through the differential local regulation of PI3K, which 
produces PtdIns(3,4,5)P3 by phosphorylating PtdIns(4,5)P2, and the PtdIns 3-phosphatase 
PTEN (phosphatase and tensin homologue deleted on chromosome ten), which 
dephosphorylates PtdIns(3,4,5)P3 back into PtdIns(4,5)P2. PTEN is then located at the 
membrane at the lateral sides and at the trailing edge of the cell where it degrades any 
PtdIns(3,4,5)P3 that might either diffuse laterally from the leading edge or be produced along 
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the lateral sides of the cell, thus restricting the polarized accumulation of PtdIns(3,4,5)P3 
(Huang et al., 2003; Iijima and Devreotes, 2002; Funamoto et al., 2002).  
This role for local PI(3,4,5)P3 in polarity and directional sensing appears to be conserved 
throughout phylogeny in cells such as D. melanogaster hemocytes, human neutrophils and 
fibroblasts, neurons, and a variety of embryonic cells (Stramer et al., 2005; Wang et al., 2002; 
Wu et al., 2000; Schneider and Haugh, 2005; Chadborn et al., 2006; Montero et al., 2003).  
 In multiple studies performed on different types of motile cells, including leucocytes, 
Dictyostelium, primary dendritic cells and fibroblasts, local polymerization of F-actin 
(filamentous actin) has been shown to be guided by chemoattractant-induced localized 
PtdIns(3,4,5)P3 signaling (Affolter and Weiger, 2005). 
 
In mammalian cells, directional sensing and polarization appear to be mediated by a set of 
interlinked positive feedback loops involving Rho family GTPases, PI3K, integrins, 
microtubules and vesicular transport (Ridley et al., 2003). At the rear of the cell, Myosin II 
and PTEN regulate polarity by restricting protrusions to the cell front (Vicente-Manzanares et 
al., 2007; Liliental et al., 2000). Cdc42 (cell division cycle 42) is an active regulator of cell 
polarity towards the front of a migrating cell (Itoh et al., 2002). Cdc42 defines the location 
and stability of the leading edge (Srinivasan et al., 2003), and along with Par proteins and 
aPKC, Cdc42 regulates the microtubule-organizing center (MTOC) and Golgi apparatus 
reorientation in front of the nucleus, facing the direction of the leading edge (Palazzo et al., 
2001; Etienne-Manneville and Hall, 2003). Activation of Cdc42 is mediated by PAK1 (p21-
activated kinase 1) (Li et al., 2003). Also, interaction of integrins with the extracellular matrix 
at the newly formed cell front was shown to induce activation and polarized recruitment of 
Cdc42 (Etienne-Manneville and Hall, 2001). In neutrophils, in addition to Rac activation at 
the leading edge of the cell (Gardiner et al., 2002), Gβγ-dependent activation of Cdc42 has 
been shown to be required for directional sensing (Li et al., 2003) Also, it has been proposed 
that neutrophil rear localization and activation of PTEN may involve phosphorylation by Rho 
kinase in a Rho-dependent manner (Li et al., 2005). Microtubules may also play a role in 
directed neutrophil migration via inhibition of the Rho GTPase (Xu et al., 2005). Also in other 
mammalian models, the Rho-mDia1 pathway is reported to regulate polarization by aligning 
microtubules and actin filaments and delivering Apc/Cdc42 to their respective sites of action 
(Yamana et al., 2006). In adenocarcinoma cells, Ras was also shown to be required for 
PtdIns(3,4,5)P3  and lamellipodium production (Yip et al., 2007).  
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2.2 The second step: extension of the protrusion and adhesion 
formation 
In the current paradigm for cell migration, formation and extension of the cell protrusion is 
controlled by actin polymerization (Pollard and Borisy, 2003; Ridley et al., 2003).  
The core constituent of the actin cytoskeleton is a monomeric globular (G)-actin, a 43-kDa 
ATPase that can self-assemble into filamentous (F)-actin. Each asymmetric filament 
possesses a fast growing barbed end also called the + end, which is the more dynamic end of 
the actin filament, where growth and shrinkage are fast, and a slower less dynamic pointed 
end also called the – end. Hydrolysis of ATP in the filament is tightly coupled to 
polymerization and regulates the kinetics of assembly and disassembly, as well as the 
association of interacting proteins. The dynamic assembly and disassembly of filaments are 
under the control of at least hundred actin-binding proteins which bind directly to monomers 
or filaments and control the actin structure and dynamics and have specific coordinated 
actions: nucleating; capping; stabilizing; severing; depolymerizing; crosslinking; bundling; 
sequestering or delivering monomers; promoting monomer nucleotide exchange. 
 
 
                               
 
                      Figure 10.  Turnover of an actin filament   Adapted from Chen et al., 2000 
 
 
An important set of actin regulators initiate formation of new actin filaments by a process that 
is called nucleation. Three classes of protein have been identified that initiate new filament 
polymerization: the Actin-related protein-2/3 (ARP2/3) complex, the Formins and Spire.  
Barbed end Pointed end 
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                   Figure 11.  Paths to nucleation        Adapted from Goley and Welch, 2006 
 
- Arp2/3 complex is thought to mimic an actin dimer or trimer and binds to the sides of 
existing actin filaments and promotes the extension of a new actin filament from its pointed 
end, forming a 70° angle with the pre-existing filament (Weaver et al., 2003). Arp2/3 
regulation is controlled by WAVE/Scar, WASP and N-WASP proteins. WAVE/Scar is part of 
a multimeric complex including Abi, Nap125, Sra-1 and HSPC-300. This complex is under 
the control of the small GTPase Rac, which induces the dissociation of Abi, Nap125 and Sra-
1 from WAVE, thus mediating WAVE activation. WASP and N-WASP are regulated by 
Cdc42 (Vartiainen and Machesky, 2004; Goley and Welch, 2006). 
- Spire proteins are conserved among metazoan species, and associate with four actin subunits 
through their four tandem G-actin-binding WASP-homology-2 (WH2) domains to function as 
a scaffold for polymerization into an unbranched filament (Quinlan et al., 2005; Kerkhoff, 
2006).  
- Formins are widely expressed in most eukaryotes and promote nucleation of unbranched 
filaments (Kovar, 2006). In contrast to Spire and Arp2/3, formins bind to the barbed end of 
actin filaments and promote actin growth in a linear movement. Mammalian Formins mDia1 
and mDia2 are regulated by small GTPases (RhoA and Cdc42 for mDia1 and mDia2, 
respectively) and require interaction with G-actin bound profilin to promote actin 
polymerization (Watanabe and Higashida, 2004). 
 
Polymerization/organization. Polymerization of the actin cytoskeletal network drives the 
initial extension of the plasma membrane at the cell front. This step is regulated by proteins 
that control the availability of activated monomers, capping proteins as well as 
depolymerization/severing proteins.  
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                                                                                                          Taken  from Paavilainen al., 2004 
Figure 12.  Regulation of actin-monomer turnover. Actin-depolymerizing factor (ADF)/cofilin (green 
circles) promotes the dissociation of actin monomers from the filament pointed end (i). Srv2/cyclase-
associated protein (CAP) (light green ovals), which associates with actin filaments through interactions 
with the actin-filament-binding protein Abp1 (purple), recycles ADF/cofilin and actin monomers for 
new rounds of filament depolymerization and polymerization. Srv2/CAP might also promote 
nucleotide exchange on actin monomers, either on its own (ii) or with profilin (cyan) (iii). If the newly 
depolymerized ADP–actin monomer diffuses away from the actin-filament structure, it could associate 
with twinfilin (red), which inhibits nucleotide exchange and the spontaneous assembly of actin 
filaments from the ADP–actin monomer (iv). The twinfilin–ADP–G-actin complex is relocalized to the 
Arp2/3-nucleated actin structure through direct interactions with capping protein (light blue) (v). The 
ADP–actin monomer can then dissociate from the twinfilin–capping-protein complex, undergo 
profilin-induced nucleotide exchange and become attached to an uncapped filament barbed end nearby 
(vi). Wiskott–Aldrich syndrome protein (WASP)/WASP family verprolin-homologous (WAVE) 
protein (violet) and verprolin/WASP-interacting protein (WIP) (beige) regulate the activity of Arp2/3, 
and the actin-monomer-binding activity of these proteins might contribute to the actin-filament-
nucleating activity of the Arp2/3 complex (dark blue) (vii). Abbreviation: Pi, inorganic phosphate. 
    
 
Profilin is a small actin-monomer-binding protein that has a higher affinity for ATP–G-actin 
than for ADP-G-actin and catalyzes nucleotide exchange on actin monomers (Pollard et al., 
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2000). When bound to an actin monomer, profilin inhibits spontaneous filament nucleation 
and, in the absence of free barbed ends, it functions as an actin-monomer-sequestering 
protein. However, when barbed ends are available and together with thymosin β-4, profilin 
promotes the assembly of actin filaments (Pollard et al., 2000; Pantaloni and Carlier, 1993). 
Profilin binds to formins, and is also required for Ena/VASP-mediated actin polymerization at 
the barbed end (Krause et al., 2003).  
 
Ena/VASP proteins are a conserved family of actin regulatory proteins that associate with 
barbed ends of actin filaments and antagonize filament capping by the capping protein CapZ. 
They are also involved in the reduction of density of Arp2/3-dependent actin filament 
branches (Krause et al., 2003).  
 
Capping proteins are highly conserved proteins in eukaryotic cells that cap actin filament 
barbed ends with high affinity, thereby preventing the addition or loss of actin subunits (Wear 
and Cooper, 2004).  
 
Twinfilin is present in eukaryotes from yeast to mammals and binds only to monomeric actin.  
This protein does not promote actin-filament depolymerization (Palmgren et al., 2002) but 
rather serves as a link between rapid actin filament depolymerization and assembly in cells. 
 
Srv2/Cap is a multimeric protein complex (Balcer et al., 2003) that recycles ADF/cofilin and 
actin monomers for further filament depolymerization and polymerization, respectively. It 
stimulates nucleotide exchange on actin monomers and relieves the inhibitory effects of 
ADF/cofilin on this exchange (Paavilainen et al., 2004). 
 
WASP/WAVE: The WASP family protein consists of two structurally distinct groups: 
WASPs and WAVEs (or SCAR). In mammals, this family comprises five members: WASP, 
N-WASP, and three WAVE proteins (Stradal et al., 2004). WASP family proteins interact 
with a large number of proteins such as Arp2/3, acting as intermediaries between signaling 
pathways and the actin cytoskeleton (Miki and Takenawa, 2003).  
 
Verprolin/WIP are large proteins that interact with several regulators of the actin cytoskeleton 
and monomeric/filamentous actin. Through its C-terminal domain, Verprolin/WIP binds to 
WASP proteins. (Ramesh et al., 1997; Moreau et al., 2000; Martinez-Quiles et al., 2001; 
Kinley et al., 2003).  
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Actin depolymerizing factor ADF/Cofilin proteins belong to a family of abundant, related 
proteins that are found in all eukaryotes. Unicellular organisms such as yeast usually have 
only one ADF/cofilin-type protein, whereas multicellular organisms typically have several 
isoforms. In mammals, there are three different ADF/cofilins: cofilin-1, cofilin-2, and ADF. 
These proteins have distinct expression patterns: cofilin-1 is expressed in most embryonic and 
adult cells, cofilin-2 is expressed in muscle, and ADF is mainly found in epithelial and 
neuronal cells (Vartiainen et al., 2002). In some cultured mammalian cell lines and invasive 
mammary tumor cells, cofilin- 1 is the most abundant isoform, whereas ADF is expressed at 
much lower levels (5%) (Hotulainen et al., 2005; Wang et al., 2006). Furthermore, actin-
depolymerizing factor and cofilin-1 were shown to play overlapping roles (Hotulainen et al., 
2005).  
 
ADF/cofilin are small ubiquitous proteins that bind to monomeric and filamentous actin in a 
pH-sensitive manner. Genetic studies in budding yeast, Caenorhabditis elegans, Drosophila 
and plants have shown that ADF/cofilins are essential for viability (Moon et al., 1993; 
McKim et al., 1994; Gunsalus et al., 1995).  
Their most important physiological function is to enhance the rate of actin filament turnover 
by depolymerizing filaments from their pointed ends, thereby providing a pool of actin 
monomers for filament assembly (Carlier et al., 1997). ADF/Cofilin binds to ADP-F actin 
with higher affinity than they bind to ATP-F actin (Bamburg et al., 1999). Binding of 
ADF/cofilin to F-actin induces actin filaments to twist by ~5° per subunit, which promotes a 
modification of the thermodynamic stability of the filaments and leads to their 
depolymerization (McGough et al., 1997). Mutations in yeast cofilin result in an accumulation 
of abnormal actin-filament structures and decreased rates of actin-filament depolymerization 
(Lappalainen et al., 1997; Lappalainen and Drubin, 1997).  
                 
                                                    Adapted from Cell motility and the cytoskeleton, Prof. Peter K. Hepler  
Figure 13.  Structure and actin interaction of actin-depolymerizing factor (ADF)/cofilin. When bound 
to actin, ADF/cofilin increases the twist of the actin filaments by 5 degrees per subunit. 
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ADF/cofilins also stimulate the dissociation of γ-phosphate from ADP-Pi filaments 
(Blanchoin et al., 2000). In addition to their depolymerizing activity, ADF/cofilins also sever 
actin filaments and consequently increase the number of filaments barbed ends, promoting 
actin polymerization (Chan et al., 2000; Zebda et al., 2000; Ichetovkin et al., 2002; Ghosh et 
al., 2004). Whether ADF/cofilins contribute to cytoskeletal dynamics by depolymerizing actin 
filaments at their pointed ends or by creating new filament barbed ends for F-actin assembly 
through their severing activity, is still a matter of controversy. Finally, ADF and cofilin-1 
bind preferentially ADP-G-actin (compared to ATP-G-actin) and inhibit spontaneous 
nucleotide exchange on monomeric actin (Carlier et al., 1997; Maciver et al., 1994; Blanchoin 
and Pollard, 1998; Vartiainen et al., 2002). ADF/cofilins are quantitatively different in their 
activities. ADF is the most efficient at turning over actin filaments and promotes a stronger 
pH-dependent actin filament disassembly than cofilin-1 or cofilin-2. The muscle cell-specific 
cofilin-2 has a weaker actin filament depolymerization activity than the other two and 
promotes filament assembly rather than disassembly (Vartiainen et al., 2002; Yeoh et al., 
2002). 
 
The regulation of ADF/cofilins activity by phosphorylation, phosphoinositides, acidity 
and interactions with other proteins: 
Phosphorylation: mammalian ADF and cofilin are inhibited in their activity towards actin 
binding and dynamics by kinases that phosphorylate the proteins on a conserved serine 
residue (Ser-3) near the N-terminus which is predicted to be the actin-binding site (Wriggers 
et al., 1998)) (Agnew et al., 1995; Moriyama et al., 1996). 
Several kinases that phosphorylate cofilin and mediate various signals for remodeling of the 
actin cytoskeleton have been identified. These include the LIM kinases (LIMK1 and LIMK2) 
(Meberg, 2000; Bernard, 2007; Wang et al., 2006) and the related testicular (TES) kinases 
(TESK1 and TESK2) (Rosok, 1999; Toshima et al., 2001). LIM kinases are regulated through 
phosphorylation by the Rho GTPase effectors Rho kinase (ROCK) and p21-activated kinase 
(PAK), whereas the TES kinases are downstream of integrin signals (Berbard, 2007; Toshima 
et al., 2001). In addition, 14-3-3  binds to phosphorylated cofilin and prevents 
dephosphorylation by a phosphatase (Gohla and Bokoch, 2002; Nagata-Ohashi et al., 2004). 
Much less is known about the enzymes that activate cofilin by dephosphorylation. The 
general phosphatases PP1, PP2A and PP2B, are able to cause dephosphorylation of cofilin in 
some systems (Ambach et al., 2001). Another specific ADF/cofilin phosphatase, Slingshot, 
has been identified (Niwa et al., 2002; Ohta et al., 2003; Kousaka et al., 2008). Gohla et al. 
also identified another cofilin phosphatase, named chronophin (CIN) (Gohla et al., 2005).  
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                                                                                                               Adapted from Wiggan et al., 2005 
Figure 14. The activity of ADF/cofilin is regulated by a balance of phosphorylation and 
dephosphorylation.  
Phosphoinositides, such as phosphatidylinositol 4,5-bisphosphate (PIP2) also regulate cofilin 
activity. Indeed, PIP2 binds to ADF/cofilin and competes with actin (Yonezawa et al., 1990). 
A PIP2 binding site on ADF/cofilin is mapped to long helix 3 and several other positively 
charged residues which overlap with the actin-binding surface (Yonezawa et al., 1991; Van 
Troys et al., 2000; Ojala et al., 2001).   
Acidity: the cofilin-mediated control of actin polymerization and depolymerization was shown 
to be pH-sensitive. In fact, when cofilin was reacted with F-actin at different pH, the 
depolymerized actin concentration was higher at elevated pH (pH>7.3) (Yonezawa et al., 
1985; Pope et al., 2004).  
In addition to these regulatory mechanisms, ADF/cofilin activity is also regulated by its 
interaction with other proteins. Tropomyosin competes with ADF/cofilin for F-actin binding 
and inhibits depolymerization (Ono and Ono, 2002). Furthermore, several actin-binding 
proteins have recently been shown to collaborate with ADF/cofilin to promote actin filament 
dynamics. Profilin competes with ADF/cofilin for G-actin binding and enhances exchange of 
actin-bound nucleotide in the presence of ADF/cofilin, thereby increasing the rate of actin 
turnover synergistically with ADF/cofilin (Blanchoin and Pollard, 1998; Didry et al., 1998). 
Also, the N-terminal domain of Cap was found to bind to the actin-cofilin complex and to 
accelerate actin depolymerization from the pointed ends (Moriyama and Yahara, 2002). 
Finally, actin-interacting protein 1 (AIP1) was shown to enhances filament severing only in 
the presence of ADF/cofilin (Ono, 2003).  
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Actin polymerization is therefore regulated by a number of proteins, leading to the formation 
of a protrusion at the leading edge of the cell. These protrusions are stabilized to the 
surroundings by the formation of adhesions.  
 
Formation of adhesions: The assembly of Focal adhesions (FAs) in response to adhesion to 
the ECM is gradual, usually occurring within 1 to 2 h after cell attachment. This process 
requires integrin activation followed by integrin aggregation and recruitment of signaling 
components to the nascent adhesions (Kiosses et al., 2001; Miyamoto et al., 1995). Integrin 
receptors support the adhesion to the extracellular matrix or to other cells and mediate the link 
with actin filaments on the inside of the cell (Geiger et al., 2001; Yamada and Miyamoto, 
1995; Schoenwaelder and Burridge, 1999). 
The integrins are heterodimeric adhesion glycoprotein receptors, consisting of α and β chains 
with a large ligand binding extracellular portion and short cytoplasmic domains. Ligand 
binding to the extracellular domain leads to conformational changes and integrin clustering 
(Emsley et al., 2000), inducing subsequent intracellular signaling such as protein tyrosine 
phosphorylation, activation of small GTPases and changes in phospholipid biosynthesis 
(Geiger et al., 2001). Proteins such as Talin, PKC, the GTPase Rap1 and PI3K regulate 
integrin activation (Kinbara et al., 2003; Hattori and Minato, 2003; Kolanus and Seed, 1997; 
Ratnikov et al., 2005; Katsumi et al., 2005; Arnaout et al., 2007). Integrin engagement and 
aggregation induces Rac activation (del Pozo et al., 2000).  
During migration, adhesions assemble at the leading edge and disassemble at the trailing 
edge. However, adhesions also disassemble at the front during protrusion and feed 
components to nascent adhesions at the leading edge in a process called adhesion turnover 
(Webb et al., 2004; Webb et al.,2002). 
                                        
                                                                                                Taken  from Broussard et al., 2008 
 Figure 15. Model of asymmetric adhesion dynamics. Nascent adhesions formed at the front either 
undergo turnover, which is predominantly controlled by kinase signaling, or mature in response to 
contractile forces. Mature adhesions can disassemble or be transformed into fibrillar adhesions. 
Trailing adhesions arise as a result of fusion of additional nascent adhesions and remaining fibrillar 
adhesions. Once formed, trailing adhesions slide because of tension from attached stress fibers and 
either eventually disassemble or detach in the form of membrane ‘footprints’. 
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The classification of adhesions is based primarily on their morphology or on the method of 
their formation, and includes focal adhesions, fibrillar adhesions, and focal complexes. 
Fibrillar adhesions are central structures that contain 5 1 integrins and tensin, whereas focal 
complexes (or nascent adhesions) are small adhesions induced by Rac activation at the 
periphery of the cell (Zamir et al., 2000; Nobes and Hall, 1995; Rottner et al., 1999). The 
small adhesions drive rapid cell migration (Beningo et al., 2001) and under tension, they 
mature into larger, relatively stable and more organized structures such as FAs 
(Chrzanowska-Wodnicka and Burridge, 1996; Sastry and Burridge, 2000; Bershadsky et al., 
2003). Mature adhesions are, in turn, either disassembled underneath the approaching cell 
body, or diminished to form fibrillar adhesions (Rid et al., 2005; Zamir et al., 2000). The 
majority of nascent adhesions undergo rapid turnover such that their components can be 
incorporated into newly formed adhesion sites. The mechanisms by which adhesions 
turnover, and the mechanisms that regulate these processes are not well understood. The 
formation and disassembly of adhesions are complex processes that require a coordinated 
interaction of actin or actin-binding proteins, signaling molecules, structural proteins, 
integrins, adaptor molecules and microtubules. Over 50 proteins have been found in adhesions 
(Zamir and Geiger, 2001) 
 
                         
                                                                                            Adapted from Mitra et al., 2005 
                                       Figure 16. Molecular architecture of focal contacts 
 
The current paradigm of cell migration favors a coupled formation of nascent-cell substratum 
contact sites at the leading edge and formation of a protrusion. Formation of these adhesions 
is dependent on Rac and Cdc42, and these adhesions stabilize the lamellipodium by mediating 
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attachment to the ECM. A sequential recruitment of individual or classes of adhesion 
components around a nucleation center is proposed. In fact, integrin aggregation leads to the 
recruitment of structural and signaling proteins to FAs; the cytoplasmic components of FAs 
include cytoskeletal proteins, such as α-actinin, vinculin and talin, and signaling proteins such 
as the integrin-linked focal adhesion kinase, pp125FAK (FAK) (Miyamoto et al., 1995a; 
Miyamoto et al., 1995b; Yamada and Miyamoto, 1995). Subsequent accumulation of multiple 
signaling molecules is induced upon tyrosine phosphorylation. Indeed, extracellular matrix-
dependent phosphorylation of FAK on Tyr-397 generates a high affinity binding site for SH2-
domain containing proteins such as Src family kinases, PI3K, Grb7, and PLCγ1 (Chen and 
Guan, 1994; Schaller et al., 1994; Schaller et al., 1999; Schlaepfer et al., 1996; Shen and 
Guan, 2001; Xing et al., 1994; Zhang et al., 1999). pp60c-Src (Src) binding to FAK apparently 
contributes to Src activation, promoting further phosphorylation of FAK at additional tyrosine 
sites (Maa and Leu, 1998; Calalb et al., 1995; Calalb et al., 1996; Leu and Maa, 2002). There 
is evidence that Src phosphorylates FAK at Tyr925, creating a binding site for the complex of 
the adapter Grb2 and Ras guanosine 5'-triphosphate exchange factor Sos (Schlaepfer et al., 
1994). These interactions link FAK to signaling pathways that modify the cytoskeleton and 
activate mitogen-activated protein kinase (MAPK) cascades. Src family kinases and Src in 
particular, were shown to have a central role in regulating protein dynamics at cell-matrix 
interfaces, both during early stages of interaction and in mature focal adhesions (Volberg et 
al., 2001; Parsons and Parsons, 1997). In particular, the complex FAK-Src phosphorylates a 
number of focal adhesion components. The major targets include paxillin and tensin, two 
cytoskeletal proteins that may also have signaling functions, and p130CAS, a docking protein 
that recruits the adapter proteins Crk and Nck (Panetti, 2002; Vuori et al., 1996; Schlaepfer et 
al., 1997; Schaller and Parsons, 1995; Lo, 2004). 
Formation of FAs may also involve the coordination of several different events, including 
actin polymerization, actin stress fibers attachment to the membrane at sites of cell–ECM 
adhesion, and stress fibers contraction. The small GTP-binding protein, RhoA, was 
established to be involved in FA assembly through RhoA-induced actomyosin contractility 
that results in bundling of actin filaments to generate stress fibers and clustering of integrins 
and associated proteins (Ridley et al., 1992; Sastry and Burridge, 2000).  
 
 
2.3 Tractional forces and cell translocation 
Nascent adhesions at the cell front exert tractional forces on the substrate that lead to cell 
translocation (Beningo et al., 2001). In fact, integrins connect the ECM to the intracellular 
cytoskeleton, therefore serving as traction sites over which the cell moves, but also as 
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mechanosensors that transmit information about the physical state of the ECM into the cell 
(Galbraith et al., 2002). The strength of attachment is dependent of the density of ligands on 
the substrate, the density of receptors on the cell surface, and the affinity of these receptors for 
the ligands. The tractional force that is exerted on adhesions is induced by the interaction of 
myosin II with actin filaments that attach to these sites. Actomyosin-based contraction is 
controlled by the small Rho GTPases, Cdc42, Rac and RhoA (Jaffe and Hall, 2005). 
  
                                
                                                                                        Adapted from Jaffe and Hall, 2005 
                                                               Figure 17.The GTPase cycle 
 
 
The regulation by these GTPases is antagonistic. Indeed, myosin II activation is regulated by 
Myosin Light Chain (MLC) phosphorylation, and results in increased contractility.  MLC is 
phosphorylated by myosin light chain kinase (MLCK) or Rho kinase (ROCK) and 
dephosphorylated by MLC phosphatase, which is itself phosphorylated and inhibited by 
ROCK. MLCK is regulated by intracellular Ca2+ levels as well as phosphorylation by a 
number of kinases, whereas ROCK is activated by RhoA (Poperechnaya et al., 2000; Amano 
et al., 1996; Leung et al., 1995; Ishizaki et al., 1996; Matsui et al., 1996; Riento and Ridley, 
2003; Kimura et al., 1996; Kaibuchi et al., 1999). RhoA is therefore promoting cell 
contractility. A similar mechanism has been shown for Cdc42, acting through the myotonic 
dystrophy kinase-related Cdc42-binding kinase (MRCK) (Wilkinson et al., 2005). 
Conversely, Rac activates PAK, which phosphorylates and inactivates MLCK, thus leading to 
decreased contractility and promoting spreading (Burridge, 1999). However, PAK may also 
phosphorylate MLC directly, thus promoting contractility (Brzeska et al., 2004).  
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2.4 The last step: retraction of the cell rear  
Release of adhesions and retraction at the rear completes the migratory cycle allowing net 
translocation of the cell in the direction of movement (Kirfel et al., 2004). High tension 
exerted on the rear adhesions breaks the linkage between integrins and the actin cytoskeleton 
and contributes to detachment (Lauffenburger and Horwitz, 1996).  This process of adhesion 
disassembly and rear retraction is mediated by several candidates and signaling pathways that 
include Rho, myosin II, Src/FAK/ERK, calcium, calcineurin, calpain and the delivery of 
components by microtubules (Ridley et al., 2003). 
                             
           
 
Rho is involved in disassembly of adhesions at the rear of migrating cells (Raftopoulou and 
Hall, 2004). In several cell types, inhibition of Rho leads to the formation of an extended tail, 
possibly because actomyosin-based contractility in the cell body is decreased. Rho may also 
act in the tail by stabilizing microtubules through the complex mDia-APC-EB1-Dynamin 
(Rodriguez et al., 2003; Palazzo et al., 2001; Small and Kaverina, 2003). Moreover, Rho and 
its effector, Rho kinase (ROCK), were shown to promote retraction of the tail of migrating 
monocytes (Worthylake and Burridge, 2003). Inhibition of ROCK or MLCK results in 
elongation of cell tails consistent with ROCK and/or MLCK being a positive effector of 
disassembly (Alblas et al., 2001; Wysolmerski and Lagunoff, 1990). PAK activation is also 
 
    Adapted from Vicente-Manzanares et al., 2005 
    Figure 18. Trailing edge retraction
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implicated, through its effects on contraction and detachment, in retraction at the cell rear 
(Kiosses et al., 1999; Sanders et al., 1999; Sells et al., 1999; Zeng et al., 2000). Rac has also 
been implicated in the detachment at the rear of migrating cells (Gardiner et al., 2002). A role 
for myosin II in this rear deadhesion process has also been suggested (Koehl and McNally, 
2002). 
In addition, intracellular calcium levels are also implicated in this adhesion disassembly 
process. Indeed, the tension that is generated by strong adhesions at the cell rear can promote 
the opening of stretch activated calcium channels (Lee et al., 1999). As potential targets for 
calcium, the calcium regulated phosphatase calcineurin and the calcium activated protease 
calpain might be implicated in this process. Calpain, which is also activated by ERK, has the 
potential to cleave several focal adhesion proteins such as talin or FAK (Hendey et al., 1992; 
Glading et al., 2002; Carragher et al., 2003; Franco et al., 2004). Talin proteolysis by calpain 
has been shown to stimulate the dissociation of several major adhesion components including 
paxillin, vinculin and zyxin.  
The involvement of microtubules in the rear deadhesion process has also been proposed 
(Wittmann and Watermann-Storer, 2001). In fact, Ballestrem and colleagues demonstrated 
that nocodazole-induced microtubule disruption resulted in cells that were unable to retract 
their tail (Ballestrem et al., 2000). Furthermore, microtubule-dependent targeting of dynamin 
and subsequent endocytosis of some adhesion components is another mechanism promoting 
focal adhesion disassembly (Ezratty et al., 2005). Also, by imaging microtubules and focal 
adhesions simultaneously in living cells, Kaverina and colleagues have revealed that focal 
adhesions are targeted by microtubule plus ends undergoing dynamic instability and that 
repeated targeting leads to focal adhesion disassembly (Kaverina et al., 1998; Kaverina et al., 
1999; Broussard et al., 2008).  
Finally, Src/FAK/ERK signaling is also involved in the focal adhesion disassembly process. 
Indeed, local rises in Ca2+ concentration can induce adhesion disassembly by increasing the 
residency of FAK at these sites (Giannone et al., 2004). Furthermore, FAK downstream 
pathways can cause a decrease in local myosin contractility. As an example, FAK-Src 
signaling stimulates adhesion disassembly through a signaling pathway that includes p130CAS, 
paxillin, ERK and MLCK (Webb et al., 2004; Carragher et al., 2003; Westhoff et al., 2004). 
Specifically, treatment of cells with a Src inhibitor or expression of a kinase-defective mutant 
of Src decreased the rate constant of FA disassembly as observed using fluorescently tagged 
paxillin and zyxin (Webb et al., 2004). A similar effect was found after expression of Y397F-
FAK mutant, consistent with Tyr-397 phosphorylation and subsequent recruitment of Src to 
FAs being necessary for FA disassembly.  
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 3. Focus on PLCγ1 and cofilin, the gradient sensing machinery in 
adenocarcinoma cells 
Phospholipase C (PLC) is involved in cellular proliferation and differentiation, and its 
enzymatic activity is up-regulated by a variety of growth factors and hormones (Rhee, 2001). 
PLC hydrolyzes phosphatidylinositol 4, 5-bisphosphate (PIP2) to generate inositol 1, 4, 5-
trisphosphate (IP3) and 1, 2-diacylglycerol (DAG), which are implicated in the mobilization 
of intracellular Ca2+ and protein kinase C activation, respectively (Berridge and Irvine, 1989). 
Many growth factors such as platelet-derived-growth factor (PDGF), epidermal growth factor 
(EGF), fibroblast growth factor (FGF), and nerve growth factor (NGF) elicit tyrosine 
phosphorylation of PLC-γ1 with stimulation of PIP2 turnover in a wide variety of cells 
(Larose et al., 1993; Rotin et al., 1992; Peters et al., 1992). As a direct substrate for these 
receptors, PLC-γ1 has been shown to mediate chemotaxis toward these growth factors (Wells, 
2000). PLC-γ1 is involved in cell adhesion and motility processes and its activation is 
therefore critical for tumor progression. The evidence for PLC-γ1 promoting tumor invasion 
has been reported in human cancer cells. Inhibiting PLC-γ1 signaling blocked human 
glioblastoma and prostate carcinoma cell invasion into normal tissue (Khoshyomn et al., 
1999; Turner et al., 1997).  
In the MTLn3 adenocarcinoma cells, EGF stimulation induces a biphasic F-actin 
polymerization response (Chan et al., 1998). The second peak of actin polymerization is 
dependent on PI3K activity, whereas the first peak is dependent on PLCγ1 and cofilin (Hill et 
al., 2000; Mouneimne et al., 2004). Additional studies strongly argue that PLC, together with 
cofilin, mediates gradient sensing in these cells (Ghosh et al., 2004; Mouneimne et al., 2006). 
Cofilin activity seems to be mainly dependent on PLCγ1-mediated PIP2 hydrolysis and does 
not involve an IP3-mediated Ca2+ release (Ma et al., 2000; Mouneimne et al.,2006; Yonezawa 
et al., 1991). Van Rheenen et al. recently showed that EGF induces a rapid loss of PIP(2) 
through PLC activity, resulting in a release and activation of a membrane-bound pool of 
cofilin. Upon release, cofilin was shown to bind to and sever F-actin, which is coincident with 
actin polymerization and lamellipod formation (Van Rheenen et al., 2007). Moreover, these 
data suggested an important role for PLC in the formation of protrusions in breast carcinoma 
cells during chemotaxis and metastasis towards EGF (Van Rheenen et al., 2007). In addition 
to activation by PLCγ1, cofilin activity in carcinoma cells is regulated by LIMK-mediated 
phosphorylation and SSH-induced dephosphorylation (Zebda et al., 2000; Nishita et al., 
2005). Upon EGF stimulation, cofilin is phosphorylated and is essential for chemotactic 
sensing (Mouneimne et al., 2006), leading to the formation of F-actin rich lamellipodial 
protrusions in which SSH becomes locally activated and thereby, re-activates cofilin in the 
lamellipodium. This balance between inactivation by phosphorylation and reactivation by 
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dephosphorylation allows actin-filament turnover and ensures the dynamic nature of the 
lamellipodium (Soosairajah et al., 2005). However, recent studies in carcinoma cells have 
shown that the initial activation of cofilin does not involve ligand-induced dephosphorylation 
(Mouneimne et al., 2004; Song et al., 2006), but rather involves PLCγ1-mediated PIP2 
hydrolysis and simultaneous inactivation by LIMK (Mouneimne et al., 2006; Hitchcock-
DeGregori, 2006). When activated by PLCγ1-induced PIP2 hydrolysis, cofilin induces actin 
filament severing, thereby increasing the number of free actin barbed ends which become 
available for the binding of the Arp2/3 complex and Ena/VASP proteins, allowing initial 
protrusion and setting the direction of the movement. Activation of PI3K via EGF stimulation 
signals to Arp2/3 and promotes the formation of stable lamellipodia. Thus, the PLCγ1-cofilin 
and PI3K-Arp2/3 signalling pathways cooperate in chemotactic gradient sensing and 
lamellipodia generation in response to EGF stimulation.  
 
 
                       
                                                                                           Adapted from Kolsch et al., 2008 
                                     Figure 19. PLC and cofilin activities in adenocarcinoma cells   
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 4. Memo: a novel component of the migratory machinery 
Migration of breast tumor cells in response to EGF-related peptides is dependent upon ErbB2 
activity (Spencer et al., 2000). In a screen for ErbB2 interacting proteins with roles in 
migration, a novel protein, Memo (Mediator for ErbB2-driven cell Motility) was identified as 
a binding partner of the ErbB2 autophosphorylation site Tyr1227 (Marone et al., 2004). 
Memo corresponds to the CGI-27/c21orf19-like hypothetical protein, which was identified by 
comparative genome identification using the C-elegans proteome as scaffold (Lai et al., 
2000).  A single Memo protein is encoded by the human genome, and Memo homologs are 
found in all branches of life. The sequence of Memo does not provide any relevant 
information about Memo’s function since it does not contain any characterized domain. The 
2.1Å crystal structure of Memo revealed that Memo is homologous to a bacterial class III 
nonheme iron-dependent dioxygenase (Qiu et al., 2008). Some of the key active site residues 
are conserved between dioxygenases and Memo, however, no evidence for a binding of 
Memo to metals or for an enzymatic activity was shown. Memo down-regulation in breast 
tumor cells resulted in a defect of cell migration, reflecting the requirement of this novel 
protein for ErbB2 dependent cell migration. Furthermore, following ErbB2 activation, Memo 
defective cells form actin fibers and grow lamellipodia, but fail to extend microtubules 
towards the cell cortex, suggesting that Memo controls cell migration by relaying 
extracellular chemotactic signals to the microtubule cytoskeleton (Marone et al., 2004). 
However, the mechanism whereby Memo mediates ErbB2-dependent cell motility is largely 
unknown and is under current investigation. 
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-------------------AIMS OF THE WORK------------------- 
 
Clinical studies have demonstrated that cancer patients with ErbB2 overexpressing tumors 
tend to have more aggressive, metastatic disease, which is associated with parameters 
predicting a poor outcome. However, the molecular basis underlying ErbB2-dependent cell 
motility and metastases formation still remains poorly understood. An initial study in our lab 
focused on the contribution of individual ErbB2 tyrosine autophosphorylation sites in cell 
migration. This study revealed that signaling downstream of Tyr 1201 and 1227 is important 
to induce efficient cell migration. Further investigation of the molecular interacting partners 
of these two tyrosine sites led to the identification of the novel protein Memo that specifically 
interacts with the phosphorylated Tyr 1227. This previous study also demonstrated that Memo 
is required for ErbB2-mediated breast carcinoma cell migration, and proposed that Memo 
controls cell motility by relaying extracellular chemotactic signals to the microtubule 
cytoskeleton. In the present study, we aimed at investigating in more detail Memo’s function 
during ErbB2-induced cell migration, and determining the steps of the migratory process that 
involve Memo. We also aimed at positioning Memo within a genetic network by studying 
Memo in the model organism S. cerevisiae.  
 
Our initial work on the role of Memo in mammalian cell migration was done with the Boyden 
chamber model that only allows quantification of migrated cells in response to a steep 
gradient of a chemotactic ligand. One important goal of the first study in the present thesis 
work was to explore the migratory process in more detail using the Dunn chamber model.  
This technique measures the chemotactic response of cells to a shallow gradient of ligand, and 
allows a direct visualization of the cell movement under video time-lapse microscopy. A 
quantification of different parameters such as track displacement, track speed and directional 
persistence is then possible. A second challenge in this first thesis project was to discover new 
partners of interaction for Memo in order to gain more insight into Memo’s function. This 
was accomplished by the use of the Yeast-Two-Hybrid technique, which identified the cofilin 
protein among a number of interesting candidates. Considering the important role of cofilin 
on cell migration, particularly during the initial stages of the migratory process, we 
investigated the connection between Memo and cofilin, and examined the role of Memo on 
cofilin activation. 
 
In the second part of the thesis, we aimed at positioning Memo in a downstream ErbB2 
signaling pathway. In the original Memo study, the authors showed that there is a constitutive 
association of Memo and the adaptator Shc protein. Shc has three isoforms: p46Shc, p52Shc, 
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and p66Shc and each of them have different cellular functions. To orientate Memo in a specific 
cellular pathway, we investigated the ability of Memo to bind each of the three isoforms by 
using Shc-deficient mouse embryonic fibroblasts (MEFs) reconstituted with individual Shc 
isoforms. Furthermore, to uncover Memo’s cellular and biochemical roles, we used two 
different models of Memo-deficient cells, and scored them for activation of different 
signaling cascades. Also, considering the previously described effect of Memo on HRG-
induced breast carcinoma cell migration, we examined in more detail the morphology as well 
as cell motility and adhesion properties of Memo-null mouse fibroblasts, a good model for 
studying Memo function. 
 
Memo orthologues are found in all species, from bacteria to human. To date, the function of 
Memo has only been studied in mammalian cells. In the third part of the present thesis work, 
we examined Memo in a model organism that is amenable to genetic manipulation in order to 
provide more information on Memo’s role in other species. Genetic approaches in the model 
organism S.cerevisiae have been useful for gaining insight into the function of evolutionary 
conserved proteins. Thereby, to advance our knowledge of Memo’s cellular and molecular 
role, we carried out a study of Memo in S.cerevisiae. We investigated Memo cellular 
localization, and generated a memoΔ strain that appeared to be viable. Considering the known 
role of mammalian Memo in the microtubule and actin cytoskeleton, we examined the memoΔ 
strain for defects in these networks. Also, given the viability of the memoΔ strain, we 
performed a Synthetic Lethal Screen (SLS) to characterize Memo’s functions and dissect 
pathway structures.  
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Summary  
 
Heregulin (HRG) activates ErbB2/ErbB3 heterodimers thereby stimulating many cellular 
responses, including motility. Memo and PLCγ1 interact with ErbB2 autophosphorylation 
sites and are essential for HRG-induced chemotaxis. By tracing HRG-stimulated cell 
migration in Dunn chambers, we found that Memo- or PLCγ1 knock-down (KD) strongly 
impairs cell directionality. Memo has no obvious enzymatic activity and was discovered via 
its ability to complex with ErbB2. Using the yeast two-hybrid approach to gain insight into 
Memo function, an interaction between Memo and cofilin, a regulator of actin dynamics, was 
uncovered. The interaction was confirmed in vitro using recombinant proteins and in vivo in 
coimmunoprecipitation experiments where Memo was detected in complexes with cofilin, 
ErbB2 and PLCγ1. Interestingly, in Memo KD cells, HRG-induced PLCγ1 phosphorylation 
was decreased, suggesting that Memo regulates PLCγ1 activation. Furthermore, HRG-
induced recruitment of GFP-cofilin to lamellipodia is impaired in Memo- and in PLCγ1 KD 
cells, suggesting that both proteins lie upstream of cofilin in models of ErbB2-driven tumor 
cell migration. Finally, in vitro F-actin binding and depolymerization assays showed that 
Memo binds F-actin and induces an enhancement of cofilin depolymerizing/severing activity. 
In summary, these data indicate that Memo also regulates actin dynamics by interacting with 
cofilin and enhancing its function. 
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Introduction 
Cell migration is important in normal physiology and in disease. Acquisition of migratory 
ability by cancer cells is a characteristic that contributes to metastatic tumor cell spread to 
distant organs (Gupta and Massague, 2006). Proteins with essential roles in metastasis are 
under intense scrutiny in order to provide additional targets for cancer therapy. The ErbB2 
receptor tyrosine kinase plays an important role in many human tumors (Hynes and Lane, 
2005). In breast cancer, ErbB2 gene amplification and overexpression correlate with an 
aggressive metastatic phenotype (Hynes and Lane, 2005; Slamon et al., 1987). Accordingly, 
we have explored signaling pathways activated by ErbB2 in breast cancer, with the specific 
aim of identifying proteins recruited by the receptor that are essential for tumor cell 
migration.  
 
ErbB2 is a member of the epidermal growth factor (EGF/ErbB) family that also includes 
EGFR, ErbB3 and ErbB4. ErbB receptor signaling is initiated by ligand binding to the 
extracellular region causing formation of receptor homo- and heterodimeric complexes, 
resulting in autophosphorylation at multiple Tyr residues in the cytoplasmic domain 
(Schlessinger, 2000; Yarden and Sliwkowski, 2001). ErbB2 has a central role in the family 
and is activated by heterodimerization with each of the other ErbB receptors (Graus-Porta et 
al., 1997). Functional inactivation of ErbB2 in T47D human breast cancer cells (Graus-Porta 
et al., 1995) impairs the ability of the EGF family ligands, EGF, betacellulin and heregulin 
(HRG), to stimulate cell migration in Boyden chamber assays (Spencer et al., 2000). 
Furthermore, introduction of Neu (rat ErbB2 homologue) mutants into the T47D cells showed 
that two Neu-Tyrosine add-back mutants, 1201/1196 and 1227/1222 (human/rat) are able to 
restore the ability of EGF and HRG to stimulate cell migration (Marone et al., 2004). In a 
screen for ErbB2 effector proteins with roles in migration, we identified PLCγ1 and Memo. 
These proteins are recruited to the ErbB2 autophosphorylation sites Tyr 1201 and Tyr 1227, 
respectively and both have essential roles in cell motility (Marone et al., 2004).  
 
In contrast to the well-characterized PLCγ1, Memo is a novel protein. The 2.1 Å crystal 
structure of Memo revealed that it is structurally homologous to a class of non-heme iron 
dioxygenases that are mainly found in bacteria (Andujar and Santero, 2003), however, we 
were unable to detect metal binding or enzymatic activity (Qiu et al., 2008). To gain more 
insight into Memo function, we used the yeast two-hybrid (YTH) approach to identify Memo 
interacting proteins. We report here that Memo interacts with cofilin, a member of the 
conserved, ubiquitously expressed actin depolymerizing factor (ADF)/cofilin family, proteins 
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that control actin dynamics and regulate actin filament turnover (Moon and Drubin, 1995) 
(Ono, 2007).  
 
ADF/cofilin proteins control actin dynamics at the cell membrane, a process which is 
essential for cell migration. In fact, depletion of cofilin impairs cell motility (Hotulainen et al., 
2005). ADF/cofilin proteins bind actin and are involved in the actin filament 
assembly/disassembly process (dos Remedios et al., 2003). In vitro, it has been shown that 
cofilin stimulates F-actin disassembly by accelerating the rate of pointed end 
depolymerization, and by severing actin filaments (Carlier et al., 1997; DesMarais et al., 
2005; Lappalainen and Drubin, 1997; Paavilainen et al., 2004). Although in vivo the 
predominant cofilin activity appears to be cell type dependent, cofilin has an essential role in 
promoting cytoskeletal dynamics by generating the pool of actin monomers needed for 
lamellipodium extension at the leading edge (Kiuchi et al., 2007). Cofilin is inactivated by 
LIM-kinase mediated phosphorylation at Ser-3 (Arber et al., 1998; Yang et al., 1998), and is 
reactivated by Slingshot-1L (SSH-1L) induced-dephosphorylation (Niwa et al., 2002). PLCγ1 
is another regulator of cofilin; indeed, PLCγ1-mediated PIP2 hydrolysis releases PIP2-bound 
cofilin thereby increasing the pool of active cofilin available for interaction with F-actin (Ono, 
2007; van Rheenen et al., 2007). Local activation of cofilin by PLCγ1 at the leading edge of 
migrating cells has been shown to be required for directed protrusion (Mouneimne et al., 
2006; Mouneimne et al., 2004). 
 
Using a KD strategy in this study, we observed that depletion of Memo or of PLCγ1 resulted 
in very similar phenotypes, with a strong impairment of HRG-induced cytoskeletal 
organization and directional migration of breast tumor cells. In contrast, cofilin KD, or 
simultaneous KD of Memo and PLCγ1, completely blocked cell movement. Furthermore, co-
immunoprecipitation experiments revealed that complexes of active ErbB2, PLCγ1, Memo 
and cofilin are detected in HRG treated breast tumor cells. We also provide evidence that 
Memo positively regulates PLCγ1 phosphorylation and show that Memo and PLCγ1 are both 
involved in HRG-induced cofilin recruitment to the lamellipodia. We demonstrate that Memo 
also binds F-actin and promotes cofilin depolymerizing/severing activity. Considering these 
results, we propose that Memo and PLCγ1 lie upstream of cofilin in models of ErbB2 driven 
breast cancer cell migration.  
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Results  
PLCγ1 and Memo are required for ErbB2-mediated cell motility 
PLCγ1 and Memo bind to P-Tyr 1201/1196 and P-Tyr 1227/1222, respectively, two ErbB2 
phosphorylation sites that we have shown to be important for cell migration (Marone et al., 
2004). In the current study, we performed detailed studies on the role of Memo and PLCγ1 in 
HRG-induced tumor cell migration. As models, we used T47D and SKBr3 breast cancer cell 
lines that are representatives of, respectively, luminal, estrogen receptor-positive (ER+) 
cancer cells (Badache and Hynes, 2001; Marone et al., 2004) and ErbB2-overexpressing 
tumor cells (Lane et al., 2000). We have previously shown via siRNA mediated Memo knock-
down (KD) and general PLC inhibition, that in T47D cells, both proteins have important roles 
in ErbB2-induced cell motility (Marone et al., 2004). In the following experiment, we 
decreased the expression of Memo and PLCγ1 in SKBr3 cells using specific siRNAs (Fig 1A 
right panel) and examined their motility. The directional (chemotactic) and random 
(chemokinetic) migration of control and KD cells was examined in Transwell assay 
chambers. HRG was added to the lower chamber to measure chemotaxis and to both 
chambers to measure chemokinesis.  KD of Memo or PLCγ1 did not generally affect 
signaling in response to HRG (Marone et al., 2004) (Supp Fig S1 left panel, e.g. P-ERK). 
However, individual KD of Memo or PLCγ1 or simultaneous KD of both proteins strongly 
reduced chemotaxis in comparison to control LacZ cells (Fig 1A left panel and 
Supplementary Fig S1, right panel). Interestingly, the chemokinetic response of Memo or 
PLCγ1 KD cells was similar to that of control cells, whereas double KD of PLCγ1 and Memo 
resulted in a dramatic blockade of random cell motility (Fig 1A left panel), suggesting that 
Memo and PLCγ1 are cooperating during the migratory process. 
Signal transduction pathways downstream of ErbB2 temporally and spatially regulate 
cytoskeleton remodeling during cell migration (Feldner and Brandt, 2002). Therefore, we 
examined the effect of Memo and PLCγ1 KD, or simultaneous KD of both proteins on HRG-
dependent microtubule (MT) and actin organization.  T47D cells were used for this 
experiment since following their exposure to HRG, they form large actin-rich lamellipodial 
protrusions with abundant MT extensions (Fig 1B LacZ control), however, results with 
SKBr3 cells are essentially the same ((Marone et al., 2004) and unpublished).  Both Memo 
KD and PLCγ1 KD cells, as well as double KD cells, displayed similar actin-rich protrusions, 
however, the F-actin stress fibers appeared thicker and more predominant in the KD cells, 
suggesting a role for Memo and PLCγ1 in actin organization (Fig 1B). Furthermore, in 
comparison to control cells, the single and the double KD cells showed a strong reduction in 
MT extension to the cell periphery, a phenomenon previously reported for Memo KD cells 
(Marone et al., 2004). Thus, in response to ErbB2 activation, decreased expression of Memo 
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and of PLCγ1 have very similar consequences on the actin and MT network, raising the 
possibility that Memo and PLCγ1 act in concert during cytoskeleton organization. 
 
PLCγ1 and Memo have important roles in directed tumor cell migration 
Decreased expression of Memo or PLCγ1 reduces HRG-induced motility of tumor cells in 
Transwell assays (Fig 1A, Supplementary Fig S1 and (Marone et al., 2004)). We investigated 
these results in more detail using Dunn chambers, a system that allows real-time visualization 
of migratory cells (Wells and Ridley, 2005; Zicha et al., 1991). The data generated in Dunn 
chambers provides additional information on the behavior of migratory cells compared to data 
obtained with Boyden chambers in which only the final distribution of cells can be monitored. 
For these assays, T47D cells were transiently transfected for 72 hrs with LacZ, Memo or 
PLCγ1 siRNA (Fig 2A right panel) and tracks of cells migrating on the bridge of Dunn 
chambers in a chemo-attractant gradient of HRG were traced using time-lapse video 
microscopy (Fig 2A left panels). Quantitative analyses of the tracks made by cells with Memo 
KD or  PLCγ1 KD revealed that there was a 44% decrease in the net translocation distance 
(straight distance from the start to the end point) and a 30-35% decrease in their migration 
speed, compared to control cells (Fig 2B left and middle panels). Thus, as observed in the 
Boyden chamber assays (Fig 1A), the cells are still able to migrate although less potently than 
control cells. Importantly, there was a dramatic difference in their directional persistence. KD 
of Memo or PLCγ1 in T47D cells led to a 67% and 72% decrease, respectively, in the 
directional persistency index (Fig 2B right panel). The overall directionality of cell migration 
in control and KD cells is depicted in Fig 2C. Considering the final location of migrating cells 
positioned in the 180°C arc facing the HRG source, 86.6 % of  control cells were located 
there, while only 37.5 % and 37.4 % of Memo KD and PLCγ1 KD cells, respectively were in 
this location. In summary, these results show that down-regulation of either Memo or PLCγ1 
does not totally impair cell migration; however, the cells move in a more random manner 
compared to control cells that move up the HRG gradient. Thus, both Memo and PLCγ1 have 
important roles in orchestrating directional cell migration.   
 
Complexes of ErbB2, PLCγ1, and Memo form upon HRG treatment of breast tumor 
cells. 
Considering the similar role that Memo and PLCγ1 play in HRG induced cell migration, we 
explored the Memo-PLCγ1 connection in more detail. In Memo IPs from T47D cells (Fig 3A 
left panel) and from HEK293 cells (Supplementary Fig S2 right panel), complexed PLCγ1 
could be detected. In the reverse immunoprecipitation, IPs of PLCγ1 revealed complexed 
Memo (Fig 3A right panel and Supplementary Fig S2 right panel). In each case, there is an 
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increase in the co-immunoprecipitating protein when lysates from HRG treated cells were 
used, probably reflecting stabilized complexes interacting with active ErbB2 (see 
Supplementary Fig S2 middle panel). Indeed, Memo and PLCγ1 were both detected in ErbB2 
IPs from SKBr3 cells that have constitutive receptor activation (Supplementary Fig S2, left 
panel). 
 
Memo has a role in HRG induced PLCγ1 activation  
Phosphorylation of PLCγ1 on Tyr783 has been linked to its activation (Rhee, 2001). Upon 
HRG treatment of T47D breast tumor cells, there is a rapid increase in the P-Tyr content of 
immunoprecipitated PLCγ1 (Fig 3B left panel), showing that HRG activates PLCγ1. 
Interestingly, in Memo KD T47D cells, there was a strong decrease in the P-Tyr content of 
the immunoprecipitated PLCγ1 (Fig 3B middle panel), while the level of PLCγ1 remained the 
same (Fig 3B right panel). These results suggest that Memo has an important role in PLCγ1 
phosphorylation in response to ErbB2 activation. Loss of Memo might directly or indirectly 
affect PLCγ1 activity, perhaps as a result of the alterations in the actin cytoskeleton following 
Memo KD.  
 
Memo interacts directly with cofilin: results from yeast two-hybrid and GST-pull-downs 
The molecular mechanisms underlying Memo’s role in cell migration are not well understood. 
To gain more insight into Memo function, a YTH screen was performed (Pedrazzi and 
Stagljar, 2004). By screening a peripheral blood cDNA library, we identified cofilin-1, a 
ubiquitously expressed protein of ~19kDa that binds monomeric and filamentous (F)-actin 
(Ono, 2007), as a potential interacting partner for Memo. Mammalian cells express multiple 
ADF/cofilin-type proteins. Cofilin-1 is the dominant isoform expressed in many cells lines 
(Wang et al., 2004) (Hotulainen et al., 2005) and we will refer to cofilin-1 as cofilin 
throughout the text. The specificity of the YTH Memo-cofilin interaction was confirmed 
using control plasmids (Fig 4A). A bait dependency test also demonstrated a specific 
interaction between Memo and cofilin in the YTH system (Supplementary Fig S3).  
 
To confirm the interaction between Memo and cofilin using purified proteins, Memo was 
expressed as a GST-fusion protein and its interaction with cofilin was tested in pull-down 
assays. Glutathione-sepharose bound GST-Memo was incubated with recombinant cofilin. 
Cofilin was recovered from GST-Memo beads but not from empty beads (Fig 4B lanes 4 and 
6). The interaction is specific since preincubation of cofilin with an excess of soluble Memo 
decreased the amount of cofilin interacting with GST-Memo beads (Fig 4B lane 7). In 
summary, Memo is a novel cofilin interacting protein.   
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Memo and cofilin interact in mammalian cells and complex with active ErbB2.  
Considering the importance of ADF/cofilin family members in cell migration (Ono, 2007) 
(Hitchcock-Degregori, 2006), we explored the Memo-cofilin interaction in mammalian cells.  
Memo IPs from lysates of T47D or MDA-MB435 cells, which express high cofilin levels 
(Wang et al., 2007) (Fig 4C upper and middle panel, respectively) were probed with a cofilin 
antibody (Song et al., 2006) revealing complexed cofilin. ErbB2 was also detected in Memo 
IPs from lysates of HRG-treated tumor cells, showing that Memo is recruited to the active 
receptor. The Memo interaction with cofilin and ErbB2 is specific since neither protein was 
detected in IPs carried out with an isotype matched control (Fig 4C). The cofilin specific 
antibody is not suitable for immunoprecipitation, which has precluded an examination of 
cofilin IPs for Memo and ErbB2.  
The activity of cofilin is inhibited by LIMK mediated phosphorylation on Ser-3, a 
modification that prevents the interaction of cofilin with F-actin (Ono, 2007). We examined 
the ability of Memo to interact with P-cofilin using a specific antiserum. In Memo IPs from 
T47D cells, P-cofilin was detected (Fig 4C lower panel), suggesting that Memo binds both 
active and inactive cofilin. Interestingly, in comparison to control cells where low levels of 
cofilin (Fig 4C upper and middle panel) and P-cofilin (Fig 4C lower panel) were found in 
Memo IPs, higher levels of cofilin/P-cofilin were complexed with Memo in lysates from 
HRG-treated tumor cells (Figs 4C). Whether or not this result reflects stabilization of the 
Memo-cofilin interaction at the activated receptor remains to be explored. 
Finally we examined the kinetics of formation of ErbB2, PLCγ1, cofilin and Memo 
containing complexes in response to HRG treated cells (Fig 4D). In lysates made from T47D 
cells treated 5 min with HRG, there was a strong increase in ErbB2 and cofilin 
coimmunoprecipitating with Memo and this complex was maintained throughout the 30 min 
time course. PLCγ1 was also evident in this complex after 5 minutes of HRG treatment and its 
level increased at 10 and 30 minutes (Fig 4D). 
 
Cofilin is essential for cell movement in response to HRG in Dunn chambers  
Cofilin has been shown to set the direction of tumor cell motility in response to EGF (Ghosh 
et al., 2004). We used Dunn chambers to examine the effect of cofilin KD on cell motility 
following ErbB2 activation. Cofilin levels were efficiently decreased in T47D cells (Fig 5 
insert) and tracks of migrating cells in a gradient of HRG were traced. The cofilin KD cells 
showed a dramatic reduction in their migratory ability. The speed of migration was 16% that 
of control cells (Fig 5 lower panel), resulting in a net translocation distance that was 13% of 
that achieved by control cells (Fig 5 upper panel). Double KD of Memo and PLCγ1 in the 
cells resulted in a stronger block in movement compared to cells with individual KD (Fig 5 
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vs. Fig 2). These results are in accordance with those obtained in Transwell assays (Fig 1A), 
where double KD of Memo and PLCγ1 had the strongest effect on random 
migration/chemokinesis. Since the cofilin KD cells and the double Memo and PLCγ1 KD 
cells were essentially stationary, it was not informative to calculate a directional persistence 
index. These results provide additional evidence that cofilin has an essential role in the 
motility behavior of cells in response to ErbB2 stimulation. Furthermore, the results suggest 
that in the initial stages of migration, Memo and PLCγ1 cooperate to stimulate migration and 
that cofilin is likely mediating these effects.  
 
PLCγ1 and Memo control GFP-cofilin localization in response to HRG. 
To gain more insight into the effect of ErbB2 on cofilin, we introduced GFP-tagged cofilin 
into SKBr3 breast tumor cells and examined its cellular distribution in response to HRG. 
SKBr3 cells were used since T47D cells are not suitable for transient expression of proteins. 
In the absence of ligand, GFP-cofilin was diffusely distributed in the cytoplasm, while 
following HRG treatment, it was recruited to the actin-rich lamellipodium (Fig 6A). These 
results are similar to what has previously been reported for cofilin distribution in a variety of 
cell types following growth factor stimulation (Dawe et al., 2003; Nagata-Ohashi et al., 2004). 
GFP-tagged Memo also localizes to the lamellipodium in HRG-treated SKBr3 cells (Fig 6B). 
 
Next, we monitored the localization of GFP-cofilin in Memo KD and PLCγ1 KD cells. In 
contrast to HRG-treated LacZ control cells in which GFP-cofilin localized to the lamellipodia, 
GFP-cofilin failed to be recruited to the F-actin rich lamellipodium and remained diffusely 
distributed in the cytoplasm of PLCγ1 KD cells (Fig 6C right panel) and Memo KD cells (Fig 
6C middle panel). These results suggest that both PLCγ1 and Memo have a role in cofilin 
cellular distribution, perhaps reflecting the fact that Memo-depleted or PLCγ1-depleted cells 
have alterations in the actin cytoskeleton.   
 
We also examined the effect of cofilin KD on the cellular distribution of Memo. Cofilin 
depletion in SKBr3 cells had a stronger effect on morphology than Memo KD or PLCγ1 KD, 
with the formation of multipolar lamellipodia. Individual cells (a typical one is shown in Fig 
6D middle panel) displayed extensions of several protrusions in different directions, a 
phenotype that has been reported in other models (Nishita et al., 2005; Sidani et al., 2007). 
Similar results were seen with cofilin KD T47D cells (data not shown). In striking contrast to 
the effects of Memo or PLCγ1 KD on GFP-cofilin localization, neither cofilin KD nor PLCγ1 
KD affected the ability of GFP-Memo to associate with the plasma membrane in response to 
HRG (Fig 6D, middle and right panels). In conclusion, these results suggest that PLCγ1 as 
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well as Memo are upstream of cofilin in response to ErbB2 activation. Cofilin activity is 
influenced by multiple mechanisms including PIP2 binding (Moon and Drubin, 1995). PLCγ1 
mediated hydrolysis of PIP2, as reported downstream of EGFR (van Rheenen et al., 2007), 
likely contributes to the release of an active pool of cofilin that participates in actin dynamics 
in stimulated treated cells. Considering that Memo is involved in PLCγ1 activation, the effect 
of Memo KD on GFP-cofilin localization might be through PLCγ1, something that will be 
examined in the future.  
 
Furthermore, phosphorylation of cofilin on Ser-3 also influences its activity. As a measure of 
cofilin activity in HRG-treated breast tumor cells, we examined its P-Ser3 status with a 
specific antiserum. The basal level of P-cofilin in T47D and SKBr3 tumor cells is high, and 
there were no obvious decrease in P-cofilin levels in response to HRG (Fig 4C, lower panel, 
Supplementary Fig S4 panel A). Furthermore, there were no changes in P-cofilin levels in 
Memo KD or in PLCγ1 KD cells (Supplementary Fig S4 panel B), suggesting that only a 
small pool of cofilin might participate in generating the dynamic actin structures observed 
following ErbB2 activation.  
 
F-actin binding and depolymerization assays. 
In the following experiments we examined the effects of Memo and cofilin on in vitro F-actin 
depolymerization. First, the ability of recombinant Memo and cofilin proteins to bind F-actin 
was examined. Actin was polymerized then mixed with Memo or cofilin alone, or in 
combination. Actin filaments were sedimented by centrifugation and the supernatant and F-
actin containing pellet fractions were recovered. Scanning densitometry of the Coomassie 
Brilliant Blue-stained gels (Fig 7A upper panel) was performed to quantify the amount of 
proteins in each fraction (Fig 7A lower panel). Assays with α-actinin and BSA served as 
positive and negative binding controls, respectively. When incubated with F-actin, the 
majority of α-actinin, was found in the pellet (sample 3), while BSA remained in the 
supernatant (sample 4).  Cofilin, a well established F-actin binding protein (Bamburg, 1999; 
Paavilainen et al., 2004) shifted from 35% in the pellet when alone (sample 5) to 58% in the 
pellet in the presence of F-actin (sample 6). Interestingly, there was also a shift for Memo 
from 35% in the pellet when alone (sample 7) to 45% when incubated with F-actin (sample 
9), suggesting that Memo directly binds F-actin. When Memo and cofilin were both incubated 
with F-actin (sample 10), there were no differences in cofilin or Memo content in the F-actin 
pellet (58% and 47%, respectively). To confirm the Memo-actin interaction in vivo, Memo 
was immunoprecipitated from lysates of T47D breast tumor cells. In control IgG IPs, no actin 
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was evident, while actin was present in Memo IPs from cells treated or not with HRG (Fig 
7B).   
 
The ability of a protein to depolymerize/severe F-actin can be assessed by measuring the shift 
of actin from the pellet to the supernatant fraction. Memo addition to F-actin did not alter the 
% of actin in the supernatant (Fig 7A, 13.4% vs. 14% sample 1 vs. 9); while addition of 
cofilin, a known F-actin depolymerizing protein resulted in a shift of actin from 13.4% to 
16% in the supernatant (Fig 7A, sample 1 vs. 6). Interestingly, there was a further increase of 
actin in the supernatant to 20% when cofilin and Memo were added together with F-actin (Fig 
7A sample 10), suggesting that Memo might influence the activity of cofilin. 
 
In Fig 8, additional experiments were performed to test Memo’s effect on cofilin 
depolymerizing/severing activity. Increasing amounts of Memo were mixed with 
fixed amounts of G-actin and cofilin. Actin polymerization was initiated then the 
pellet and supernatant fractions were analyzed as above (Fig 8). When incubated 
alone, 9% of the actin was detected in the supernatant (sample 1), while addition of 
cofilin to actin resulted in an increase of the actin content in the supernatant to 12% 
(sample 3). In samples 4-6, increasing amounts of Memo were included in the assay.  
This resulted in an increase of cofilin (24%, 27% & 31%, resp.) and actin (17.3%, 
19.8% & 17%, resp.) in the supernatant fractions. These results suggest that in the 
presence of Memo, the ability of cofilin to mediate F-actin depolymerization/severing 
is promoted.   
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Discussion 
In breast cancer, ErbB2 overexpression correlates with an aggressive metastatic phenotype 
(Hynes and Lane, 2005). We have been exploring signaling pathways activated by ErbB2 
with the aim of identifying proteins recruited by the receptor that are essential for tumor cell 
migration. Activated ErbB2 is complexed with multiple proteins that couple the receptor to a 
variety of intracellular signaling pathways (Olayioye et al., 2000). We show here that two 
proteins, Memo and PLCγ1, are required for HRG-induced tumor cell migration. Depletion of 
either Memo or PLCγ1 has similar effects on cell motility and on the actin and MT 
cytoskeleton. Furthermore, in Dunn chambers, we observed that in the absence of either 
Memo or PLCγ1, cells could migrate in response to HRG, albeit more slowly than control 
cells. However, loss of Memo or PLCγ1 had a dramatic effect on cell directionality. Indeed, 
both proteins are essential for the persistent directed migration of tumor cells up a gradient of 
HRG. Furthermore, we show that Memo binds cofilin and stimulates its F-actin 
depolymerization/severing activity.  Finally, simultaneous KD of Memo and PLCγ1, like 
cofilin KD, almost completely blocked migration. Taken together, these results suggest that 
both Memo and PLCγ1 converge on cofilin, in an ErbB2 initiated migratory pathway.  
 
PLCγ1 has a well-described role in PIP2 hydrolysis (Patterson et al., 2005) and is known to 
mediate chemotaxis towards a number of growth factor activated RTKs (Wells, 2000). We 
show here that transient KD of Memo in T47D cells causes an impairment of PLCγ1 
activation in response to HRG.  These results were confirmed using T47D cells with stable 
shRNA-mediated Memo down-regulation (provided by Gwen MacDonald) (data not shown). 
Although we cannot rule out a direct effect of Memo on the activity of PLCγ1 recruited to 
ErbB2, we consider it more likely that Memo’s effects are indirect. There is accumulating 
evidence that PLCγ1 has an important role in integrin-mediated adhesion and migration. 
PLCγ1 has been detected in integrin complexes (Choi et al., 2007) where it is activated by Src 
(Jones et al., 2005). It is possible that alterations in the actin cytoskeleton resulting from 
Memo depletion impact on the ability of integrin complexes to activate PLCγ1.  
 
Considering Memo’s novel role in PLCγ1 activation, it is possible that the major effect of 
Memo depletion is via decreased PLCγ1 activity. Although it cannot be completely ruled out, 
we consider this unlikely for various reasons. Compared to cells with individual depletion of 
Memo or PLCγ1, simultaneous KD of both proteins has a more dramatic effect on the actin 
cytoskeleton of the cells (Fig 1B) and on their migration in Transwell assays (Fig 1A) and in 
Dunn Chambers (Fig 5). Interestingly, the double KD cells behave like add-back cells 
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expressing an ErbB2 mutant lacking all autophosphorylation sites (NYPD cells). These cells 
are impaired in their migratory ability in Transwell assays (Marone et al., 2004) and are 
totally blocked in the Dunn Chamber assay (supplemental data Fig S5). These results would 
not be expected if Memo’s only cellular role was to ensure proper PLCγ1 activation. 
Furthermore, F-actin sedimentation assays showed that Memo positively influences cofilin 
activity, a role of Memo that is likely to be independent of PLCγ1.  
 
We favor the hypothesis that Memo and PLCγ1 each have several roles in migration. 
Following acute ErbB2 activation, when both proteins are recruited to the receptor, they act in 
concert to stimulate the migratory process. PLCγ1 activation promotes the localized release of 
PIP2-bound cofilin, which stimulates alterations in actin dynamics. Indeed in the MTLn3 rat 
cancer cell model, rapid PLCγ1 activation following EGF treatment (van Rheenen et al., 
2007) has been implicated in an increase in cofilin-mediated severing and an increase in actin 
barbed ends at the leading edge of the cell (Chan et al., 2000; DesMarais et al., 2005). 
However, PLCγ1 is not only activated by RTKs, but has also been detected in integrin 
complexes (Choi et al., 2007), where it is activated by Src (Jones et al., 2005). Indeed, in 
some cellular models it has been found that PLCγ1 has migratory functions independent of 
RTK activation (Jones et al., 2005). 
 
Memo might also have multiple roles in the migratory process. Considering that Memo and 
cofilin were detected in complexes with activated ErbB2, and that Memo directly binds 
cofilin, it is possible that one role of Memo is to escort cofilin to the leading edge of the cell. 
Indeed, both GFP-Memo and GFP-cofilin rapidly associate with lamellipodia following HRG 
treatment (Fig 6). In the receptor complexes, Memo might also bind the pool of cofilin 
released by PLCγ1-mediated PIP2 hydrolysis. Both these activities would result in an 
enrichment of cofilin at the cell periphery where it could participate in regulating actin 
dynamics. In coimmunoprecipitation assays, Memo was also detected in complexes with 
inactive P-cofilin. Memo might also have a role in the dephosphorylation and ensuing 
activation of cofilin. Although it should be mentioned that in the breast cancer models used in 
our studies, we did not detect any changes in P-cofilin levels in response to HRG.  
 
 Memo appears to be a novel actin binding protein. A calponin homology (CH) domain has 
been identified in many actin binding proteins (Castresana and Saraste, 1995; Gimona et al., 
2002). However, no CH domain has been identified in the crystal structure of Memo (Qiu et 
al., 2008). Future work will be aimed at testing if Memo binds both G-actin and F-actin, as 
well as determining the domain of Memo needed for binding. Moreover, by testing 
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recombinant Memo and cofilin in the F-actin sedimentation assay, we showed that Memo 
stimulates the F-actin depolymerizing/severing activity of cofilin. ADF/cofilin family proteins 
are regulated by multiple mechanisms, including interactions with other proteins, such as 
Aip1 and CAP (Paavilainen et al., 2004) that also influence actin dynamics. Future 
experiments will be aimed at determining the domains of Memo and cofilin that interact and 
the mechanism underlying Memo’s role in cofilin regulation.  
 
In summary, the results presented here show that Memo is a novel player in controlling actin 
cytoskeleton dynamics. The essential role of Memo in cell migration might make it an 
interesting target in metastatic cancer.  
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Materials and Methods 
Reagents, recombinant proteins, antibodies and plasmids 
HRG-β1, referred to as HRG, was purchased from R&D Systems (Inc., Minneapolis, MN). 
Human recombinant cofilin was from Cytoskeleton. For actin cosedimentation and 
depolymerization assays, the actin binding spin-down assay kit (BK001) from Cytoskeleton 
was used. Purification of Memo was described previously (Qiu et al., 2008). Polyclonal 
antibodies to a 19 amino acid peptide of Memo were produced in rabbits (aa 25-43 human 
Memo NM_015955: NAQLEGWLSQVQSTKRPAR); the same peptide was used for Memo 
mAb production in mice. Isotype matched IgG2a control serum for Memo and IgG3 control 
serum for PLCγ1 were purchased from Sigma. The affinity-purified chicken anti-cofilin 
antibody AE774 (Song et al., 2006) was provided by Dr. John Condeelis (Albert Einstein 
college of Medicine) and the rabbit anti-cofilin antibody was from Cell Signaling (≠3312). 
Phospho-cofilin (rabbit anti P-Ser3-cofilin ≠3311) and phospho-p44/42 MAPK (Thr 202/204) 
were from Cell Signaling. Rabbit and mouse anti-PLCγ1 antisera were from Santa Cruz (≠sc-
81 and ≠sc-7290 respectively). β-Tubulin antiserum was provided by Dr. Brian Hemmings 
(FMI, Basel). Phospho-Tyrosine was detected with the 4G10 mAb (gift from Dr Juergen 
Mestan, NIBR Basel). For ErbB2, the 21N polyclonal antiserum was used in westerns (Lane 
et al., 2000) and mAb FRP5 was used in IPs (Harwerth et al., 1992). Memo was cloned into 
pCDNA3.1+ containing the GFP-tag. The GFP-Cofilin construct was provided by Dr. John. 
Condeelis. 
 
Yeast Two-Hybrid (YTH) analysis 
The analysis was carried out as described previously (Pedrazzi et al, 2004). Full-length human 
Memo cDNA was cloned into pLexA-Kan (Dualsystems Biotech AG) as a fusion with the 
LexA DNA binding domain, and was used as bait. The peripheral blood cDNA library was 
fused to the GAL4-activation domain in the pACT2 vector (Clontech Laboratories, Inc). The 
yeast reporter strain L40 was used. Transformants were selected in dropout plates and positive 
clones were identified. Growth in the absence of histidine and in the presence of 
βgalactosidase indicates an interaction. Plasmid DNA was isolated from the yeast clones and 
rescued into E.coli and a bait-dependency test was performed whereby each isolated plasmid 
was retransformed into yeast together with the control bait (pLexA-Kan without Memo), 
followed by growth selection and quantitative LacZ assay. Bait-dependent positive clones 
were sequenced and subjected to BLAST analysis. 
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Cell culture and transfections 
T47D, NYPD, SKBr3, MDA-MB435 breast carcinoma cells and HEK-293 (Human 
Embryonic Kidney) cells were maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 10 % Fetal Calf Serum (GIBCO Invitrogen AG, Basel, Switzerland). 
GFP-Memo and GFP-cofilin constructs were transfected into SKBr3 cells using FuGene -6 
Transfection Reagent (Roche Diagnostics, Indianapolis, IN). T47D and SKBr3 cells were 
transfected with siRNA using HiPerFect (Qiagen) according to the manufacturer’s 
instructions. For dual transfection of SKBr3 cells with siRNA and plasmid constructs, 
DharmaFECT DUO reagent (DHARMACON) was used. The following siRNAs obtained 
from Qiagen were used for transient KD. For control LacZ (target sequence: 
AAGCGGCTGCCGGAATTTACCTT), for PLCγ1 (target sequence: 
AAGGCCTGAAGACAGGATACA), for Memo, we used a previously validated siRNA (Marone 
et al., 2004) (target sequence: AAGACCTGCTAGAGCCATTAT), for cofilin (target sequence: 
AACCTATGAGACCAAGGAGAG). Knock-down was maximal after 72 hours; accordingly, cells 
were plated in Boyden chambers 3 days after siRNA transfections and allowed to migrate for 
24 hours. For Dunn migration assays, cells were plated on coverslips 3 days after siRNA 
transfections and migration tracks were visualized over 4 to 12 hours.  
 
Immunoprecipitations, GST-pull down and immunoblotting 
Cells were stimulated or not with 1nM HRG, extracted in NP-40 buffer and protein lysates 
were immunoblotted as described previously (Marone et al, 2004). For immunoprecipitation 
experiments, cells (stimulated or not with 10nM HRG) were lysed in Triton X-100 buffer (50 
mM Tris pH 7.5, 5 mM EGTA, 150 mM NaCl, 1.5 mM MgCl2, 25 mM β-glycerophosphate, 
25 mM NaF, 1 % Triton X-100, 1 % Glycerol, 10 μg ml-1 leupeptin, 10 μg ml-1 aprotinin, 2 
mM sodium orthovanadate, and 0.5 nM  phenylmethylsulphonylfluoride ). Equal amounts of 
cell lysates were incubated overnight at 4°C with antibody. During the course of our studies, 
we noted that pretreatment of cells with CoCl2 (500μM) enhanced the levels of Memo in the 
IPs. This was not due to a CoCl2-induced increase in Memo protein levels, but is likely a 
consequence of increasing epitope availability. Thus, in some experiments, Memo IPs were 
made with lysates from CoCl2 treated cells (Fig 4C), however, cofilin could also be detected 
in Memo IPs made with lysates from untreated cells (Fig 3A, left panel and 4D). 
Immunocomplexes were collected with protein-A or -G-sepharose beads (Sigma), and 
centrifuged. The supernatant was subjected to a second round of immunoprecipitation. The 
two pellets were combined and washed three times with Triton X-100 buffer. Proteins were 
then released by boiling in sample buffer, blotted onto polyvinylidene difluoride membranes 
(Millipore Corporation) and probed with the specific antibodies. Immunoprecipitations for 
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PLCγ1 was also performed on siRNA treated T47D cells. For GST pull-down experiments, 
purified GST-Memo was incubated with gluthatione sepharose beads (GE Healthcare) in 
TEN100 buffer (20mM Tris, pH 7.4, 0.1mM EDTA and 100mM NaCl), then beads were 
washed. Immobilized GST-Memo was incubated with 5 μg human recombinant cofilin 
(Cytoskeleton). Beads were washed four times with TEN300 buffer (20mM Tris, pH 7.4, 
0.1mM EDTA and 300mM NaCl), and bound proteins were eluted in sample buffer and 
visualized using western blot analysis. In the same experiment, cofilin was also incubated 
with a five-fold molar excess of soluble Memo (40 μg) (Qiu et al., 2008) 1hour prior to 
incubation with GST-Memo immobilized beads.  
 
 
Immunofluorescence microscopy. 
Cells were grown on glass coverslips (BD Biosciences) coated with 25ug ml-1 rat tail collagen 
I (Roche Diagnostics GmbH), serum-starved overnight at 37°C and stimulated with 1nM 
HRG for different times. Cells were fixed with 4 % paraformaldehyde and 3 % sucrose in 
PBS, permeabilized in 0.2% Triton X-100 in PBS, and blocked with 1% bovine serum 
albumin in PBS before incubation with the primary anti-α Tubulin antibody. Alexa-Fluor 546 
conjugated anti-rat antibody (Molecular Probes) was used as secondary antibody. F-actin was 
stained at RT with 2 U ml-1 FITC- labelled phalloidin (Sigma). Cells were washed with PBS-
Tween 0.1% and mounted with a mounting solution (Calbiochem). Mounted samples were 
examined using an Olympus IX70 microscope linked to the DeltaVision workstation (Applied 
Precision). For GFP-transfected cells, F-actin was stained with 2 U ml-1 TRITC-labelled 
phalloidin (Sigma). Images were recorded with an Axioskop Zeiss Microscope coupled to a 
Sony 3 CDD camera. 
 
Cell migration assays 
For cell migration assays using Boyden chambers, serum starved transfected cells were 
seeded on a 8-μm-pore polycarbonate membrane (Corning Costar Products, Acton, MA) 
previously coated with rat tail collagen I (25μg ml-1). For the chemotaxis analysis, the lower 
chamber was filled with 600μl of DMEM with or without 1nM HRG; for the chemokinesis 
analysis, both chambers contained 1nM HRG. After incubation at 37°C for 24 hours, non-
migrated cells were washed and scraped from the membrane top. Migrated cells were fixed in 
4% formaldehyde and stained with 0.1 % crystal violet. Cells were counted and migration was 
expressed as cell number per mm2. Chemotaxis was also analyzed by direct visualization of 
cell migration in a gradient of HRG using Dunn chambers (DCC100; Hawksley). Serum-
starved cells were seeded onto a glass coverslip previously coated with 25ug μl-1 rat tail 
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collagen I. Cells were inverted over the DCC chamber consisting of two concentric wells 
separated by an annular bridge. The outer well contained 10nM HRG in DMEM, whereas the 
inner well was filled with DMEM. A linear gradient of HRG was formed by diffusion across 
the bridge separating the two wells. Migration of the cells lying directly above the bridge was 
visualized using a Widefield TILL5, LONG RUN, Axiovert 200M (5 % CO2 and 37°C 
chamber). Time lapse images were digitally captured every 3 minutes with a CCD camera 
over a time frame of 4 to 12 hours. Migration paths were quantified using the Imaris software 
and the data were plotted with Microsoft Excel. The data are expressed as net translocation 
distance (straight distance between the start and the end point), migration speed (total length 
of cell migration during the capturing time) and directional persistency index (ratio between 
the straight distance and the total distance). Decagonal histograms were constructed to 
represent the directionality of cell migration. The percentage of cells whose final position was 
within the different sectors was indicated, the source of HRG was on the top.  
 
 
F-actin cosedimentation and actin depolymerization assays 
For these assays, the protocol provided by Cytoskeleton was used. For F-actin 
cosedimentation, 40μg of G-actin was polymerized in F-actin buffer (final concentration: 
5mM Tris-HCl pH 8.0, 0.2 mM CaCl2, 50mM KCl, 2mM MgCl2, and 1mM ATP). 
Polymerized F-actin was incubated for 30 minutes with: α-actinin (10μg), BSA (6.8μg), 
Cofilin (5μg) and/or Memo (3μg). Samples were ultracentrifuged at 150 000 x g. Equivalent 
amounts of supernatant and pellet fractions were separated on a 10% SDS-PAGE and stained 
with 0.1% Coomassie Brilliant Blue (CBB) prior to quantification by densitometric analysis 
of the CBB-stained gel. In Fig 7A, the molar ratios of cofilin or Memo to actin were: 
cofilin:actin, 0.25:1, memo:actin, 0.05:1. The actin depolymerization assay was performed by 
incubating G-actin (40μg) for 30 minutes together with cofilin (20μg) and/or Memo (3, 6 or 
9μg) in the same F-actin buffer. Samples were ultracentrifugated at 150 000 x g and the 
resulting precipitates and supernatants were analyzed as described above. Molar ratios of 
cofilin or Memo to actin were the following: cofilin:actin, 1:1, memo:actin, 0.05, 0.11 or 
0.16:1.  
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Figure legends 
 
Figure 1. PLCγ1 and Memo are required for ErbB2-mediated cell motility. (A) (Left 
panel) SKBr3 cells were transfected with LacZ, Memo and/or PLCγ1 siRNAs. Control 
responses in the absence of ligand, as well as chemotactic responses towards 1nM HRG and 
chemokinetic responses in the presence of 1nM HRG were determined in Boyden chamber 
assays. The data are representative of several independent experiments. (B) (Left panel) 
Immunofluorescence microscopy of HRG-stimulated T47D cells treated with LacZ, Memo, 
or/and PLCγ1 siRNAs and labeled with Alexa-Fluor-488-phalloidin (green) or an anti-α-
Tubulin (red) antibody. (A and B Right panels) Extracts were prepared and analyzed for 
Memo and/or PLCγ1 downregulation; α-Tubulin was used as a control. Bar, 10μm. 
 
 
Figure 2. Effect of Memo and PLCγ1 knock-down on HRG-induced chemotaxis in Dunn 
chambers. T47D cells were transiently transfected with LacZ, Memo or PLCγ1 siRNAs and 
3 days later were analyzed for their ability to migrate in a gradient of HRG. (A) Track 
displacement was followed during a period of 12 hours. The gradient follows the path from 
the bottom left to the top right. Gray arrows indicate the direction of individual cells. Cell 
displacement over the time course is indicated with the colored line (zero, intermediate and 
final time points are in blue, red and yellow, respectively). Down regulation of Memo or 
PLCγ1 was confirmed by western analysis, α-Tubulin was loaded as a control. (B) (Left 
panel) The net translocation distance is shown as the mean +/- SEM of the displacement of 61 
cells. (Middle panel) The migration speed is shown as the mean +/- SEM of the paths of 61 
cells. (Right panel) The directional persistency index of control LacZ, Memo or PLCγ1 KD 
cells is shown. (C) Decagonal histograms indicating the distribution of cells at their final 
location. The source of HRG is at the top.  
 
 
Figure 3. Memo complexes with PLCγ1 and ErbB2 and regulates PLCγ1 
phosphorylation in tumor cells. 
(A) (Left panel) T47D cells were stimulated or not with 10 nM HRG and cell extracts were 
subjected to immunoprecipitation using a Memo mAb. IPs were probed for PLCγ1 and 
Memo; a mouse IgG2a mAb was used as a control. (Right  panel). T47D cells were stimulated 
or not with 10 nM HRG. Cell extracts were subjected to immunoprecipitation using a PLCγ1 
antibody and IPs were probed for PLCγ1 and Memo. Whole cell lysates (W) were loaded as 
controls. (B) (Left panel) T47D cells were stimulated or not with 10 nM HRG for 5 minutes. 
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Cell extracts were subjected to immunoprecipitation using a PLCγ1 mAb; IPs were probed for 
P-Tyr and for PLCγ1. (Middle and right panels) T47D cells were transiently transfected with 
LacZ or Memo siRNA, and stimulated or not for 5 minutes with 10 nM HRG. Cell extracts 
were subjected to immunoprecipitation using a PLCγ1 mAb (Middle panel) and PLCγ1 
phosphorylation was analyzed by western blotting using a P-Tyr mAb. Blots were reprobed 
for PLCγ1. Memo and PLCγ1 levels in transfected cells were monitored in whole cell lysates 
(W) using the respective antibodies (right panel). 
 
 
Figure 4. Memo interacts with cofilin.  
(A) YTH analysis. The yeast reporter strain L40 was co-transformed with a plasmid encoding 
the LexA Binding Domain fused to Memo (pLexAKan-Memo) and a plasmid encoding 
GAL4 Activation Domain fused to the cofilin cDNA (pACT-Cofilin) (lower lane). The 
negative controls are: transformation with pLexAKan-Memo and the empty prey plasmid (2nd 
row) or pACT-BLM encoding a nuclear helicase (3rd row). βgalactosidase (βgal+) strain is 
used as a positive control (top row). (B) Pull down assay of GST-Memo/cofilin. Immobilized 
GST-Memo on gluthatione-sepharose beads was incubated with (lane 4) or without (lane 5) 
0.24 nmoles of recombinant human cofilin. As a control, cofilin was incubated with the 
glutathione sepharose beads (lane 6). In lane 7, a five fold molar excess of soluble Memo was 
added to cofilin 1 hour prior incubation with the GST-Memo immobilized beads. After 
incubation the beads were pelleted, washed, and the bound proteins were eluted and 
visualized after western analysis with Memo and cofilin polyclonal antibodies. GST-Memo 
immobilized beads, glutathione-sepharose beads and cofilin were loaded on the same gel 
(lanes 1, 2 and 3, respectively). (C) T47D (upper and lower panels) and MDA-MB435 
(middle panel) cells were stimulated or not with 10 nM HRG. Memo was immunoprecipitated 
using a mouse mAb; a mouse mAb IgG2a was used as a negative control. Co-
immunoprecipitating proteins were analyzed by western blotting and probed with ErbB2, 
Memo, cofilin or P-cofilin polyclonal antibodies. Whole cell lysates (W) were loaded as 
controls. (D) T47D cells were treated with 10 nM HRG for the indicated times. Cell extracts 
were subjected to immunoprecipitation using a Memo mAb and IPs were probed for ErbB2, 
PLCγ1, Memo and cofilin. Whole cell lysates (W) were loaded as controls.  
 
 
 Figure 5. PLCγ1, Memo and cofilin are required for ErbB2 mediated directional 
migration in Dunn chambers. T47D cells were transiently transfected with either LacZ or 
cofilin siRNAs, or simultaneously transfected with Memo and PLCγ1 siRNAs. Cell migration 
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was analyzed in a gradient of HRG in Dunn chambers for 4.5 hours. Net translocation 
distance and migration speed were calculated for 78 cells. Cofilin, Memo and PLCγ1 levels in 
KD cells were checked by western blotting with the respective antibodies. α-tubulin levels 
were monitored as a control. 
 
Figure 6. HRG-induced recruitment of cofilin to the lamellipodia is dependent on Memo 
and PLCγ1. (A) GFP-Cofilin-transfected and (B) GFP-Memo-transfected SKBr3 were 
stimulated or not with 1 nM HRG for 20 minutes. Cells were stained with a TRITC-labeled 
phalloidin antibody. Merged images are shown in the bottom panels. (C) SKBr3 cells were 
simultaneously transfected with GFP-Cofilin and LacZ, Memo or PLCγ1 siRNAs and HRG-
dependent recruitment of GFP-cofilin to the lamellipodia was visualized. The actin 
cytoskeleton was examined with a TRITC-labeled phalloidin antibody. (D) SKBr3 cells were 
simultaneously transfected with GFP-Memo and siRNAs for LacZ, cofilin or PLCγ1 and 
HRG-dependent recruitment of GFP-Memo to the lamellipodia was visualized. The actin 
cytoskeleton was examined with a TRITC-labeled phalloidin antibody. Bar, 10μm. 
 
 
Figure 7. F-actin binding experiments. For each reaction, samples of the supernatant (S) and 
pellet (P) fractions were collected and separated on a 10% SDS-gel. The gel was stained with 
0.1% Coomassie Brilliant Blue and quantified for actin, Memo and cofilin levels. The molar 
ratios of cofilin or Memo to actin were: cofilin:actin, 0.25:1, memo:actin, 0.05:1. (A) (Upper 
panel; left) F-actin binding assay. Reactions: 1, F-actin; 2, α-actinin; 3, α-actinin and F-actin; 
4, BSA and F-actin; 5, cofilin; 6, F-actin and cofilin (A+C); 7, Memo (M); 8, Memo and 
cofilin; 9, F-actin and Memo (A+M); 10, F-actin, Memo, and cofilin (A+M+C). (Upper 
panel; right) Percent of actin detected in the supernatant. (Lower panel) Quantification of 
cofilin (left) and Memo (right) levels in the supernatant and pellet fractions. (B) T47D cells 
were stimulated or not with 10 nM HRG for 5 minutes. Cell extracts were subjected to 
immunoprecipitation using a Memo mAb and an IgG mAb as a control ; IPs were probed for 
complexed actin and for Memo. Whole cell lysates (W) were loaded as controls. 
 
 
Figure 8. Effect of Memo on cofilin-induced actin depolymerization. For each reaction, 
supernatant (S) and pellet (P) fractions were collected, separated on a 10% SDS-gel and 
quantified after staining of the gel with 0.1% Coomassie Brilliant Blue. Molar ratios of cofilin 
or Memo to actin were the following: cofilin:actin, 1:1, memo:actin, 0.05, 0.11 or 0.16:1. 
Reactions: 1, G-actin; 2, G-actin and Memo; 3, G-actin and cofilin; 4 to 6, G-actin and cofilin 
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plus increasing Memo amounts. Actin (middle panel) and cofilin (lower panel) levels were 
quantified. 
 
 
Figure S1. Memo and PLCγ1 are required for HRG-induced SKBr3 migration (Left 
panel) SKBr3 cells were treated 10 minutes or not with HRG. Down-regulation of PLCγ1 
and/or Memo in SKBr3 cells with specific siRNAs was confirmed by western blotting using 
specific antibodies. Phosphorylation of ERK in response to HRG was tested in control (LacZ) 
and KD cells. (Right panel) HRG-dependent chemotactic migration of SKBr3 cells was 
measured in Boyden chamber assays after Memo and/or PLCγ1 siRNA transfections. The 
results are representative of independent experiments. 
 
 
Figure S2. Memo is found in a complex with ErbB2 and PLCγ1 (Left panel) SKBr3 cells 
were stimulated with 10 nM HRG for 10 minutes. Cell extracts were subjected to 
immunoprecipitation using an ErbB2 mAb; IPs were probed for P-Tyr, PLCγ1, Memo and for 
ErbB2. (Middle panel) T47D cells were stimulated or not with 10 nM HRG for 10 minutes. 
Cell extracts were subjected to immuno-precipitation using a Memo mAb. IPs were probed 
for ErbB2, PLCγ1 and Memo. (Right panel) HEK293 cells were stimulated or not with 10 nM 
HRG for 10 minutes. Cell extracts were subjected to immunoprecipitation using either a 
Memo mAb and complexed PLCγ1 was detected, or using a PLCγ1 antibody and complexed 
Memo was detected; a mouse IgG3 mAb was used as a control for PLCγ1 IP. Whole cell 
lysates (W) are indicated in the three panels. 
 
 
Figure S3. Bait dependency assay. Binding specificity was verified with a bait-dependency 
test whereby the reporter strain was transformed with the empty bait plasmid (pLexAKan) 
and the pACT-Cofilin plasmid. A false positive candidate is shown (pACT-TZF encoding for 
a testis zinc finger protein).  
 
 
Figure S4. Analysis of P-cofilin levels in breast tumor cells. (A) T47D (upper panel) and 
SKBr3 (lower panel) breast tumor cells were stimulated with 1 nM HRG for the indicated 
periods of time. Western blot analysis was performed on extracts using a P-cofilin specific 
antibody. α-Tubulin was loaded as a control. (B) T47D cells were treated with LacZ, Memo 
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and PLCγ1 siRNA and stimulated with 1 nM HRG for the indicated periods of time. Extracts 
were prepared and a western analysis was performed to control for PLCγ1 and Memo down-
regulation and to examine P-Ser3 Cofilin levels. 
 
 
Figure S5. HRG-induced chemotaxis of T47D and NYPD cells in a Dunn chamber assay. 
T47D and NYPD were analyzed for their ability to migrate in a gradient of HRG. The 
migration of 23 cells was followed during 4.5 hours. Net translocation distance and migration 
speed were evaluated. 
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Summary 
 
ErbB2 controls key intracellular pathways that govern fundamental cellular processes 
including migration. Studies on the functional role of ErbB2 phosphorylation sites identified 
Memo (Mediator of ErbB2-driven Cell Motility), a 297 amino-acid protein that is required for 
ErbB2-induced cell motility. Memo has no characterized domains, nor does it have obvious 
catalytic activity, and its biochemical and cellular functions still remain poorly understood. In 
this study, we show that Memo interacts with the three Shc isoforms, p46shc, p52shc, and 
p66shc, and we provide evidence that Shc is required for Memo binding to the ErbB2 receptor. 
To gain more insight into Memo’s function, we used Memo-defective cells and showed that 
inhibition of Memo impairs activation of a number of signaling molecules including Src, Shc, 
ERK, and PLCγ1. Furthermore, Memo-deficient cells exhibited defective migration and 
adhesion properties. A morphological study revealed that inhibition of Memo results in a 
defect in rear cell deadhesion. Biochemical approaches indicated that Memo is involved in 
focal adhesion organization. Our data suggest a broad engagement of Memo in distinct steps 
of the metastatic process, making it an interesting target for cancer therapy.  
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Introduction 
Cell migration is an essential and complex multistep process that plays an important role 
during development and adult life ((Kurosaka and Kashina, 2008); (Martin and Parkhurst, 
2004); (Yang et al., 2002); (Moser and Loetscher, 2001); (Thelen, 2001)). Migration also 
contributes to several pathological disorders, such as cancer or vascular and inflammatory 
diseases ((Condeelis et al., 2005), (Smart and Riley, 2008); (Le et al., 2004); (Murphy, 2001); 
(Wardlaw et al., 2000); (Worthley et al., 2001); (Tarrant and Patel, 2006)). Increased motility 
and invasiveness are important properties that contribute to metastasis of cancer cells to 
distant organs (Kedrin et al., 2007). A growing number of proteins with roles in the metastatic 
process are being pursued as potential therapeutic targets. The ErbB2 receptor tyrosine kinase 
has been implicated in the development of many types of human cancer, including breast and 
ovarian cancer (Slamon et al., 1989). Clinical studies revealed that ErbB2 gene amplification 
and overexpression correlate with an aggressive metastatic phenotype ((Slamon et al., 1987); 
(Berger et al., 1988)). Accordingly, the role of ErbB2 in cancer biology and in the metastatic 
process has been under intense scrutiny (Hynes and Lane, 2005).  
 
ErbB2 belongs to the epidermal growth factor (EGF/ErbB) family of receptor tyrosine kinases 
(RTK), which also includes EGF receptor (EGFR), ErbB3 and ErbB4 (Yarden and 
Sliwkowski, 2001). Ligand binding initiates signaling by inducing the formation of specific 
homo- or heterodimeric complexes, followed by activation of the cytoplasmic kinase domain 
which phosphorylates diverse Tyrosines (Tyr) in the tail region of the receptor (Burgess et al., 
2003). Phosphorylation of these Tyr residues induces the binding of specific signaling 
molecules that initiates downstream signaling events (Schlessinger, 2000). ErbB2 is the 
preferred heterodimerization partner of the other ErbB members (Graus-Porta et al., 1997), 
and is exclusively activated via heterodimerization with another ligand bound ErbB receptor 
(Olayioye et al., 2000). In a screen for ErbB2 interacting proteins with roles in cell migration, 
a novel protein, Memo, and ShcA, were found to bind specifically the Tyr 1201 ErbB2 
autophosphorylation site (Marone et al., 2004). 
 
The adaptor protein ShcA, which is referred as Shc throughout the text, is involved in 
coupling receptor and non-receptor tyrosine kinases, to downstream signaling pathways 
(Ravichandran, 2001). ShcA encodes three widely expressed isoforms, p46shc, p52shc, or p66shc 
that derive from differential transcription and alternative splicing (Ravichandran, 2001) (Luzi 
et al., 2000). ShcA contains both phosphotyrosine-binding (PTB) and SH2 domains that bind 
to the activated receptors (Sakaguchi et al., 1998) and becomes phosphorylated on tyrosine 
residues in response to diverse stimuli ((van der Geer and Pawson, 1995); (Bonfini et al., 
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1996)). All three isoforms contain three conserved tyrosine residues (Tyr 239/240 and Tyr 
317) within the central proline rich CH1 domain that are phosphorylated, and serve as 
docking sites for downstream signaling molecules such as Grb2 ((van der Geer et al., 1996); 
(Salcini et al., 1994)). Activation of tyrosine kinases including Src, Fyn, and focal adhesion 
kinase (FAK) that phosphorylate Shc, lead to Grb2 recruitment , Ras and MAPK activation 
and entry into the cell cycle ((McGlade et al., 1992); (Mainiero et al., 1995); (Wary et al., 
1996); (Wary et al., 1998); (Schlaepfer et al., 1998)).  
 
Memo is encoded by a unique gene and orthologues are found in all branches of life, from 
bacteria to human. The 2.1 Å crystal structure of Memo revealed that it is homologous to 
LigB from Sphingomonas paucimobilis, a bacterial class III nonheme iron-dependent 
dioxygenase (Qiu et al., 2008). However to date, no enzymatic activity or metal binding have 
been detected, making it unlikely to be a novel dioxygenase. Memo was initially detected 
based on its important role in ErbB2-induced cell motility. In fact, tumor cells with a specific 
knock-down (KD) of Memo failed to grow microtubules in response to Heregulin (HRG) 
induced ErbB2 activation and were impaired in their migration (Marone et al., 2004). In a 
recent study, we explored in more detail the mechanism underlying Memo-mediated ErbB2-
dependent cell motility, and showed that Memo regulates actin dynamics by interacting with 
cofilin, a known actin depolymerizing/severing factor, enhancing cofilin function (Meira et 
al., submitted). We also found that Memo is a novel F-actin binding protein that is required 
for HRG-induced cytoskeletal organization and directional migration of breast tumor cells 
(Meira et al., submitted), suggesting a novel role for Memo in the migratory process.  
 
Cell migration proceeds in distinct coordinated steps which operate cyclically (Lauffenburger 
and Horwitz, 1996) and are controlled by different effector proteins (Raftopoulou and Hall, 
2004). In response to a chemotactic stimulus, regulators of polarity at the front and the rear 
are activated ((Itoh et al., 2002); (Iijima et al., 2002); (Merlot and Firtel, 2003; Sakaguchi et 
al., 1998); (Yam et al., 2007); (Vicente-Manzanares et al., 2007)), leading to a polarized 
extension of protrusions and adhesion formation at the front ((Geiger and Bershadsky, 2001); 
(Rottner et al., 1999)). Actin polymerization and nucleation generates the protrusive force 
allowing cell translocation. This is followed by contraction of the cell body and tail 
detachment at the rear inducing movement in the direction of the ligand ((Kolega, 2003); 
(Kaverina et al., 1999); (Wehrle-Haller and Imhof, 2003)). Therefore, chemotaxis also 
depends upon focal adhesion disassembly at the cell rear and inhibition of this process results 
in a contractile or tail-retraction defect that impairs migration (Sturge et al., 2006). 
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Focal adhesions are specialized regions of tight interaction between cytoskeletal or membrane 
components of a cell and the extracellular matrix (Burridge and Chrzanowska-Wodnicka, 
1996). These domains of integrin clustering are also sites of signal transmission into the 
intracellular compartment ((Juliano and Haskill, 1993); (Clark and Brugge, 1995)). A number 
of proteins with structural roles or with roles in signal transduction have been identified, 
mainly at the cytoplasmic face of focal adhesions (Sastry and Burridge, 2000). 
Focal adhesion kinase (pp125FAK or FAK) is a non-receptor protein tyrosine kinase that acts 
both as a signaling and a scaffolding protein at sites of integrin adhesion ((Mitra et al., 2005); 
(Parsons et al., 2000); (Sieg et al., 2000)). Integrin clustering promotes FAK 
autophosphorylation at Tyr 397, which creates a binding site for the Src-homology (SH)2 
domain of Src ((Schaller et al., 1994); (Calalb et al., 1995)). Src binding to FAK contributes 
to Src activation, promoting further phosphorylation of FAK at additional tyrosines (Brunton 
et al., 2005). The catalytic activity of Src has been shown to trigger focal adhesion 
disassembly (Fincham and Frame, 1998). Moreover, Src-dependent FAK phosphorylation has 
been shown to be required for focal adhesion turnover and cell migration (Westhoff et al., 
2004). FAK null fibroblasts exhibit a decreased rate of migration and spreading, and an 
increase in the number and size of peripherally localized adhesions (Ilic et al., 1995). 
Similarly, inhibition of Src also results in a reduced motility and spreading, with the 
formation of large peripheral adhesions ((Klinghoffer et al., 1999); (Fincham and Frame, 
1998)). 
The FAK−Src complex mediates the phosphorylation of the well-studied scaffolding paxillin 
protein, which recruits other molecules to the adhesions ((Bellis et al., 1995); (Webb et al., 
2004)). Another important target of FAK-Src signaling is the mitogen-activated protein kinase 
(MAP kinase)/ERK cascade (Schlaepfer et al., 1999). Activation of calpain-2 by ERK2 
induces calpain-2 mediated cleavage of focal adhesion components, resulting in focal 
adhesion disassembly ((Carragher et al., 2003); (Franco et al., 2004); (Glading et al., 2004)). 
FAK was also shown to be involved in the recruitment of PLCγ1, a downstream effector of 
Src, to the plasma membrane at sites of cell-matrix adhesion, where it promotes PLCγ1 
tyrosine phosphorylation and enzymatic activity (Zhang et al., 1999).  
Remodeling of the actin cytoskeleton is a crucial step of the cell migration process that 
controls adhesion dynamics. Diverse key effectors of FAK, such as the members of the 
RhoGTPase family,  are involved in actin remodeling ((Schlaepfer et al., 2004); (Zhai et al., 
2003); (Chikumi et al., 2002)). Indeed, RhoA, a downstream FAK effector, regulates the 
assembly and disassembly of focal adhesions and their associated bundles of actin filaments 
((Burridge et al., 1997); (Ridley, 1995)). 
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In this study, we show that Memo binds the three Shc isoforms, p46shc, p52shc, and p66shc, and 
we provide evidence that Shc is necessary for Memo binding to the activated ErbB2 receptor. 
We also demonstrate that Memo is required for ErbB2-induced Src activation, and that loss of 
Memo impairs ErbB2-mediated phosphorylation of a number of signaling molecules, 
including ERK, PLCγ1 and Shc. Furthermore, in addition to their impaired migration and 
adhesion properties, Memo-defective cells exhibit a rear retraction defect, reflective of 
abnormal focal adhesion disassembly. The biochemical analysis of regulators of focal 
adhesions, such as FAK Paxillin, Rho, and Src, suggests that Memo is involved in focal 
adhesion organization.  
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Results 
 
Shc interacts with Memo and is required for Memo binding to ErbB2 
Shc and Memo bind to P-Tyr 1227/1222, one of the ErbB2 phosphorylation sites that have 
been previously shown to be important for cell migration ((Dankort et al., 1997);  (Marone et 
al., 2004)). In our initial studies, various results suggested that memo’s ability to interact with 
active ErbB2 might be dependent upon Shc. First, it was shown that immunodepletion of 
endogenous Shc from reticulocytes lysates expressing in vitro translated Myc-Memo resulted 
in a dramatic blockade of Memo binding to the phospho-mimetic Tyr 1227/1222 peptide. 
Secondly, Myc-Memo ectopically expressed in SKBr3 cells was shown to be constitutively 
complexed with Shc (Marone et al., 2004) and immunoprecipitations of ErbB2 revealed that it 
was complexed to Memo and Shc. Considering the importance of ShcA family members in 
the regulation of diverse cellular functions ((Ravichandran, 2001) (Migliaccio et al., 1997)), 
we explored the Memo-Shc interaction in more detail.  
To directly test the role of Shc in Memo binding to active ErbB2, we used wild type (WT) 
mouse embryo fibroblasts (MEFs) and ShcA-deficient MEFs. Upon stimulation with EGF, 
there was a rapid increase in the phosphorylation of AKT and ERK, reflecting activation of 
these major cellular signaling pathways (Figure 1A). To note is the fact that those pathways 
are more activated in ShcA-deficient MEFs. Next, we examined the ability of Memo to bind 
to the activated receptor in control and Shc-null MEFs. Memo IPs from lysates of WT and 
ShcA-deficient MEFs were probed with ErbB2, Shc and Memo antibodies. Upon EGF 
treatment, there is a rapid increase in the P-Tyr content of ErbB2 (Figure 1B, left panel), 
reflecting receptor activation. Furthermore, Memo and Shc were constitutively complexed in 
WT control MEFs and there was an increase in co-immunoprecipitating Shc protein in Memo 
IPs from EGF-stimulated WT MEFs (Figure 1B, right panel). Importantly, ErbB2 was only 
detected in Memo IPs from lysates of EGF-induced WT MEFs, but not ShcA-deficient MEFs. 
These results clearly demonstrate that Shc is required for the binding of Memo to the active 
ErbB2 receptor (Figure 1B, right panel).  
Next, we examined the ability of Memo to interact with the individual ShcA isoforms using 
Shc KO MEFs reconstituted with the individual HA tagged p46shc, p52shc, and p66shc. Memo 
immunoprecipitations (IPs) from lysates of ShcA-deficient MEFs  ectopically expressing the 
empty vector or one of the three Shc isoforms, p46shc, p52shc, or p66shc, revealed complexed 
p46shc, p52shc and p66shc molecules (Figure 1A). As seen in WT MEFs, Memo appears to bind 
slightly less to p66shc than to the p46shc and p52shc isoforms. The three isoforms were also 
detected in Memo IPs from T47D lysates (Supplementary Figure S1), where we observed an 
increase in the co-immunoprecipitating proteins in HRG-stimulated cells, probably reflecting 
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stabilized complexes interacting with ErbB2. The Memo interaction with p46shc, p52shc, and 
p66shc is specific since neither protein was detected in IPs carried out with an isotype matched 
control (Supplementary Figure S1). 
 
Memo has a role in EGF-induced Shc phosphorylation 
Upon stimulation of most receptor tyrosine kinases, Shc is phosphorylated on Tyr 239/240 
and Tyr 317, which serve as docking sites for the binding of molecules such as Grb2 and 
subsequent activation of the MAPK pathway (Ravichandran, 2001). Considering the Memo-
Shc interaction, we asked if Memo has a role in EGF-induced Shc phosphorylation using WT 
and Memo-deficient MEFs. In WT MEFs, all three Shc isoforms were phosphorylated on Tyr 
239/240 rapidly after EGF stimulation (3 minutes). Shc was also phosphorylated at 3 minutes 
after EGF treatment of Memo-deficient MEFs, however, lower p46 phosphorylated levels 
were observed. Phosphorylation was maximal at 5 minutes then decreased throughout the 60 
minutes time course. By contrast, in the Memo KO MEFs, phospho-Tyr 239/240 levels were 
lower and decreased more rapidly than in WT MEFs. We also noted a pronounced decrease in 
the mobility of the p66 shc isoform in WT cells, but not in Memo KO MEFs, which likely 
reflects changes in its Ser-phosphorylation content. Altogether, these results suggest that 
Memo loss influences Shc phosphorylation in response to ErbB activation. Loss of Memo 
might directly or indirectly affect Shc activation, perhaps as a consequence of alterations in 
signaling molecules that act upstream of Shc.  
 
Memo is required for proper ErbB-induced Src-phosphorylation 
Src has been shown to phosphorylate Shc in vitro, mainly on Y239/240 (van der Geer et al., 
1996). Furthermore, considering a report from our lab showing that Src inhibition reduces 
EGF and NRG-induced Shc phosphorylation (Olayioye et al., 2001), we examined Src 
activation in WT control and Memo-deficient cells. Upon EGF stimulation of WT MEFs, we 
observed a rapid increase in Src Y416 phosphorylated levels (lower band), being maximal at 
5 minutes, and progressively decreasing throughout the 60 minutes time course (Figure 3A, 
upper panel). Interestingly, EGF-induced Src Y416 phosphorylation was impaired in Memo-
deficient MEFs, suggesting an important role for Memo in Src activation. To confirm these 
results, we used the T47D breast tumor cellular model where Memo expression was stably 
down-regulated following introduction of lentiviral shRNA expression vectors specific for 
Memo. A kinetic of Src activation following HRG stimulation was performed in shLacZ 
control or shMemo 5.2 expressing cells. HRG induced rapid Src phosphorylation in T47D 
LacZ control cells, being maximal at 1 to 3 minutes and rapidly decreasing after 5 minutes of 
stimulation (Figure 3A, lower panel). In accordance with the results obtained with Memo-
deficient MEFs, in response to HRG, Src Y416 phosphorylation was impaired in T47D 
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shMemo 5.2 cells. These data suggest that Memo is required for efficient ErbB- induced Src 
activation. 
 
ErbB receptor-induced Erk and PLCγ1 activation are impaired in cells lacking Memo 
Src has been shown to be involved in ErbB-induced phosphorylation and activation of Erk1/2 
(Olayioye et al., 2001). Therefore, we examined Erk1/2 phosphorylation status in WT control 
and Memo-deficient cells. Consistent with a previous report showing that EGF and HRG 
induced Erk1/2 phosphorylation (Graus-Porta et al., 1995), Erk1/2 (p42/p44) was activated 
rapidly (≤3 minutes) in WT control MEFs upon EGF stimulation, and in T47D LacZ control 
cells stimulated with HRG (Figure 4A upper and lower panels, respectively). Perhaps as a 
consequence of inhibition of Src activation, Erk phosphorylation was impaired in EGF-
stimulated Memo-deficient MEFs and HRG-treated T47D shMemo5.2 cells. In fact, in 
Memo-deficient cells, there was a delay in full Erk1/2 activation (10 minutes in Memo-
deficient MEFs vs 3 minutes in control cells). The level of phosphorylated Erk1/2 did not 
reach control levels, and decreased more rapidly. In T47D shMemo5.2 cells, HRG-induced 
Erk1/2 phosphorylated levels were also lower and delayed (10 minutes vs 5 minutes in control 
LacZ cells).  
PLCγ1 is another downstream effector of Src. Indeed, pharmacological inactivation of Src has 
been shown to induce inhibition of PLCγ1 Tyr 783 phosphorylation (Tvorogov et al., 2005). 
Accordingly, we examined growth factor induced-PLCγ1 phosphorylation in WT and Memo-
deficient cells. As shown in Figure 4B, EGF (upper panel) and HRG (lower panel) induce 
rapid phosphorylation of PLCγ1 in WT MEFs and T47D shLacZ cells, respectively. PLCγ1 
phosphorylation on Tyr 783 in response to growth factor induction was impaired in Memo 
KO-deficient MEFs and T47D shMemo 5.2 cells. Altogether, these results indicate that loss 
of Memo is correlated with a major impairment of Src phosphorylation and downstream 
signaling components, more specifically Shc, Erk1/2 and PLCγ1. Whether or not these results 
reflect a direct or an indirect role of Memo on Src activation remains to be explored.  
 
Memo has an important role in cell adhesion and migration processes 
Memo is a novel protein that was discovered in a screen for ErbB2 effector proteins with roles 
in migration (Marone et al., 2004). Detailed studies on the role of Memo in HRG-induced 
tumor cell migration ((Marone et al., 2004); (Meira et al, submitted)) in T47D and SKBr3 
models revealed an essential role for Memo in the migratory process. In the following 
experiments, we enlarged the study on the role of Memo in cell migration using WT control 
and Memo-deficient MEFs. The directional (chemotactic) and random (chemokinetic) 
migration of WT control and Memo-deficient cells was examined in Transwell assay 
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chambers. EGF was added to the lower chamber to measure chemotaxis and to both chambers 
to measure chemokinesis. In accordance with the results obtained using a knock-down 
strategy in the human breast carcinoma models, Memo-deficient MEFs displayed a dramatic 
blockade of cell motility (Figure 5A), confirming the importance of Memo in the cell 
migration. However, since the chemokinetic response of WT control cells was not significant, 
we could not assign a specific role for Memo in directional or random cell motility in this 
assay.  
Cell adhesion also influences the migratory process. Thus, we investigated adhesion 
properties of WT control and Memo-deficient MEFs on different substrates. Cells were 
seeded onto collagen, laminin or fibronectin coated wells. After 45 minutes incubation at 
37°C, cells were washed and adherent cells were fixed and stained. Representative images are 
depicted in Figure 5B. Compared to WT control cells, adhesion of Memo-deficient MEFs to 
collagen, laminin and fibronectin was impaired, suggesting that Memo is involved in the cell 
adhesion process.  
Adhesion of a cell to the extra-cellular matrix (ECM) via transmembrane integrin molecules 
leads to the formation of focal adhesions complexes, which provide a link between the ECM 
and the actin cytoskeleton (Zamir and Geiger, 2001). We examined actin distribution in WT 
control and Memo-deficient MEFs seeded on collagen coated glass coverslips (Figure 5C). In 
contrast to WT control cells in which F-actin fibers were diffusely and strongly distributed in 
the cytoplasm, Memo-deficient MEFs exhibited an altered actin distribution, with a 
concentration of F-actin fibers in the center of the cell. Interestingly, Memo depletion in MEF 
cells resulted in a striking elongated phenotype which is indicative of a tail-retraction defect in 
some published models (Sturge et al., 2006). Defective cellular rear retraction resulting from 
the down-regulation of Memo was not restricted to MEF cells but was also confirmed in other 
cellular models, such as T47D (Figure 5D) and MDA-MB231 (Supplementary Figure S2) 
human breast carcinoma cells transiently transfected for 72 hours with LacZ control or Memo 
siRNA. The morphology of these cells migrating on the bridge of Dunn chambers in a chemo-
attractant gradient of HRG was examined using time-lapse video microscopy. In both cellular 
models, Memo KD (Knock-Down) had a strong effect on cell morphology, with the formation 
of elongated tails (Figure 5D and Supplementary Figure S2 left panels). A quantification 
performed over 10 different time points revealed a significant increase in the percent of 
unretracted tails in T47D Memo KD cells (8-fold over the control cells) (Figure 5D right 
panel). We also examined the morphology of MDA-MB231 cells that were seeded on 
collagen coated glass coverslips and stimulated for 20 minutes with HRG before fixation and 
immunostaining (Supplementary Figure S2 right panel). In contrast to control cells in which 
no defect in rear cell deadhesion was apparent, Memo KD cells exhibit a collapsed 
morphology with the formation of visible unretracted tails. 
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Memo inhibition impairs focal adhesion organization 
To understand the mechanism underlying Memo’s effect on cellular adhesion disassembly 
and retraction, we performed a biochemical analysis of the pathways involved in this process. 
The exact mechanism involved in this migration step has not been completely described and 
might be cell specific since different studies have suggested the requirement of different 
candidates including the Rho-ROCK pathway, microtubules, calpains, FAK/Src and myosin 
II, for adhesion disassembly and retraction (Ridley et al., 2003). Considering our results 
showing that Memo inhibition impairs ErbB-induced Src-phosphorylation, and the described 
role of FAK/Src signaling in the regulation of adhesion disassembly ((Hamadi et al., 2005); 
(Webb et al., 2004)), we examined FAK activation in WT control and Memo deficient cells. 
A significant baseline level of phosphorylated FAK Y397 was observed in both WT control 
and Memo-deficient MEFs. Furthermore, in response to EGF, there was no change in FAK 
Y397 phosphorylation (Figure 6A) in either cell line. Phosphorylation of tyrosine Y397 is 
mainly due to autophosphorylation and it occurs in response to diverse stimuli, including 
integrin engagement (McLean et al., 2005). By contrast, focal adhesion kinase Tyr 861 has 
been described as a major Src phosphorylation site (Calalb et al., 1996). In accordance with 
inhibition of Src phosphorylation in EGF/HRG-stimulated Memo deficient MEFs and T47D 
cells, in both cell lines, there was a strong decrease of ligand-induced FAK Tyr 861 
phosphorylation compared to control cells (Figure 6B, upper and lower panels).  
To gain more insight into a possible role for Memo in the organization of focal adhesion 
complexes, and because many Src substrates, including FAK and Paxillin, are localized to 
focal adhesions, we examined focal adhesion distribution in EGF-stimulated WT control and 
Memo-deficient MEFs.  Phospho-FAK Y397 (Figure 6C) and phospho-paxillin (Figure 6D) 
immunoreactivity were diffusely distributed on mature fibrillar adhesions in the cytoplasm as 
well as at sites of stress fibers attachment in WT MEFs. By contrast, phospho-FAK (Figure 
6C) and phospho-paxillin (Figure 6D) labeled Memo-deficient cells did not exhibit a fibrillar 
staining distribution. Immunofluorescence remained concentrated in the cell periphery, 
perhaps at the sites of nascent adhesions (Figure 6C and 6D). Also in this experiment, Memo 
deficient MEFs exhibit an elongated phenotype with a number of visible unretracted tails 
(Figure 6C and 6D). 
FAK-mediated phosphorylation of GTPases exchange factors has been shown to correlate 
with enhanced RhoA activation (Chikumi et al., 2002). Furthermore, considering another 
study showing that inhibition of ROCK, a downstream effector of RhoA, induces the 
formation of multiple and elongated tails (Sturge et al., 2006), we tested the hypothesis that 
Memo influences RHO-GTPase pathways. To examine the amount of active GTP bound-
RhoA, the GST-C21 fusion protein was used in a pull-down assay (Malliri et al., 2002). 
Active RhoA was measured in lysates of WT control and Memo-deficient MEFs subjected to 
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a kinetic of EGF stimulation (Figure 6E). Lower levels of active RhoA levels were observed 
after 5 minutes of stimulation in Memo-deficient cells compared to WT control cells. The 
results suggest that the kinetics of RhoA activation are slower in the Memo null MEFs 
compared to WT cells. 
Altogether, these results suggest that Memo is likely involved, directly or indirectly via Src 
inhibition, in the regulation of focal adhesion organization and in disassembly of focal 
adhesions. 
 
 
 
 
Discussion 
 
In the past decades, remarkable advances in the understanding of the role of ErbB2 in cancer 
and the development of targeted therapies for ErbB2-overexpressing tumors have emerged. In 
fact, ErbB2 activation turns on signaling pathways that enhance diverse metastasis-associated 
properties such as adhesion, migration and invasiveness, leading to an increase of cancer 
metastasis. Studies of individuals with ErbB2-overexpressing tumors have shown that they 
have a significantly poorer clinical outcome compared to patients whose tumors do not 
overexpress ErbB2 (Berchuck et al., 1990) (Slamon et al., 1987) (Slamon et al., 1989). 
Clinical trials using a recombinant monoclonal ErbB-2 antibody, Herceptin, have shown clear 
survival benefits when it is used in combination with chemotherapy for the treatment of 
patients in particular those with early-stage breast cancer (Hudis, 2007) (Romond et al., 2005) 
(Slamon and Pegram, 2001). Accordingly, ErbB2 and downstream signaling pathways have 
been intensely studied with the specific aim of identifying proteins that are essential for tumor 
development and progression. Once phosphorylated upon receptor dimerization, tyrosine 
residues that are located in the cytoplasmic tail of ErbB2 receptors serve as docking sites for 
diverse signaling molecules. These Src homology 2 (SH2) and phosphotyrosine binding 
(PTB) domain-containing proteins are either enzymes that are tyrosine phosphorylated and 
activated, such as PLCγ1 and Src, or adaptator molecules that link receptor activation with 
downstream signaling pathways, such as Shc and Grb2 (Marmor et al., 2004). In a previous 
study, Marone and colleagues identified Memo as a novel ErbB2-interacting protein that 
binds Y-1227 of the receptor cytoplasmic tail (Marone et al., 2004). Shc was also found to 
bind the same residue, and was suggested to be an adaptator molecule for Memo binding to 
the receptor. 
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In the present study, we demonstrate that Memo interacts with the three Shc isoforms, p46shc, 
p52shc, and p66shc, and we show that Shc is required for Memo binding to the ErbB2 receptor. 
Furthermore, when analyzed for the activation of ErbB2 downstream signaling molecules, 
Memo-deficient cells exhibited impaired phosphorylation of Src, Shc, ERK and PLCγ1. The 
adaptator protein Shc is a proto-oncogene product that has no intrinsic catalytic activity 
(Pelicci et al., 1992). Shc was assumed to work as an adaptator protein which, upon tyrosine 
phosphorylation, mediates the recruitment of other SH2-containing proteins such as Grb2, to 
the tyrosine residues. The activated receptor-Shc-Grb2 complex then activates the MAP 
(Mitogen-activated protein) kinase cascade through Sos (Bonfini et al., 1996). Interestingly, 
Sato and colleagues demonstrated that the Shc adaptor protein is a direct activator of c-Src in 
epidermal growth factor receptor signaling in A431 human epidermoid carcinoma cells (Sato 
et al., 2002). Furthermore, among the three Shc isoforms, p66sh and p52shc, but not p46shc, 
were found to interact with and activate c-Src in vitro and in vivo. In addition, Shc-mediated 
activation of c-Src was enhanced by EGF signaling. Considering our results indicating that 
EGF or HRG-induced Shc and Src phosphorylation are impaired in Memo deficient MEFs, 
and given that Memo is found to bind all three isoforms, we propose a mechanism whereby 
Memo, through its binding to Shc, regulates Src activation. In cells lacking Memo, Src 
phosphorylation is decreased, leading to impaired phosphorylation of downstream 
components, such as Shc, Erk, and PLCγ1. To note also, is the fact that in our previous study, 
we did not detect any change in Erk phosphorylation in Memo down regulated breast tumor 
cell lines (Meira et al., submitted). In the present study however, stable shlacZ and shMemo 
transfections were performed in breast tumor cells, which were further subjected to a time 
course of HRG stimulation. We favour the model where Memo loss, rather than influencing 
the phosphorylation levels of Erk, and perhaps Shc, PLCγ1 and Src, delays the activation of 
these components. This could suggest the possible existence of a “compensatory” pathway for 
Memo.  
 
Importantly, considering that Src and PLCγ1 activation are impaired in Memo deficient cells, 
Memo appears to be an important mediator of cellular processes such as migration and 
adhesion. In fact, in a previous study, we have shown that Memo KD in breast tumor cells 
resulted in a dramatic impairment of cell directionality during movement (Meira et al., 
submitted). In the present study, using another model of Memo deficient cells, we confirm the 
requirement of Memo for cell migration. Furthermore, we suggest an important role for 
Memo during the adhesion step, and propose a possible link for Memo, PLCγ1 and Src during 
this particular process. In fact, PLCγ1 has been shown to potentiate integrin-mediated cell 
spreading and motility (Choi et al., 2007). Furthermore, when scoring PLCγ1-/- fibroblasts 
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(Null) for their cell adhesion properties, Tvorogov and colleagues showed that Null cells 
displayed a significantly impaired rate of Src-mediated adhesion compared with PLCγ1 
reconstituted fibroblasts (Tvorogov et al., 2005). Interestingly, Memo null MEFs also 
displayed a significant defect in cell adhesion, suggesting a possible connection between 
Memo, Src and PLCγ1 during the cell adhesion process.   
 
Furthemore, by performing a morphological study of Memo deficient cells, we observed that 
inhibition of Memo results in a defect in rear cell deadhesion. Briefly, in the Dunn chamber 
assay, Memo KD in breast tumor cells resulted in a decrease of migration speed, translocation 
distance and directional persistency values (Meira et al., submitted). The directional 
persistency index reflects the ability of cells to migrate towards the ligand source and a 
decreased translocation distance could be directly due to decreased directional sensing. 
However, the moderate effect on migration speed could be related to impaired tail retraction 
during movement, therefore influencing general cell motility. Different candidates including 
the Rho-ROCK pathway, microtubules, calpains, FAK/Src and myosin II, have been 
suggested to be required for adhesion disassembly and retraction (Ridley et al., 2003). In the 
present study, we demonstrated that activation or distribution of components of the focal 
adhesion assembly/disassembly processes such as Src, FAK, paxillin, and RhoA, are affected. 
In addition, immunofluorescence labeling of focal adhesion components revealed an absence 
of fibrillar adhesions in Memo deficient cells, with the predominance of large, peripheral 
focal contacts. This could suggest that mature adhesions are not able to disassemble and be 
transformed into fibrillar adhesions, thus remaining at the periphery of the cell (Broussard et 
al., 2008).  
 
Memo could also affect focal adhesion turnover. Indeed, in the initial assembly of focal 
adhesions, integrin-mediated phosphorylation of focal-adhesion kinase (FAK) leads to the 
recruitment a number of signaling and structural proteins. Once phosphorylated by Src, FAK 
recruits other signaling molecules, such as Erk2 and calpain-2 to focal adhesion sites, which 
subsequently mediate the cleavage of focal adhesion components, resulting in focal adhesion 
disassembly (McLean et al., 2005). Therefore, Src kinase activity is required for adhesion 
turnover. Src may also function as an adaptator to recruit other kinases that can phosphorylate 
key substrates including FAK (Brunton et al., 2005). Considering that Src phosphorylation is 
impaired in Memo deficient cells, and that phosphorylation of Y861, a Src site on FAK, is 
dramatically affected in Memo deficient cells we suggest that there is a direct effect of Src on 
subsequent FAK function, resulting in a defect of focal adhesion turnover. Interestingly, a 
significant correlation of FAK Tyr-861 activation and HER2 overexpression suggested that 
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HER2 is involved in tumor malignancy and metastatic ability of breast cancer through a novel 
signaling pathway in which FAK and Src participate (Schmitz et al., 2005). Considering the 
present results, we propose the involvement of Memo in this particular pathway.   
 
 
 
 
Materials and methods 
 
Reagents, antibodies and plasmids 
HRG-β1, referred to as HRG, was purchased from R&D Systems (Inc., Minneapolis, MN). 
EGF was from Becton Dickinson. Polyclonal antibodies to a 19 amino acid peptide of Memo 
were produced in rabbits (aa 25-43 human Memo NM_015955: NAQLEGWLSQVQSTKRPAR); 
the same peptide was used for Memo mAb production in mice. Isotype matched IgG2a 
control serum for Memo was purchased from Sigma. Mouse anti-HA.11 antibody was from 
Covance. Phospho-AKT, AKT, phospho-Shc (Tyr 239/240), phospho-FAK (Tyr 861), 
phospho-Paxillin, p44/42 MAPK and phospho-p44/42 MAPK (Thr 202/204) were from Cell 
Signaling. Mouse anti-RhoA, rabbit anti-PLCγ1 and anti-FAK antisera were from Santa Cruz 
(≠sc-418, ≠sc-81 and ≠sc-932 respectively). Rabbit anti-Shc was from Transduction Labs. 
Phospho-Src (Tyr 418) and phospho-FAK (Tyr 397) were purchased from Biosource. 
Phospho-PLCγ1 (Tyr 783) was from Upstate. Phospho-Tyrosine was detected with the 4G10 
mAb (gift from Dr Juergen Mestan, NIBR Basel). For ErbB2, the 21N polyclonal antiserum 
was used in westerns (Olayioye et al., 2000). Collagen I was purchased from Roche 
Diagnostics GmbH. Laminin and Fibronectin were provided by Dr. Ruth Chiquet-Ehrismann 
(FMI, Basel). pCDNA 3.HA vector,  pCDNA 3 HAp46shc, pCDNA 3 HAp52 shc, and pCDNA 
3 HAp66 shc constructs were kindly provided by Dr. Yoshikuni Nagamine. The pBabe-puro 
vector was previously described (Morgenstern and Land, 1990).  
 
Cell culture and transfections 
Wild-type (WT) and ShcA-deficient MEFs were kindly provided by Dr. Yoshikuni 
Nagamine. Memo-deficient MEFs were provided by Dr. Régis Masson and Barbara Haenzi. 
WT MEFs, ShcA-deficient MEFs, Memo-deficient MEFs, T47D and MDA-MB231 human 
breast carcinoma cells were maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 10 % Fetal Calf Serum (GIBCO Invitrogen AG, Basel, Switzerland).  
Transient siRNA transfection. T47D and MDA-MB231 cells were transiently transfected 
with siRNA using HiPerFect (Qiagen) according to the manufacturer’s instructions. The 
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following siRNAs obtained from Qiagen were used for transient knock-down. For control 
LacZ (target sequence: AAGCGGCTGCCGGAATTTACCTT), for Memo, we used a previously 
validated siRNA (Marone et al., 2004) (target sequence: AAGACCTGCTAGAGCCATTAT). 
Knock-down was maximal after 72 hours; accordingly, for Dunn chambers assays, T47D and 
MDA-MB231 cells were plated on coverslips 3 days after siRNA transfections and migration 
tracks were visualized during 12 hours. For immunofluorescence, MDA-MB 231 cells were 
seeded on coverslips 3 days after siRNA transfections and allowed to attach before 
stimulation with 1nM HRG and fixation. 
Stable shRNA transfection. shRNA sequences: the shLacZ vector was produced by cloning 
the sequence CCGGGCGGCTGCCGGAATTTACCTTCTCGAGGGTAAAT 
TCCGGCAGCCGCTTTTTAATT into the pLKO.1-puro plasmid using the AgeI and EcoRI 
restriction sites. The glycerol stock for the shMemo1 vector was purchased from the Sigma 
(MISSION shRNA library, TRCN0000122898). Production of retroviruses: HEK 293 
packaging cells were transiently transfected with polyethylenimine (PEI) (Polysciences Inc.) 
at a PEI:DNA ratio of 4:1.  PEI was added to DNA diluted in serum-free media (8 µg 
pLKO.1-puro backbone with shLacZ or shMemo1, 0.4 µg HDM-tat16, 0.4 µg HDM-HgPM2, 
0.4 µg pRC-CMV-RaII and 0.8 µg HDM-VSV-G), vortexed and incubated at room 
temperature for 15 minutes.  The PEI/DNA mix was then added to the cells and incubated for 
16 hours at 37 °C, at which point the media was changed.  Media containing viruses was 
collected 72 hours post-transfection, filter sterilized, aliquoted and stored at -80 °C. Infection 
of T47D cells: T47D cells were infected by incubation in media containing 8 µg/mL 
polybrene (Sigma) and 600 µL of viral supernatant for 24 hours at 37 °C.  The media was 
then changed and the cells were incubated another 24 hours at 37 °C.  Successfully infected 
cells were then selected for using 0.5 µg/mL puromycin and knock-down of Memo1 was 
confirmed by western blot analysis.   
Plasmid transfection. ShcA-deficient MEFs were co-transfected with 1 μg pBabe-puro and 6 
μg pCDNA 3. HA vector control, pCDNA 3 HAp46shc, pCDNA 3 HAp52shc, or pCDNA 3 
HAp66shc constructs. Transfections were performed using polyethylenimine (PEI) 
(Polysciences Inc.) according to the manufacturer’s instructions.  
 
Immunoprecipitations and immunoblotting 
For direct western blot analysis, cells were stimulated or not with 1nM HRG (for T47D and 
MDA-MB231 cells) or 100 ng ml-1 EGF (for MEFs), extracted in NP-40 buffer and protein 
lysates were immunoblotted as described previously (Marone et al, 2004). For 
immunoprecipitation experiments, cells (stimulated or not either with 10nM HRG in T47D 
cells, or 100 ng ml-1 EGF in WT and Shc or Memo-deficient cells) were lysed in Triton X-
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100 buffer (50 mM Tris pH 7.5, 5 mM EGTA, 150 mM NaCl, 1.5 mM MgCl2, 25 mM β-
glycerophosphate, 25 mM NaF, 1 % Triton X-100, 1 % Glycerol, 10 μg ml-1 leupeptin, 10 μg 
ml-1 aprotinin, 2 mM sodium orthovanadate, and 0.5 nM  phenylmethylsulphonylfluoride 
(PMSF) ). Equal amounts of cell lysates were incubated overnight at 4°C with antibody. 
Immunocomplexes were collected with protein G-sepharose beads (Sigma), and centrifuged. 
The supernatant was subjected to a second round of immunoprecipitation. The two pellets 
were combined and washed three times with Triton X-100 buffer. Proteins were then released 
by boiling in sample buffer, blotted onto polyvinylidene difluoride membranes (Millipore 
Corporation) and probed with the specific antibodies.  
 
RhoA activity assay 
To measure RhoA activation in WT and Memo-deficient cells, the GST-C21 fusion protein 
pull down assay was performed. Cells were stimulated with 100 ng ml-1 EGF for different 
time points, and extracted in GST-Fish buffer (10% Glycerol, 50mM Tris pH 7.4, 100 mM 
NaCl, 1% NP-40, 2mM MgCl2, 1 nM PMSF, 10 μg ml-1 leupeptin, 10 μg ml-1 aprotinin, 2 
mM sodium orthovanadate). Cell lysates were mixed with bacterially produced GST-C21 
fusion protein bound to gluthatione-sepharose beads for 30 minutes at 4 °C. Beads were 
centrifuged, washed and captured active RhoA was eluted in sample-loading buffer.  Protein 
was resolved by SDS-PAGE as described above, transferred to membrane and probed with a 
RhoA-specific antibody. Aliquots from the cell lysates were taken to analyse total amount of 
RhoA. 
 
Immunofluorescence microscopy 
Cells were grown on glass coverslips (BD Biosciences) coated with 25ug ml-1 rat tail collagen 
I (Roche Diagnostics GmbH), serum-starved overnight at 37°C and stimulated with 1nM 
HRG (for MDA-MB231 cells) or 100 ng ml-1 EGF (for WT and ShcA or Memo-deficient 
cells) for 20 minutes. Cells were fixed with 4 % paraformaldehyde and 3 % sucrose in PBS, 
permeabilized in 0.2% Triton X-100 in PBS, and blocked with 1% bovine serum albumin in 
PBS. Incubation with primary and secondary antibodies was done in the same buffer. Alexa-
Fluor 488 goat anti-rabbit IgG (Invitrogen) was used for phospho-FAK and phospho-Paxillin 
stainings. F-actin was stained at RT with 2 U ml-1 TRITC-labelled phalloidin (Sigma). DNA 
was counterstained with 0.25 mg.ml-1 Hoechst (Sigma). Cells were washed with PBS-Tween 
0.1% and mounted with a mounting solution (Calbiochem). Mounted samples were examined 
using an Axioskop Zeiss Microscope coupled to a Sony 3 CDD camera.  
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Cell migration assays 
For cell migration assays on MEFs using Boyden chambers, serum starved cells were seeded 
on a 8-μm-pore polycarbonate membrane (Corning Costar Products, Acton, MA) previously 
coated with rat tail collagen I (25μg ml-1). For the chemotaxis analysis, the lower chamber 
was filled with 600μl of DMEM with or without 100 ng ml-1 EGF; for the chemokinesis 
analysis, both chambers contained 100 ng ml-1 EGF. After incubation at 37°C for 24 hours, 
non-migrated cells were washed and scraped from the membrane top. Migrated cells were 
fixed in 4% formaldehyde and stained with 0.1 % crystal violet. Cells were counted and 
migration was expressed as cell number per mm2. Chemotaxis of T47D and MDA-MB231 
cells were also analyzed by direct visualization of cell migration in a gradient of HRG using 
Dunn chambers (DCC100; Hawksley). Serum-starved cells were seeded onto a glass coverslip 
previously coated with 25ug μl-1 rat tail collagen I. Cells were inverted over the DCC 
chamber consisting of two concentric wells separated by an annular bridge. The outer well 
contained 10nM HRG in DMEM, whereas the inner well was filled with DMEM. A linear 
gradient of HRG was formed by diffusion across the bridge separating the two wells. 
Migration of the cells lying directly above the bridge was visualized using a Widefield 
TILL5, LONG RUN, Axiovert 200M (5 % CO2 and 37°C chamber). Time lapse images were 
digitally captured every 3 minutes with a CCD camera during 12 hours.  
 
Cell adhesion assays 
Cell adhesion assays were performed with WT and Memo-deficient MEFs. Microtitre plates 
(60wells; Nunc) were coated for 1 hour at room temperature with 5 μl per well PBS 
containing 0.01 % Tween and either 25μg ml-1 collagen I, fibronectin or 10 μg μl-1 laminin. 
Wells were then blocked for 30 minutes with PBS containing 0.025 % BSA. Cells were plated 
and allowed to attach for 45 minutes. Cells were then fixed with 4 % formaldehyde in PBS for 
30 minutes at room temperature, and stained with 0.1 % crystal violet in H20 for 30 minutes. 
Photographs were taken with an Axioskop Zeiss Microscope equipped with a Sony 3 CDD 
camera. 
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Figure legends 
 
 
Figure 1. Shc interacts with Memo and is required for Memo binding to ErbB2 receptor. 
(A) WT and Shc-deficient MEFs were stimulated or not for the indicated periods of time with 
EGF. Western-blot was performed on extracts using P-AKT, AKT, P-ERK and ERK specific 
antibodies. (B) WT and Shc-deficient cells were stimulated or not with EGF for 10 minutes. 
(Right panel) Cell extracts were subjected to immunoprecipitation using a Memo mAb. IPs 
were probed for ErbB2, SHC and Memo. (Left panel) ErbB2 phosphorylated levels, as well as 
total ErbB2, SHC, and Memo levels in transfected cells were monitored in whole cell lysates 
(W) using the respective antibodies. (C) Shc-deficient MEFs were transfected with HA vector 
control, HAp46, HAp52 or HAp66 expressing constructs. Cell extracts were prepared and 
subjected to immunoprecipitation using a HA mAb or a Memo mAb. IPs were probed for Shc 
and Memo. Memo levels and Shc expression in WT control and Shc-deficient cells were 
monitored in whole cell lysates (W) using the respective antibodies.  
 
 
Figure 2. Effect of Memo on EGF-induced SHC phosphorylation. WT and Memo-
deficient MEFs were treated with EGF for the indicated periods of time. Western-blot was 
performed on extracts using P-SHC (Tyr 239/240) and SHC specific antibodies. 
 
 
Figure 3. Effect of Memo on EGF-induced Src phosphorylation. (A) WT and Memo-
deficient MEFs (upper panel) and T47D cells stably transfected with shLacZ control or 
shMemo 5.2 (lower panel) were stimulated or not with EGF or HRG, respectively, for the 
indicated periods of time. Western-blot was performed on extracts using P-Src (Tyr 416) and 
Memo specific antibodies. 
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Figure 4. Effect of Memo on EGF-induced ERK and PLCγ1 phosphorylation. (A and B) 
WT and Memo-deficient MEFs (upper panel) and T47D cells stably transfected with shLacZ 
control or shMemo 5.2 (lower panel) were stimulated or not with EGF or HRG, respectively, 
for the indicated periods of time. (A) Western-blot was performed on extracts using P-ERK 
(p42/44) and ERK (p42/44) specific antibodies. (B) (Upper panel) Western-blot was 
performed on WT and Memo-deficient MEF extracts using P-PLCγ1 (Tyr 783) and PLCγ1 
specific antibodies. (Lower panel) Extracts from T47D cells transfected with shLacZ control 
or shMemo 5.2 cells were subjected to immunoprecipitation using a PLCγ1 mAb. PLCγ1 
phosphorylated levels were monitored using P-Tyr and PLCγ1 antibodies. 
 
 
Figure 5. Effect of Memo on the cell adhesion and cell migration processes. (A) Migration 
of WT and Memo-deficient MEFs was analyzed. Control responses in the absence of ligand, 
as well as chemotactic responses towards EGF and chemokinetic responses in the presence of 
EGF were determined in Boyden chamber assays. The data are representative of several 
independent experiments. Data are mean ± SEM. (B) WT and Memo-deficient cells were 
seeded onto coverslips coated with collagen type I, laminin or fibronectin and allowed to 
adhere and spread for 45 minutes before fixation. Adherent cells were stained and visualized. 
Images shown are representative of two separate experiments. (C) Immunofluorescence 
microscopy of EGF-stimulated WT and Memo-deficient MEFs labeled with a TRITC-labeled 
phalloidin antibody. (D) T47D cells were transiently transfected with LacZ or Memo siRNAs 
and 3 days later were analyzed for their ability to migrate in a gradient of HRG in Dunn 
chambers. Migration of the cells lying directly above the bridge was visualized during a 
period of 12 hours. The gradient follows the path from the top left to the bottom right. (Upper 
panels) Snapshot from representative time lapse videos taken at 8 hours are shown. Arrows 
indicate examples of the tails formed during the experiment. (Lower panel) Cells were scored 
for tail formation by counting >80 cells in each of the 10 time point acquisition. Data are 
mean ± SEM.  
 
 
Figure 6. Inhibition of Memo impairs regulation of focal adhesions. (A) WT and Memo-
deficient MEFs were stimulated with EGF for the indicated periods of time. Western-blot was 
performed on extracts using P-FAK (Tyr 397), FAK and Memo specific antibodies. (B) WT 
and Memo-deficient MEFs (upper panel) or T47D cells stably transfected with shLacZ 
control or shMemo 5.2 (lower panel) were stimulated for the indicated periods of time with 
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EGF or HRG, respectively. Extracts were collected and monitored for P-FAK (Tyr861) and 
FAK expression using the respective specific antibodies. (C and D) P-FAK (Tyr 397) (C) and 
P-Paxillin (D) stainings were examined in WT and Memo-deficient MEFs using the 
respective antibodies. (E) GST-RhoA pull down assay in WT and Memo-deficient MEFs 
stimulated or not for the indicated periods of time. Western-blot was performed using a 
specific RhoA antibody, and RhoA activation levels were quantified by densitometry. Data 
are representative of independent experiments.  
 
Figure S1. Memo interacts with the three Shc isoforms, p46shc, p52 shc, or p66 shc. T47D 
cells were stimulated or not with 10 nM HRG for 10 minutes. Memo was immunoprecipitated 
using a mouse mAb; a mouse mAb IgG2a was used as a negative control. Co-
immunoprecipitating proteins were analyzed by western blotting and probed with Shc and 
Memo polyclonal antibodies. Whole cell lysates (W) were loaded as controls. 
 
 
Figure S2. Memo is required for rear cell deadhesion. MDA-MB231 breast carcinoma cells 
were transiently transfected with LacZ or Memo siRNAs and 3 days later were analyzed for 
their ability to migrate in a gradient of HRG in Dunn chambers. Migration of the cells lying 
directly above the bridge was visualized during a period of 12 hours. (Upper panels) Snapshot 
from representative time lapse videos taken at 8 hours are shown. Arrows indicate examples 
of the tails formed during the experiment. (Lower panels) MDA-MB231 cells were transiently 
transfected with LacZ or Memo siRNAs and 3 days later were seeded on coverslips, and 
stimulated for 20 with HRG minutes before fixation. The actin cytoskeleton and cell 
morphology were visualized using a TRITC-labeled phalloidin antibody. 
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FIGURE S1.  
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----- III. Memo in a model organism- S.cerevisiae ----- 
 
1. INTRODUCTION 
Genetic approaches in powerful molecular models such as Saccharomyces cerevisiae have 
been useful for gaining insight into the function of evolutionary conserved proteins. In fact, 
complex processes such as chromosome replication, transcription and translation, cell 
division, secretion, membrane trafficking, energy metabolism, cytoskeletal structure and 
mechanics, and intracellular signaling that occur in all eukaryotes can be explored in detail in 
this well-developed and simple-to-use genetic system which contains a nucleus and 
membrane bound organelles like mitochondria, peroxisomes, endoplasmic reticulum, and a 
Golgi complex.  
To position Memo within a genetic network, experiments in the model organism S. cerevisiae 
that lends itself to rapid genetic screening were performed. S. cerevisiae has one homologue 
of the human MEMO gene, YJR008W. According to SGD (Saccharomyces Genome 
Database), YJR008W codes for the protein Yjr008wp, a putative protein of unknown function 
with 338 amino acids. We will refer to the gene and protein as MEMO (ScMEMO) and Memo 
(ScMemo), respectively. The yeast and the human proteins share over 50% sequence 
similarity and about 35% sequence identity.  
 
 
 
              Figure 1. Memo is encoded by a single-copy gene present in all major taxonomic groups 
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2. RESULTS 
  2.1. Memo localization and function in S. cerevisiae 
(In collaboration with Dr. Dominic Hoepfner and Dr. Peter Philippsen, Biozentrum, BASEL) 
All experiments have been done according to the EUROFAN guidelines for gene deletions 
and modifications in Saccharomyces cerevisiae. The materials and methods used in this study 
are described in paragraph 2.1.4. 
Table 1. Yeast strains (all are FY1679 background). 
 
     2.1.1. Memo localization study 
To examine the localization of Memo in yeast, in-frame fusion proteins of the green or yellow 
fluorescent protein (GFP/YFP) ORFs to that encoding Memo were constructed. Memo was 
either expressed under its own promoter and fused upstream of the GFP/YFP ORFs, or under 
the Galactose inducible Gal1/10 promoter and fused downstream of the GFP ORF (Figure 2). 
GFP/YFP fusions were introduced into FY1679 cells, and transformants (Table 1) were 
analyzed for Memo subcellular localization using fluorescence microscopy. When expressed 
under its own promoter, some cytoplasmic and strong nuclear Memo-GFP/YFP fluorescence 
were observed (Figure 2a). Overexpression of Memo from the inducible GAL promoter 
resulted in cells that don’t exhibit GFP fluorescence when grown on Glucose, whereas growth 
on Galactose induced Memo-GFP expression in the cytoplasm and a particular intense nuclear 
fluorescence (Figure 2b). These results suggest possible nuclear and cytoplasmic functions of 
Memo in yeast. 
  
                                                                                               
 
Figure 2. Yeast Memo localization. Wild-type cells (FY1679) expressing the indicated GFP fusion 
proteins from the endogenous promoter (a) or the GAL promoter (b) were analyzed by GFP 
microscopy. 
Prom 
Memo MemoKAN MX GFP
Gal1/10 
KAN MX
             Yeast Memo-GFP                                   Yeast Gal-GFP-Memo 
a. b. 
GFP 
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     2.1.2. Memo-GFP expression study 
Only a certain percentage of GFP::kanMX-tagged cells showed detectable signal and only 
few accumulated Memo in the nucleus as observed in the overexpressing cells. Also, when 
checking the YFP tagged cells on the primary transformation plates, all cells showed clear 
cytoplasmic and nuclear Memo localization. But once replated on full YPD medium, Memo-
YFP was no longer detectable. When the cells were plated back from the YPD to synthetic 
plates, Memo was again detected in all cells but only in some cells in the nucleus. These 
results suggest that i) Memo is only expressed under certain conditions, and that ii) Memo 
shuttles between cytoplasmic and nucleus and only accumulates in the nucleus upon a certain 
stimulus 
In order to study in more detail Memo’s function, and find out what induces the expression of 
Memo, particularly on the synthetic plates, we examined the expression of Memo-GFP 
transformants under different conditions of culture (pH, stress, N-source, temperature, 
osmolarity) (Figure 3).  
 
 
               Media and conditions  Memo-GFP expression 
YPGal pH6.0 30°C                   - 
YPGluc pH6.0 30°C                   - 
YPGluc pH6.0 37°C                  + 
YPGluc pH6.0 42°C                  + 
YPGluc pH6.0 30°C stationary phase culture                 ++ 
YPGluc pH6.0 30°C 12mM Caffeine                  + 
YPGluc pH6.0 30°C 0.04% SDS               ++++ 
YPGluc pH6.0 30°C 0.1M NaCl                   - 
YNB (NH4)2SO4 all AS, Glc               ++++ 
YNB (NH4)2SO4 all AS, Gal               ++++ 
YNB (NH4)2SO4 1/2x all AS, Glc               ++++ 
YNB MSG all AS, Glc               ++++ 
YNB CO(NH2)2 all AS, Glc               ++++ 
YPGluc pH3.0 30°C               ++++ 
YPGluc pH4.0 30°C                 ++ 
YPGluc pH5.0 30°C                   - 
YPGluc pH6.0 30°C                   - 
YPGluc pH7.0 30°C                  + 
YPGluc pH8.0 30°C                 ++ 
YPGluc pH9.0 30°C               ++++ 
YPGluc pH10.0 30°C               ++++ 
Figure 3.  Memo-GFP expression. FY1679 transformants were analyzed for Memo’s expression levels 
under different culture conditions.  
 
Memo appears to be strongly expressed in diverse stress conditions such as synthetic media, 
pH, and temperature. However, no individual triggering event for the induction of Memo’s 
expression was uncovered. According to the expression data, Memo appears to be rather a 
general stress responder of unknown function. 
-         Not expressed 
+        Weakly expressed 
++      Expressed 
++++  Strongly expressed 
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     2.1.3. memoΔ phenotype study 
To gain more insight into the function of Memo in yeast, we carried out gene disruption 
experiments that replace Memo’s sequence in the genome with the selectable marker gene 
TRP1 (Figure 4), resulting in Memo’s deletion. This process occurs by homologous 
recombination and uses the enzymes of the homologous recombination pathway. 
                         
                     Figure 4.  Memo disruption/deletion strategy.  
 
S. cerevisiae memo∆ strains (haploïd a, α or diploïd a/α) grown at 30°C or 37°C were viable 
and showed no obvious phenotype compared to wild-type (WT) strains. We further scored 
memo∆ strains for their growth speed, pH sensitivity, sporulation efficiency, and sensitivity to 
several reagents such as Rapamycin, Cafféine, SDS, MMS, Cobalt Chloride and Hydroxyurea 
(HU). No obvious differences were observed in memo∆ strains compared to WT strains in any 
condition. Cell polarity is important not only during growth and division, but also during the 
mating response, shmoo formation and cell fusion. memoΔ cells were tested in appropriate 
assays for each and were found to behave as WT strains. 
To examine the role of Memo in cellular processes such as cell division, actin/microtubule 
dynamics and metabolite transport, we generated memo∆ strains in which nuclei (HHF2), 
microtubules (TUB1), actin patches (CAP2), actin cables (ABP140), and peroxisomes (PTS1) 
were GFP/YFP or CFP labeled (Table1). Since expression of Memo was found to be induced 
upon stress conditions (SD medium or alkalinized medium), yeast strains were cultured at 
30°C in different media conditions: YPD, SD-medium or at pH4.0. Considering the known 
role of mammalian Memo in the microtubule and actin cytoskeleton, we carefully examined 
the memo∆ strain for defects in these networks. However, memo∆ microtubule and actin 
cable/patches morphology and distribution were indistinguishable from WT strains. 
Peroxisomes are ubiquitous subcellular organelles, which are highly dynamic and display 
large plasticity in response to cellular and environmental conditions (Visser et al., 2007). We 
examined peroxisome morphology and distribution in memo∆ and WT cells. No obvious 
difference was detected. Also, nuclear distribution was not affected in memo∆ cells in any of 
the culture conditions. Altogether, these results do not support a role for Memo in cytoskeletal 
organization in yeast, and indicate that Memo is rather involved in a general stress response.  
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     2.1.4. Materials and methods used in this study 
YPGlc liquid: 10g/l Yeast Extract (Oxoid), 20g/l Bacto Peptone (Becton Dickinson), 20g/l 
Glucose (Fluka); YPGal liquid: 10g/l Yeast Extract (Oxoid),20g/l Bacto Peptone (Becton 
Dickinson), 40g/l Galacotose (Fluka); Synthetic medium liquid: 6.7g/l Yeast Nitrogen Base 
w/o Amino Acids (Becton Dickinson), 0.69g/l CSM complete (Bio101), 20g/l Glucose 
(Fluka); Synthetic medium liquid, special Nitrogen Source: 1.7g/l Yeast Nitrogen Base w/o 
Amino Acids and Ammonium Sulfate (Becton Dickinson), 1g/l Monosodium Glutamate or 
1/gl, Urea, or 1g/l Glutamine, 0.69g/l CSM complete (Bio101), 20g/l Glucose (Fluka); YPGlc 
plates: 10g/l Yeast Extract (Oxoid), 20g/l Bacto Peptone (Becton Dickinson), 15g/l Bacto 
Agar (Becton Dickinson), 20g/l Glucose (Fluka); YPGal plates: 10g/l Yeast Extract (Oxoid), 
20g/l Bacto Peptone (Becton Dickinson), 15g/l Bacto Agar (Becton Dickinson), 40g/l 
Galactose (Fluka).  
To test for pH sensitivity the YPGlc and YPGal medium was acidified with 37% HCL. To 
make it alkaline, 10M NaOH was used. To test for SDS sensitivity, SDS in aqueous solution 
from a 10% stock was diluted and added to luke-warm YPGlc+Agar and YPGal+Agar 
medium prior to pouring the plates. To test for caffeine sensitivity, caffeine in aqueous 
solution from a 0.1M stock was diluted and added to luke-warm YPGlc+Agar and 
YPGal+Agar medium prior to pouring the plates. 800μM Cobalt Chloride, or 0.03% MMS, or 
200mM HU were added to YPD and SD medium prior pouring the plates.  
For sporulation the cells were grown in liquid presporulation medium (8g/l Yeast extract, 3g/l 
Peptone,100g/l Glucose) for 8 hours, washed twice and then plated on sporulation plates 
(10g/l Kac, 1g/l Yeast extract, 0.5g/l Glucose, 15g/l Agar) and incubated at 20° for 4-10 days. 
Rapamycin sensitivity was tested using a stock solution (kindly provided by Mike Hall) of 
1mg/ml Rapamycin in 90%EtOH/10%Tween-20. The drug was diluted 1/100 in 
90%EtOH/10%Tween-20 and appropriate amounts were dissolved in luke-warm, sterile 
YPGlc+Agar or YPGal+Agar prior to pouring the plates. Sensitivity of the tester strain was 
compared to a WT control as well as Rapamycin hypersensitive and resistant control strains 
also provided by Mike Hall. 
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  2.2. Synthetic lethal screen 
(In collaboration with Dr. Marc Sohrmann and Dr. Matthias Peter,ETH, Zurich) 
The study of genetic interactions is useful to characterize gene functions and to dissect 
pathway structures. Synthetic lethal mutants are often used to identify genetic interactions 
(Bender and Pringle, 1991; Guarente, 1993; Appling, 1999; Forsburg, 2001). The goal is to 
identify a double mutant combination that is inviable when both of the single mutants A and 
B alone are viable. A synthetic lethal screen can be performed with a deletion mutation in a 
nonessential gene or with a mutation in an essential gene that does not eliminate function. The 
interaction is assumed to reflect the compensatory relationship between the two genes. This 
strategy can be particularly useful for uncovering redundant pathways or direct protein 
interactions. In fact, synthetic lethality can indicate that A and B encode proteins that perform 
redundant functions in an essential pathway, such that mutation of both genes is necessary to 
eliminate the pathway. A second possibility is that the A and B gene products perform 
discrete steps in the same pathway. This would be more likely for non null mutations, where 
each protein retains partial function. The pathway can still function with reduced activity at 
one step, but ceases to function when two steps have reduced activity. Neither of these 
mechanisms implies a physical protein–protein interaction between A and B. In a third 
possible mechanism, a mutation in A weakens, but does not eliminate, its interaction with B. 
A mutation in B that further weakens the required interaction might then be synthetically 
lethal with the first mutation in A. 
 
     2.2.1 Synthetic lethal screen strategy 
MEMO was identified in our memoΔ phenotype study as a nonessential gene since its deletion 
results in a viable mutant strain. We therefore performed a high-throughput synthetic lethal 
analysis using an assembled ordered array of ~4700 viable yeast gene-deletion mutants 
(Winzeler et al., 1999). Series of pinning procedures in which mating and meiotic 
recombination are used to generate haploid double mutants were performed. A query 
mutation, in our case MEMO deletion, was first generated in a haploid starting strain of 
mating type MAT  (Figure 5).  
                                
Figure 5. Memo disruption/deletion strategy for the synthetic lethal screen 
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The haploid memo∆ strain MAT  was then crossed to the array of gene-deletion mutants of 
the opposite mating type, MATa (Figure 6) using a robotic system for manipulation of high-
density yeast arrays (Figure 7). Sporulation of resultant diploid cells leads to the formation of 
double-mutant meiotic progeny. The MAT  starting strain carries a reporter, MFA1pr-HIS3, 
that is only expressed in MATa cells and allows for germination of MATa meiotic progeny. 
Both the query mutation and the gene-deletion mutations were linked to dominant selectable 
markers (CloNAT or nourseothricin for MEMO, G418 for genes in the array) to allow for 
selection of double mutants. Final pinning results in an ordered array of double-mutant 
haploid strains whose growth rate is monitored by visual inspection or image analysis of 
colony size. To ensure reproducibility within a screen and to facilitate visual scoring, the 
deletion strains were arrayed in pairs. All materials and protocols were kindly provided by Dr. 
M. Peter, ETH Zurich.  
                                      
Figure 6. Synthetic lethal screen methodology. A MAT  strain carrying a query mutation 
(memo ) linked to a dominant selectable marker, such as the nourseothricin-resistance marker 
natMX that confers resistance to the antibiotic nourseothricin, and an MFA1pr-HIS3 reporter is 
crossed to an ordered array of MATa viable yeast deletion mutants, each carrying a gene 
deletion mutation linked to a kanamycin-resistance marker (kanMX). Growth of resultant 
heterozygous diploids is selected for on medium containing nourseothricin and kanamycin. The 
heterozygous diploids are transferred to medium with reduced levels of carbon and nitrogen to 
induce sporulation and the formation of haploid meiotic spore progeny. Spores are transferred 
to synthetic medium lacking histidine, which allows for selective germination of MATa meiotic 
progeny because these cells express the MFA1pr-HIS3 reporter specifically. The MATa meiotic 
progeny are transferred to medium that contains both nourseothricin and kanamycin, which 
then selects for growth of double-mutant meiotic progeny. 
                                                                                                       
Adapted from Tong et al., 2001 
Figure 7. Robotic system for manipulation of high-density yeast arrays. 
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     2.2.2. Synthetic lethal screen results                    
The analysis of genetic interactions between the memo∆ strain and ~ 4,700 viable gene 
deletion mutants revealed lethality with a plc1∆ strain (PLC1:YPL268W) (Figure 8). Indeed, 
the double-mutant cells memo plc  failed to grow, forming residual colonies that were 
relatively smaller than the equivalent colony on the wild-type control plate. Of note is the fact 
that the single plc  mutant strain exhibits a growth defect as reported previously (Yoko-o et 
al., 1993). Also, when the query mutation was identical to one of the gene deletions within the 
array, double mutants could not form because haploids carry a single copy of each allele; 
therefore, memo  appeared synthetic lethal with itself (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. MEMO and PLC1 are synthetic lethal. For each pinning, duplicates are shown. (Left panels, 
red square) memo∆ strain and plc1∆ strain are viable. (Right panels, red squares) memo∆memo∆ and 
memo∆ plc1∆ strains are inviable.  
                                                                                
 
PLC1 encodes the single phosphoinositides-specific phospholipase C of yeast. In mammalian 
cells there are multiple β-, γ-, and δ-PLC isoforms; the one found in yeast closely resembles 
the human δ- isoforms of PLC. PLC1p hyrdolyzes phosphatidylinositol 4-5-biphosphate 
(PIP2) to generate inositol 1, 4, 5-triphosphate (IP3) and 1, 2-diacylglycerol (DAG) (Yoko-o 
et al., 1993; Flick and Thorner, 1993). PLC1p is also involved in kinetochore function and 
pseudohyphal differentiation (DeLillo et al., 2003; Ansari et al., 1999). In most yeast strains, 
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the PLC1 gene is not essential for viability at 25 °C, but Plc1p-deficient mutants arrest at 
temperatures above 35 °C as multi-budded enlarged cells unable to complete cytokinesis, they 
are sensitive against osmotic stress and nitrogen starvation, they do not sporulate as 
homozygous diploids, and they are defective in the utilization of non-fermentable carbon 
sources, suggesting that the hydrolysis of PIP2 is required for a number of nutritional and 
stress-related responses (Flick and Thorner, 1993; Flick and Thorner, 1998).  
These results are intriguing considering that mammalian PLCγ1 and Memo are found in a 
complex, and that Memo regulates PLCγ1 phosphorylation. Also, both PLCγ1 and Memo 
were shown to have essential roles in tumor cell motility (Meira et al., submitted). We 
hypothesize that in yeast, Memo and Plc1p act in the same or in distinct but compensatory 
pathways. 
 
The synthetic lethal also identified a number of double mutants that were associated with a 
slower growth rate or "synthetic sick" phenotype, reflecting reduced fitness of the double 
mutant relative to the respective single mutants (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                
                
 
 
               Table 2.  Synthetic sick mutants of Memo 
 
 
       GENE                                 FUNCTION 
IMP2’/YIL154C Transcriptional activator involved in maintenance of ion 
homeostasis and protection against DNA damage 
(Masson and Ramotar, 1996). 
RAS2/YNL098C GTP-binding protein that regulates the nitrogen 
starvation response, sporulation, and filamentous 
growth; localization to plasma membrane; homolog of 
mammalian Ras proto-oncogenes (Gimeno et al., 1992; 
Bhattacharya et al., 1995; Kataoka et al.,1984). 
 
CAT5/YOR125C Mitochondrial inner membrane protein directly involved 
in ubiquinone biosynthesis, essential for several other 
metabolic pathways including respiration (Jonassen et 
al., 1998; Marbois and Clarke, 1996).  
MDG1/YNL173C Plasma membrane protein involved in G-protein 
mediated pheromone signaling pathway (Leberer et al., 
1996). 
 
PPT2/YPL148C Phosphopantetheine:protein transferase (PPTase), 
activates mitochondrial acyl carrier protein (Acp1p) 
(Stuible et al., 1998). 
 
COQ5/YML110C Putative mitochondrial C-methyltransferase, ubiquinone 
metabolism,mitochondrion (Dibrov et al., 1997; 
Barkovich et al., 1997). 
 
PET8/YNL003C Member of the mitochondrial carrier family (Marrobio et 
al., 2003).  
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  2.3. Memo in filamentous growth 
The polarity of cell division is critical in determining the size and shape of organisms. A cell 
that undergoes polarized cell division specifically orients its division axis or plane of division 
with respect to some reference point. The yeast S. cerevisiae divides mitotically by budding 
(Hartwell et al., 1974). A dimorphic transition in the life cycle of S. cerevisiae was described 
and called pseudohyphal growth (Gimeno et al., 1992). A pseudohypha is defined as a 
“fragile chain of cells which have arisen by budding and have elongated without detaching 
from adjacent cells, with morphological characteristics intermediate between a chain of yeast 
cells and a hypha” (Figure 9).  
                                         
          Adapted from Pan et al.,2000 
 
This dimorphic transition is induced by starvation for a nitrogen source and is controlled by 
the RAS signal transduction pathway (Gimeno et al., 1992; Lorenz and Heitman, 1997). The 
enzyme phospholipaseC (Plc1p) was also shown to function with Gpr1 and Gpa2 to regulate 
yeast filamentous growth (Ansari et al., 1999). Given that genetic interactions of MEMO with 
PLC1 and RAS2 genes were identified in our synthetic lethal screen, we scored memo  
strains for their ability to induce pseudohyphal differentiation under nitrogen starvation 
Figure 10). Nitrogen-limiting (SLAD) medium was used to allow diploid cells of the 1278b 
strain background to undergo pseudohyphal differentiation. MLY40 and MLY41 and MLY61 
yeast strains were kindly provided by Dr. J. Heitman and described (Lorenz and al., 2000). 
memo  strains were generated and diploids were grown on SLAD medium containing only 
0.05mM ammonium sulfate as sole nitrogen source. As shown in Figure 10, the transition 
from unpolarized colonial growth to pseudohyphal growth occurred on agar-based synthetic 
growth medium deficient in nitrogen in both Wild Type and and memo  strains, indicating 
that Memo is not involved in pseudohyphal differentiation in yeast.  
 
 
 
 
                               
 
 
 
Figure 9. Pseudohypahl growth Diploid cells of the yeast 
Saccharomyces cerevisiae undergo pseudohyphal 
differentiation in response to nitrogen limitation. In 
response to nitrogen-limiting conditions, diploid cells of S. 
cerevisiae change their growth pattern: the cells elongate 
and switch from bipolar to unipolar budding, the mother 
and daughter cells remain physically attached, and the cells 
invade the growth substrate. As a result, filamentous 
pseudohyphal colonies are formed. 
WT 
memo  
Figure 10. Memo does not control 
pseudohyphal growth. Wild-type cells 
(MLY61a/α) or memo  strains were grown 
on SLAD medium at 30°C for 5 days. 
Colonies were photographed. 
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3. CONCLUSIONS AND PERSPECTIVES 
 
The expression data suggested that Memo is a general stress responder, however, no specific 
function was uncovered for Memo. These results showing that stress conditions lead to 
elevated levels of expression of Memo will be explored in more detail in different culture 
conditions (log-phase versus stationary phase) and using diverse drugs/reagents. By 
performing a synthetic lethal screen, we identified a genetic interaction between MEMO and 
PLC1. This result could reflect different possibilities; either Memo and Plc1p perform 
redundant functions in an essential pathway or Memo and Plc1p perform discrete steps in the 
same pathway. Interestingly, in mammalian cells, complexes of Memo and PLCγ1 were 
detected, and Memo was found to be required for efficient PLCγ1 phosphorylation, 
suggesting that Memo has a role in efficient PLCγ1 activation (Meira et al., in revision). 
Furthermore, Memo or PLCγ1 down regulation in breast tumor cells resulted in a strong 
impairment of cell directionality during cell migration; however, simultaneous down-
regulation of Memo and PLCγ1 led to a stronger phenotype with a total blockade of cell 
movement and increased formation of actin stress fibers. These results indicate that, similarly 
to their homologues in yeast, mammalian Memo and PLCγ1 “cooperate” in essential steps in 
migration. To test a potential rescue of the memoΔplcΔ synthetic lethal interaction, yeast 
Memo will be replaced with the human Memo. Future experiments also include the use of the 
efficient inhibitor of the yeast Plc1p, 3-Nitrocoumarin (Tisi et al., 2001), to determine a 
potential effect of PLC1p activity on Memo localization. Furthermore, experiments in 
mammalian cells suggested that both Memo and PLCγ1 lie upstream of cofilin in models of 
ErbB2-driven cell motility, and Memo was found to bind directly to cofilin (Meira et al., 
submitted). Yeast cofilin is functionally similar to its human homolog, and binds to both 
monomeric and filamentous actin, promoting actin filament depolymerization/severing 
function (Theriot, 1997). COF1 is an essential yeast gene (Iida et al., 1993; Moon et al., 
1993). Its protein product, cofilin, is localized to the cortical patches, small, rapidly moving, 
actin-rich structures usually concentrated at sites of cell surface growth in budding yeast 
(Moon et al., 1993). Although no evidence was found for a role of Memo in actin patch 
distribution and actin cables formation/distribution, we can not exclude a link between Memo 
and cofilin in yeast. Currently, there is not much information on interacting proteins for yeast 
Memo. Only one candidate, Arp1, has been identified in a yeast high -throughput two hybrid 
screen (Ito et al., 2001). Arp1 is an actin-related protein of the dynactin complex that is 
required for spindle orientation and nuclear migration (Muhua et al., 1994). This interaction 
was confirmed in mammalian systems (data not shown). Interestingly, mammalian Memo was 
found to be required for microtubule cytoskeletal organization. However, memoΔ strains did 
                                    RESULTS: Memo in S. cerevisiae 
                                                       - 170 -
not exhibit any defect in microtubule distribution or nuclear distribution, suggesting that 
Memo does not influences Arp1 function. In order to confirm the Memo-Arp1 interaction and 
identify other Memo-interacting proteins, another technique will be used where Memo is 
expressed in the yeast strain with a C-terminus TAPtag (Tandem Affinity Purification tag). 
TAPtagged-Memo will be purified and complexed proteins will be processed by mass 
spectrometry analysis.  Considering that expression of Memo is enhanced upon stress, Memo-
complexed proteins content will be examined in different environmental conditions. 
Furthermore, to examine potential differences in binding partners, TAP-tagged-Plc1p will be 
expressed in the memoΔ strain or inversely, TAP-tagged-Memo will be expressed in plc1Δ 
strain. A TAP-tagged-cofilin construct will be also generated in order to test cofilin-Memo 
interaction in yeast. Finally, we will have a closer look at the “synthetic sick” candidates 
which have been identified in the yeast-two hybrid screen, in particular at the candidates 
associated with the mitochondria function and stress response in order to characterize a 
potential role of Memo in mitochondria. 
Genetic approaches in models such as S. cerevisiae are powerful tools to study the function of 
evolutionary conserved proteins. Memo homologs are present in all species, from bacteria to 
human. We hope that the rapid genetic approaches that are possible in yeast will advance our 
knowledge of Memo’s cellular and molecular role.  
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                        CANDIDATE Accesion number
Acetyl coenzyme A acyltransferase      NM_006111
Casein kinase 1 epsilon      BC006490
Cofilin-1      BC012318
Crystallin lamda      BC008562
Developmentally regulated RNA-binding protein 1      AB036991
Ets-like protein      AC069287
Eukaryotic translation elongation factor 1α1      BC029343
FAD-synthetase      BC032323
FANCC-interacting protein      AF130255
Fc receptor related protein X      AF531423
Fc receptor.like and mucin-like      NM_032738
Ferritin      NM_002032
Glucosamine 6 phosphate deaminase      NM_005471
Gluthatione reductase      AY338490
Growth inducible transmembrane protein      NM_014394
Hemidesmosomal tetraspanin      NM_139030
Hexokinase 1      BC008730
Homo sapiens chaperonin containing TCP1, subunit 2 (beta)      NM_006431
HSPC041 protein      AF125102
H-unc-like protein      BC014794
Immunoglobulin lamda constant 1      BC073769
Iron inhibited ABC transporter      AF261092
KIAA0286 protein      NM_015257
KIAA2005      AB095926
MHC class II HLA DR beta1      BC071659
Nascent-polypeptide-associated complex alpha polypeptide      AY911673
Oxidored nitro domain containing protein      BC063380
PHD finger protein 20 like 1      BC036953
PRO 0992      AF116615
Programmed cell death 2      BC067759
Proliferation-inducing protein 10      AY239295
Proteasome 26 subunit      BC002589
Prothymosin alpha      BC034921
Ribosomal protein L4 variant      AB208977
Ribosomal protein S2      BC008329
Ribosomal protein S5      BC018828
Sin3 associated polypeptide      NM_005870
Solute carrier family 1, member 4      NM_003038
Solute carrier family 25      BC068199
TACC1      AY072876
TNF receptor associated protein 1      AJ890085
Tri iso-phosphate 1 (TPI1)      NM_000365
ZHX3 transcription factor      NM_015035
Zinc finger protein 317      BC009367
Zinc finger protein 394      BC062588  
   Table 1. List of potential Memo-interacting proteins identified in the YTH screen.  
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In multicellular organisms, the regulation and coordination of complex cellular processes such 
as growth, differentiation, migration and apoptosis, require efficient communication between 
individual cells. These biological processes are mediated by a plethora of signal transduction 
networks. Polypeptide growth factors induce signaling by activating cell surface receptors 
such as RTKs which are the primary mediators of such physiological cell responses (Yarden 
and Sliwkowski, 2001). In fact, these receptors couple ligand binding to downstream 
signaling cascades and gene transcription (Schlessinger, 2000). RTKs have been regarded as 
key regulators of normal cellular processes, but also appeared to be critically involved in the 
development and progression of human cancers and other hyper-proliferative diseases 
(Kolibaba and Druker, 1997). Therefore, signaling pathways controlled by tyrosine kinases 
offer unique opportunities for pharmacological intervention.  
 
ErbB2, which belongs to the EGF/ErbB family of RTKs, has been implicated in the 
development of many types of human cancer. The ERBB2 amplicon on chromosome 17q12-
21 is found in approximately 20% of primary human breast tumors which show a dramatic 
overexpression of the receptor. The mechanism underlying the oncogenic potential of 
overexpressed HER2 may be related to the increased availability for heterodimer formation 
and heteromolecular interaction, and consequently, for high autophosphorylation levels and 
constitutive signaling (Lonardo et al., 1990) (Brennan et al., 2000). Clinical studies revealed 
that ErbB2 gene amplification and overexpression correlate with a more aggressive 
progression of disease and a reduced patient survival (Paik et al., 1990) (Slamon et al., 1987). 
Moreover, clinical and fundamental investigations revealed that overexpression of HER2 
increases the metastatic potential of human breast and lung cancer cells and correlates with 
the number of lymph node metastases in node-positive breast cancer patients (Yu and Hung, 
2000). The metastatic process is extremely complex and, unfortunately, targeting metastasis, 
the cause of 90% of deaths from solid tumors, is still a major clinical problem. The metastatic 
process, whose study suffers limitations since it can only be studied in vivo, consists of 
distinct steps, some important ones being loss of cellular adhesion and increased motility and 
invasiveness (Gupta and Massague, 2006). Data gleaned from in vitro cancer cell models 
demonstrate that ErbB2 controls key intracellular pathways that govern fundamental cellular 
processes including migration (Hynes, 2007). Accordingly, ErbB2 and downstream signaling 
pathways have been intensely studied with the specific aim of identifying ErbB2-regulated 
proteins that are essential for tumor cell migration. Marone and colleagues identified a novel 
297 amino-acid protein as an interacting partner of an ErbB2 autophosphorylation site. This 
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protein, which was called Memo, was found to be important for ErbB2-induced cell 
migration, and knock-down of Memo in tumor cells resulted in dramatic alterations in 
microtubule outgrowth and actin stress fibers distribution (Marone et al., 2004). 
 
In the present study, we dissected in more detail the diverse stages of the migratory process 
and uncovered novel functions for Memo at different steps of cell migration. By using the 
Dunn chamber model which allows direct visualization and quantification of cell movement, 
we showed that while the general movement (translocation distance and speed) of Memo-
down-regulated human breast carcinoma cells was moderately affected, the directionality of 
these cells was strongly impaired, suggesting that Memo is involved in the very first steps of 
the migratory process. How does Memo regulate directed cell migration? In fact, directional 
movement requires the cell to be able to detect an asymmetric extracellular signal, in our case 
the HRG gradient, and to generate internal amplified responses, leading to cell polarization, 
protrusion formation and adhesion in the direction of the ligand. Thus, directional migration 
of cells towards chemoattractants depends upon the spatial and temporal regulation of the 
actin cytoskeleton by actin-binding proteins. 
 
One mechanism by which Memo could affect cellular movement is by influencing the activity 
of regulator(s) of directional sensing and cell polarity. Indeed, in a screen for Memo binding 
partners, we uncovered a novel interaction between Memo and cofilin, a known F-actin 
depolymerizing/severing factor. While studying the in vivo biochemical function of cofilin 
and subsequent cellular response, Gosh and colleagues demonstrated that cofilin determines 
the direction of cell migration (Ghosh et al., 2004). Interestingly, by performing in vitro F-
actin binding and depolymerization experiments with recombinant Memo and cofilin proteins, 
we found that Memo enhances cofilin depolymerizing/severing activity, suggesting a direct 
role for Memo on cofilin function, and subsequently, on directional migration. The same 
group also showed that inhibition of PLCγ1 inhibits cofilin activity in cells during the early 
transient of actin barbing, delays the initiation of protrusions, and inhibits the ability of cells 
to sense a gradient of EGF, suggesting that both PLCγ1 and cofilin are required for setting the 
direction of cell movement in response to EGF (Mouneimne et al., 2006) (Mouneimne et al., 
2004). More recently, van Rheenen and colleagues demonstrated that EGF induces a rapid 
loss of PIP(2) through PLC hydrolysis activity, resulting in a release and activation of a 
membrane-bound pool of cofilin (van Rheenen et al., 2007). Importantly, we found that 
Memo is complexed with ErbB2 and PLCγ1 and is required for efficient ErbB2-induced 
PLCγ1 phosphorylation, suggesting another possible mechanism of action of Memo on 
cofilin. We also showed that ErbB2-induced recruitment of GFP-cofilin to the lamellipodia is 
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impaired in Memo and PLCγ1 knock-down cells, suggesting that both Memo and PLCγ1 are 
important for the lamellipodial localization of cofilin. Whether or not PLCγ1-mediated cofilin 
localization is dependent on Memo still remains unknown. Furthermore, Mouneimne and 
colleagues demonstrated that local activation of cofilin by PLCγ1 and its global inactivation 
by LIMK phosphorylation, combine to generate the local asymmetry of actin polymerization 
required for chemotaxis (Mouneimne et al., 2006). By performing co-immunoprecipitation 
experiments, we showed that Memo is able to bind both unphosphorylated and Ser3-
phosphorylated cofilin, suggesting that Memo could influence the balance between the 
phosphorylated and the non-phosphorylated status of cofilin, although it should be mentioned 
that no change in cofilin phosphorylation status was observed in the breast carcinoma models 
used in our study. 
 
The connection between PLCγ1, which appears to be important for directional migration, and 
Memo, remains to be explored in more detail. However, an increasing body of evidence 
suggests that both proteins “cooperate” to induce efficient cell migration. In the Boyden 
chamber assays performed with breast tumor cells, individual or simultaneous down 
regulation of Memo and PLCγ1 strongly impaired chemotaxis of cells, while chemokinesis, 
which reflects general movement, was only affected in double KD cells. These results are in 
accordance with those obtained using the Dunn chamber model, where individual knock 
down of Memo or PLCγ1 moderately inhibited general movement of cells and strongly 
affected cell directionality, whereas double knock-down, similarly to cofilin KD,  resulted in a 
total blockade of cell movement. These results indicate an additive effect of Memo and 
PLCγ1 down regulation, and suggest that these two proteins act in concert to promote cell 
migration, either in the same or in parallel pathways. 
 
In our study, we also used T47D breast carcinoma cell lines in which endogenous ErbB2 had 
been functionally inhibited and substituted with Neu mutants harboring none (NYPD) or only 
one of the two major autophosphorylation sites (YC or YD) that were found to be important 
for cell migration (Marone et al., 2004). In accordance with the previous report showing that 
parental T47D, YC and YD cells, but not NYPD cells, were able to migrate upon HRG 
stimulation, we observed that T47D, YC and YD cells migrated towards the HRG source in 
the Dunn chamber model, whereas NYPD cells were totally blocked in their movement (data 
not shown).  
 
Furthermore, phosphorylation of PLCγ1 was induced by HRG in T47D, YC and YD cells, but 
not in NYPD cells, suggesting that cooperation between effectors downstream of the YC and 
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YD autophosphorylation sites is required for PLCγ1 activation (data not shown). These results 
also suggest that PLCγ1 phosphorylation is required for cell migration. In accordance with 
this hypothesis, Chen and colleagues have previously investigated the role of PLC-γ1 in EGF-
induced cell movement or migration into an acellular area created by wounding a monolayer 
of 3T3 cells. Based on the analysis of transfected EGF receptor deletion mutants, 
pharmacological inhibition of PLC activity with the drug U73122, antisense reduction of 
PLC-γ1 levels, and expression of a dominant negative fragment of PLC-γ1, this group also 
concluded that PLC-γ1 function is required for cell migration (Chen et al., 1994). 
Subsequently, gelsolin was identified as a downstream target of EGF-induced PLC-γ1 activity  
(Chen et al., 1996).  
Gelsolin is a Ca2+- and PIP2-regulated actin filament severing and capping protein that has a 
role in actin remodeling (Sun et al., 1999). Interestingly, gelsolin null fibroblasts exhibit 
defective chemotaxis and wound healing (Azuma et al., 1998). Furthermore, similarly to our 
breast tumor cell models with a KD of Memo or PLCγ1, gelsolin null fibroblasts have 
pronounced actin stress fibers (Witke et al., 1995), a phenotype that is consistent with an 
inability to sever and remodel actin filaments. Accordingly, reduction of ADF/cofilin protein 
levels in B16F1 cells also induced an increase in the number and thickness of stress fibers 
(Hotulainen et al., 2005). ADF/cofilins catalyze depolymerization of actin filaments and thus 
increase the rate of actin turnover by providing new actin monomers for polymerization 
(Carlier et al., 1997). In a study performed by Hotulainen and colleagues, direct evidence was 
provided that actin filament treadmilling rates in stress fibers were severely diminished in 
cofilin knockdown cells (Hotulainen et al., 2005). 
 
Based on their sub-cellular localization and interactions with focal adhesions, stress fibers of 
cultured mammalian cells can be divided into three classes (Naumanen et al., 2008). Ventral 
stress fibers are contractile actin bundles, which are typically associated with focal adhesions 
at both their ends (Small et al., 1998). Ventral stress fibers are responsible for the tail 
retraction and other cell shape changes due to increased contractility (Chen, 1981) and they 
also work against membrane tension at cell borders (Thery et al., 2006). Transverse arcs are 
curved actin bundles which are typically not directly attached to focal adhesions, but they are 
connected to the substrate via dorsal stress fibers. In migrating cells, they flow from the 
leading edge towards the cell center (Small et al., 1998) (Hotulainen and Lappalainen, 2006) 
and increased contractility enhances their motility. The contractile force is then transmitted to 
the substrate via dorsal stress fibers, which are actin filament bundles that attach to focal 
adhesion at one end and rise towards the dorsal section of the cells at the other end, but do not 
contract. Our results suggest that Memo or PLCγ1 down regulation in breast tumor cells, 
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affected the organization of ventral and transversal stress fibers, reflecting enhanced 
contractility. 
Also of note is the fact that simultaneous down regulation of Memo and PLCγ1 resulted in a 
more striking effect on actin stress fiber organization, strengthening the hypothesis of a 
“collaboration” between these two proteins.  
 
Considering these effects on actin organization, and given that Memo was found to be 
important for PLCγ1 phosphorylation, we hypothesize a possible function for Memo whereby 
it mediates activation of downstream PLCγ1 effectors such as cofilin and perhaps even 
gelsolin. However, the mechanism whereby Memo influences PLCγ1 activation remains to be 
explored. It is worth mentioning that this “collaborative” connection between Memo and PLC 
is conserved through evolution, since a synthetic lethal interaction was identified for yeast 
MEMO and PLC1 gene products. 
 
Rho-family GTPases, including Cdc42, Rac1 and RhoA, were shown to play a central role in 
establishing cell polarization (Fukata et al., 2003). In fact, activation of Rac maintains the 
lamellipodium. Simultaneously, a Rho-dependent pathway determines the trailing edge (Xu et 
al., 2003). This antagonistic response with Rho that is suppressed at the front of the cell 
whereas Rac is suppressed at the back, allows cells to maintain polarity in one direction. 
During the course of our studies, we found that RhoA activation was delayed in Memo knock 
out mouse fibroblasts, suggesting a possible disorganization in the establishment of cell 
polarity during cell migration. Furthermore, Rho GTPases also capture and stabilize 
microtubules (MT) through their effectors (e.g. IQGAP1, mDia and Par6) near the cell cortex, 
leading to polarized cell morphology and directional cell migration (Fukata et al., 2003) 
(Watanabe et al., 1999) (Palazzo et al., 2001) (Cook et al., 1998) (Ishizaki et al., 2001). MT 
minus ends are anchored in the MTOC, whereas MT plus ends are directed to the cell 
periphery and continually alternate elongation and shrinkage phases (Burbank and Mitchison, 
2006). Thus, when the cells are polarized, the plus ends of MTs are targeted, captured and 
stabilized near the leading edge, where MTs play critical roles in directed transport of specific 
proteins and vesicles for cell polarization. As an example, Yamana and colleagues showed 
that depletion of mDia1 by RNA interference impaired directed migration of rat C6 glioma 
cells by inhibiting both cell polarization and adhesion turnover (Yamana et al., 2006). In fact, 
the Rho-mDia1 pathway was shown to regulate polarization by aligning MT and actin 
filaments and delivering Apc/Cdc42 to the front of migrating cells where they work together 
for cell polarization. Also, Rho-mDia was found to promote MT-mediated Src localization to 
focal adhesions where it participates in the formation and adhesion turnover of focal contacts. 
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Interestingly, Memo knock down in breast tumor cell lines resulted in a dramatic alteration of 
MT organization such that MT failed to extend to the periphery of the cell (Marone et al., 
2004). Considering this particular model, we hypothesize a possible role for Memo on Rho 
activation and consequently on MT-mediated molecular transport, contributing to directed 
cell migration and Src localization. Also of note is the fact that HRG or EGF-induced Src and 
Erk phosphorylation was impaired in cells that lost Memo. We hypothesize that Memo loss 
might affect FAK/Src-induced recruitment or activation of molecules such as Erk2 and 
calpain-2 which regulate focal adhesion disassembly (McLean et al., 2005). This model could 
explain why Memo deficient cells exhibit a defect in focal adhesion disassembly. Also, Zhang 
and colleagues suggested a role for FAK in recruiting PLCγ1 to the plasma membrane at sites 
of cell-matrix adhesion through the FAK autophosphorylation site Tyr-397 which mediates a 
direct interaction with PLCγ1 (Zhang et al., 1999). This interaction was shown to promote 
PLCγ1 enzymatic activity, possibly by releasing the repression caused by intramolecular 
interactions of the PLCγ1 Src homology domains and/or by positioning it for phosphorylation 
by associated Src-family kinases. Considering that PLCγ1 phosphorylation is impaired in 
Memo-deficient cells, and despite showing no effect on FAK Y397 phosphorylation, it is 
possible that Memo affects Src-mediated PLCγ1 phosphorylation at focal contact sites.  
 
Although MTs do not appear be essential for actin/dependent ruffling and lamellipodia 
formation, MTs were shown to be required for tail retraction during cell movement 
(Ballestrem et al., 2000) (Wehrle-Haller and Imhof, 2003). Interestingly, when scored for 
their ability to migrate in a shallow gradient of HRG that was created in a Dunn chamber, 
Memo knock down breast tumour cells exhibited a tail retraction defect, suggesting an 
involvement of Memo at different stages of the migratory process. This tail retraction defect 
that we observed in knock down cells and also in Memo KO MEFs was similar to the one 
observed in B16 cells treated with the microtubule-disrupting reagent nocodazole in 
combination with PMA (phorbol 12-myristate 13-acetate), a known inducer of the 
reorganization of the actin cytoskeleton  (Ballestrem et al., 2000). Also similarly to the 
nocodazole-treated B16 cells, and probably because of the driving force created by 
polymerizing actin at the leading edge and the stable contact at the rear, Memo knock down 
cells were sometimes torn apart, resulting in fragments separated form the main cell body, 
leaving a trace of actin-containing membrane behind. However, the tail retraction defect 
observed in Memo deficient cells is independent of impaired PLCγ1 phosphorylation since 
inhibition of PLCγ1 by siRNA transfection of breast tumour cells did not affect the retraction 
step during cellular movement (data not shown). We favour the hypothesis that through its 
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effect on FAK/Src signaling, Memo loss could affect focal adhesion disassembly, resulting in 
a tail retraction defect. 
 
In the course of our studies, we also found that Memo is involved in cell adhesion, another 
important step of the metastatic process. The ability of a cell to adhere to its neighbor and to 
the extracellular environment is an essential process that defines in part a normal multicellular 
organism. During the process of tumor metastasis, adhesion molecules provide a selective 
advantage for migration of the tumor cell to a distant site (Cooper and Pienta, 2000). 
Adhesion complexes are platforms where many molecules meet to organize the cytoskeleton 
and trigger signaling (Lo, 2006). Integrins are a widely expressed family of cell adhesion 
receptors that are composed of αβ heterodimeric units, and are expressed on a wide variety of 
cells (Arnaout et al., 2007; Mousa, 2008). They play a critical role in the connection between 
focal adhesions and proteins of the extracellular matrix (Hynes, 2002). Furthermore, upon 
engagement of integrin cell adhesion receptors, FAK is activated and initiates several 
signaling events. In fact, the FAK-Src complex acts to recruit and/or phosphorylate a number 
of signaling proteins and is involved in regulation of adhesion. Memo possibly affects cellular 
adhesion by regulating FAK/Src complex signaling. Moreover, in an interesting study, 
Tvorogov and colleagues showed that PLCγ1 deficient cells have an adhesion, spreading and 
migration defect (Tvorogov et al., 2005). In addition, they demonstrated that integrin 
engagement by fibronectin induces tyrosine phosphorylation of PLCγ1 at Tyr783 and that this 
signaling event requires Src activity. Furthermore, mutagenesis of Tyr783 abrogated the 
capacity of PLCγ1 to facilitate adhesion. Considering the effect of Memo on PLCγ1 and Src 
phosphorylation, a possible role for Memo on the regulation of integrin function remains to be 
explored. 
  
Cell adhesion can also be regulated by members of the tetraspanin family (Lazo, 2007) (Levy 
and Shoham, 2005). Human tetraspanin proteins are a group of highly hydrophobic membrane 
proteins that can form complexes in cholesterol-rich microdomains on the cell surface. These 
complexes are composed of a core of several tetraspanin proteins that organize other 
membrane proteins such as integrins, and some growth factor receptors. Tetraspanin proteins 
and their complexes were shown to affect cellular adhesion and motility, interactions with 
stroma or affect signaling by growth factors. These proteins have been mostly studied in cells 
of lymphoid lineage, but they are present in all cell types. Interestingly, among the candidates 
obtained in our YTH screen, the tetraspanin CD151 was identified as a potential interacting 
partner of Memo (Table 1 in Appendix). CD151-α6 integrin complexes were recently shown 
to play a functional role in basal-like mammary tumor progression (Yang et al., 2008). Also, 
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both α3β1- and α6β4-dependent cell adhesion to laminin-5 were impaired in CD151-silenced 
cells (Winterwood et al., 2006). Furthermore, those cells displayed markedly impaired 
motility, accompanied by unusually persistent lateral and trailing edge adhesive contacts.  In 
another study, Yamada and colleagues demonstrated that CD151 KD cells have aberrant 
membrane protrusions and exhibit reductions in the tyrosine phosphorylation of FAK, Src, 
p130Cas and paxillin (Yamada et al., 2008). Considering these results and some similar 
effects obtained in Memo defective cells, we suggest a possible connection between Memo 
and CD151 that would be important for cell adhesion and migration processes. 
 
Finally, another possible role for Memo during the metastatic process has to be explored in 
more detail; this is regulation of MMPs. In fact, MMPs contribute to cancer development by 
degrading ECM molecules, thereby facilitating cancer cell migration/invasion across tissue 
boundaries (Steeg, 2006). Interestingly, expression of MMP9 (RNA and protein) was 
impaired in Memo deficient cells, suggesting that proteolysis of the ECM during invasion 
might be decreased in those cells. Considering that ErbB2 overexpression was shown to 
activate transcription and enhance secretion of MMP9 proteases, leading to increased 
membrane degradation and invasiveness of ErbB2-overexpressing breast cancer cells (Tan et 
al., 1997), Memo appears to be a potential downstream ErbB2 mediator of cellular 
invasiveness. 
 
To conclude, our study suggests the involvement of Memo at different stages of the metastatic 
process and reveals a potential role for Memo on the regulation of critical components of 
multiple signaling pathways that regulate proliferation, survival, angiogenesis and metastasis.  
As an example, aberrant activation of Src family members is common in solid tumor 
malignancies and may contribute to the development and/or progression of these tumors. As a 
result, Src has emerged as a potential therapeutic target in the prevention of tumor spreading 
and inhibitors have been developed and tested for the treatment of different types of solid 
tumors (Kopetz et al., 2007) (Angelucci et al., 2006) (Hiscox and Nicholson, 2008). Inhibitors 
of FAK have also entered clinical studies for the treatment of solid tumors (Brunton and 
Frame, 2008) (McLean et al., 2005). PLCγ1 was also shown to function as a key molecular 
switch in the initiation of signaling cascades that regulate tumor migration (Wells and 
Grandis, 2003). Considering a potential role for Memo in the regulation of these three 
important actors of tumor progression, Memo might also become a biochemically relevant 
target in cancer research.  
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